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Abstract 
Methicillin resistant Staphylococcus aureus (MRSA) is an important nosocomial 
pathogen and morbidity and mortality rates associated with this pathogen have 
increased markedly in recent years. The prevalence of MRSA is no longer confined to 
hospital patients since MRSA infections have been increasingly reported in the 
community. More recently, community-acquired MRSA strains have become more 
prevalent and their infections are no longer confined to the community but have started 
to replace hospital-acquired MRSA in some health care settings. MRSA strains are 
generally resistant to several classes of antibiotics and are therefore difficult and costly 
to treat. Consequently, an understanding of the epidemiological characteristics of S. 
aureus is an essential tool for the management of its infections in both the hospital and 
community setting. The purpose of any epidemiology study, such as the investigation of 
an outbreak, is to identify the potential source(s) of an infection and to monitor their 
dissemination. The early identification of an outbreak, making use of a rapid, precise 
and simple MRSA typing technique, can lead to prompt and effective precautions that 
avoid further spread of the infection. Pulsed-field gel electrophoresis (PFGE) is 
considered the gold standard for MRSA typing and has been recently supported by 
multi-locus sequence typing (MLST). However, technical limitations restrict the use of 
PFGE and MLST in the majority of routine hospital laboratories: they are time-
consuming, expensive, require specific expertise and specialist equipment.  
 
In this study a novel typing technique was developed for S. aureus, based on single 
nucleotide polymorphism (SNP) variations in and around SmaI-restriction sites 
(CCCGGG), following the analysis of eighteen S. aureus strains that have had their 
genomes sequenced. The developed SmaI-multiplex PCR genotyping method combines 
the high discriminatory power and reproducibility of PFGE, with the simplicity of a 
multiplex PCR-based technique that can be performed in a routine clinical laboratory. 
The validity of SmaI-multiplex PCR was carefully assessed in comparison with PFGE 
and MLST against many sequenced S. aureus strains and showed high discriminatory 
power and reproducibility. There was also high level of concordance in the clustering of 
strains analyzed by each of the techniques. The SmaI-multiplex PCR was ultimately 
evaluated against a large number of clinical S. aureus outbreak strains and was shown to 
be a useful tool for providing reliable epidemiological information for the investigation 
of clinical staphylococcal outbreaks. The newly developed technology is suitable for 
high throughput sample analysis, is relatively cheap and provides reliable and 
comparable genotyping data. At the same time, the SmaI-multiplex PCR meets most of 
the criteria of practical typing method: it is simple, inexpensive, highly discriminatory 
and does not require sophisticated equipment or expertise. Consequently, SmaI-
multiplex PCR could be used routinely in any clinical microbiology laboratory since it 
relies on standard clinical laboratory apparatus (i.e. PCR machine and agarose gel 
electrophoresis). SmaI-multiplex PCR proved to be more discriminatory than 
MLST/SCCmec typing, but less discriminatory than PFGE. Currently the SmaI-
multiplex PCR protocol takes between 4 to 6 hours; however, it would be possible to 
adapt this technology towards an automated genotyping assay using RT-multiplex PCR. 
This would reduce the processing time to less than 60 minutes. Since individual targets 
are identifiable on the basis of the size of their amplicons, the RT-PCR output could be 
processed directly via dedicated analytical software. 
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Clonal complex A group of bacterial isolates that show a high degree of 
similarity based on a defined typing or identification 
scheme. 
 
Clone Bacterial isolates that are genetically identical or very 
similar that are derived from a common ancestor. 
 
Cluster analysis Comparative analysis of data that can group a data of 
according to similarity. 
 
Dendrogram Tree diagram illustrating a cluster analysis using any 
chosen data sets. 
 
Discriminatory power The ability of any technique to differentiate effectively and 
operationally between individuals. Ideally, each unrelated 
individual is assigned as unique. 
 
Endemic Strain that is continuously present in giving place over a 
long period of time. 
 
Epidemic The occurrence of an infection/organism more than usual 
/endemic level or exceed what is expected number of an 
infection/organism in given human population. 
 
Evolutionary or 
phylogenetic tree 
 
A diagram showing evolutionary relationships among 
bacterial species based on their genetic diversity and 
similarity. The taxa grouped together in the tree represent 
taxa descended from a common ancestor taxa. 
 
Genotype Genetic constitution of an organism that is determined by 
molecular or genetic techniques 
 
Incidence  The proportion of a defined infection that develops within 
a stated period. It is lower than prevalence rate 
 
xviii 
 
Isolate A population of bacterial cells derived from single colony. 
In clinical microbiology, an isolate is defined as a 
population that derived from clinical specimen obtained 
from an individual.  
           
Lineage A group of isolates derived from a common ancestor that 
share similar characteristics.  
Mutation A change in the nucleotide sequence or arrangement of 
DNA. Mutation can be point mutations (one nucleotide 
change) or macro-mutations that include inversion, 
deletion and duplication. 
Pathogenicity Ability of a pathogen to cause disease. 
Phenotype Any observable characteristic or treat of a bacterial strain 
including its morphology, biochemical properties and 
behavior. 
Prevalence  The total number of a defined infection in a given 
population at a particular period.   
Sporadic Rare or occurring at irregular intervals in time and 
locations, disconnected in space and time. It is the opposite 
of endemic and epidemic.   
Technical reproducibility The ability of a typing technique to assign the same type to 
an isolate tested on independent occasions. 
Typing Phenotypic and genetic analysis of bacterial isolates, that 
can be carried out to generate fingerprints (profiles) or 
database that can be used to assign an isolate to a particular 
group or class. 
Typeability The ability of a typing method to assign an analysed isolate 
to a group of class. 
Virulence The degree and properties of pathogenicity of pathogens. 
The pathogenic capacity of a microorganism can be 
determined by defining it so called virulence factors, such 
as toxins and enzymes. 
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1.1. Introduction 
Nosocomial or hospital-acquired infections (HAI) are one of the most common 
problems in hospitals throughout the world. It is considered one of the main reasons of 
morbidity and mortality amongst hospital patients, as well as the increasing costs of 
infection control. It is noteworthy that hospital-acquired infections are far from being a 
recent phenomenon, since they not only preceded the antibiotic era (1940s onwards), 
but have also been a recognised problem since 1847 and the pioneering work of Ignaz 
Semmelweis on puerperal fever (Wyklicky and Skopec, 1983). During most of the 20th 
century Staphylococcus aureus has been recognised as a major life-threatening 
pathogen. Although the clinical use of penicillin (1940s) initially led to a dramatic 
reduction in mortality from S. aureus infections, penicillin resistant strains soon 
emerged (Cookson et al., 2003). Concern was not only confined to the increase 
mortality rate among patients, but also to the spread of skin infections amongst health-
care workers. Furthermore, the ability of S. aureus to acquire multiple antibiotic 
resistances further reduced the effectiveness of chemotherapy for the treatment of 
staphylococcal infections. Subsequently, the development of new antibiotics, such as 
methicillin in 1960, led to the expectation that infections caused by this bacterium 
would be treatable. However, S. aureus rapidly developed resistance to methicillin and 
the first methicillin-resistant strains of S. aureus (MRSA) were reported in the UK in 
1961. Since then, the frequency of isolation of MRSA strains has increased significantly 
every year worldwide (Jevons, 1961; Grundmann et al., 2006).   
Nowadays, MRSA is considered to be one of the most important nosocomial 
pathogens and the infection frequency has grown progressively both in hospitals and, 
more recently, in the community. It is worth noting that MRSA is no more virulent than 
other S. aureus strains, but its infections are significantly more difficult to treat due to 
their resistance to front-line antibiotics (Rozgonyi et al., 2007). The glycopeptides have 
emerged as the most effective anti-MRSA agents, although the emergence of MRSA 
strains with reduced sensitivity to vancomycin has led to increasing concerns about the 
use of this antibiotic as the last resort for the treatment of MRSA infections (Hiramatsu 
et al., 1997). Therefore, the infection control is given priority by infection control teams 
in hospitals as a means of limiting MRSA infections.  
Early detection is crucial for the effective treatment and control of MRSA 
infections. There are various approaches for diagnosing MRSA, ranging from 
conventional methods, such as cultural characteristics and biochemical analysis, to more 
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advanced molecular diagnostic methods. In recent years a greater emphasis has been 
place on determining the source and monitoring the spread of infections. Initially this 
was done with phage-typing, however, in the last ten years or so, molecular 
epidemiology techniques have become the methods of choice because they can be 
performed rapidly with an extremely high level of accuracy. Pulsed-field gel 
electrophoresis (PFGE) is currently considered to be the gold standard for MRSA 
epidemiological typing (Tenover et al., 1997; Weller, 2000).  
1.2 Staphylococcus aureus: 
1.2.1 History of S. aureus 
Pasteur and Koch were the first to discover and culture Staphylococcus but 
without carrying out any detailed studies. Ogston in 1881 and Rosenbach in 1884 
performed the first detailed studies on Staphylococcus. Ogston gave Staphylococcus its 
genus name when he saw these bacteria formed grape-like clusters in human pus. 
Thereafter, Rosenbach isolated Staphylococcus aureus in pure culture, adding its 
species name aureus (=gold). Rosenbach also reported that S. aureus caused some 
wound infections whereas S. epidermidis lived on the skin as a colonizer (Cookson et 
al., 2003). 
1.2.2 General description  
S. aureus is a member of the Staphylococcaceae family (Firmicutes), Gram-positive 
facultative anaerobes that exhibit a coccal morphology, and are non-motile and non-
sporulating. Its cells are 0.5-1.5µm in diameter and forms grape-like clusters. It is 
catalase and coagulase positive and some strains produce capsules. On blood agar, 
colonies of S. aureus appear golden (caused by staphyloxanthin, a membrane-bound 
carotenoid) surrounded by haemolytic zones (Wieland et al., 1994). In addition, S. 
aureus strains secrete various extracellular virulence factors such as coagulase and 
enterotoxins. Despite the fact that S. aureus is a normal component of the microbiota of 
the nasal passages, skin and mucous membranes of humans and animals, it is the cause 
of several important diseases (Brown et al., 2005; Humphreys, 2002; Bergey et al., 
1994; Marshall and Wilmoth, 1981). 
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1.2.3 Cell envelope 
The cell walls of Gram-positive bacteria differ from those of Gram-negative 
bacteria. The S. aureus cell wall is a multilayered structure (20-40 nm), comprising a 
copolymer of peptidoglycan and teichoic acid. Peptidoglycan represents ~50% of cell 
wall by weight and is a polymer consisting of repeating units of sugars of 1, 4 β-linked 
N-acetylglucosamine and N-acetylmuramic acid. The glycan chains are cross-linked by 
tetrapeptide chains (L-alanine, D-glutamine, L-lysine, and D-alanine) bound to N-
acetylmuramic acid and a pentaglycine bridge that links tetrapeptide chains on adjacent 
glycan strands. This cross-linking is catalysed by the transpeptidase (TPases) activities 
of penicillin banding proteins (PBPs) (Fig. 1.1) (Stapleton and Taylor, 2002; Lowy, 
1998). Another major cell wall component is teichoic acid, an anionic polymer that 
consists of repeating alditol phosphate groups covalently linked to the muramic acid 
residue of peptidoglycan.  
  In some S. aureus strains the cell wall is coated with an extracellular 
polysaccharide capsule. More than 90% of clinical strains of S. aureus can produce 
polysaccharide capsules that are usually thin (<0.05µm) and consist of aminouronic acid 
sugars and fucosamine (Wright and Novick, 2003; Seaman et al., 2004). Serotyping has 
identified 11 serotypes, with serotypes 5 and 8 being responsible for about 75% of 
human infections. Most MRSA strains are serotype 5 (Lowy, 1998).  
 
Figure 1.1: Three-dimensional structure of S. aureus peptidoglycan, consisting of repeating 
units of 1, 4 β-linked N-acetylglucosamine and N-acetylmuramic acid with 
tetrapeptides and cross-linked by pentaglycine bridge. (adapted from Tomasz, 
2006,  and Todar, 2002). 
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1.2.4 S. aureus genome  
The genome of S. aureus has been extensively studied and currently 18 
staphylococcal genomes (Table.1.1) have been completely sequenced (nine are MRSA 
(four of which are vancomycin-intermediate resistant S. aureus (VISA)) and nine are 
MSSA) and a further 28 genomes are currently being sequenced (some of them in the 
finishing stage). This has provided an extraordinary glimpse into this so-called “super 
genome” and has led to a significant increase in our knowledge of the structure and 
functioning of S. aureus.     
The staphylococcal genome is a closed circular molecule of double-stranded (ds) 
DNA of between 2.7 – 3.0 Mbp in length, encoding between 2509 to 2892 open reading 
frames (ORFs).  It is composed of two domains called the core genome and the 
accessory genome. The core genome is inherited from the ancestors and is highly 
conserved in all staphylococcal species (Shittu et al., 2007). The core comprises 
approximately 75% of S. aureus chromosome and it is highly conserved between strains 
(Lindsay and Holden, 2004). It contains all the housekeeping genes that are required for 
essential cell functions, such as DNA replication, proteins synthesis and core 
metabolism etc.  The genome includes a wide variety of genes encode functions that 
contribute to virulence, such as toxins, exoenzymes and capsule biosynthetic cluster. 
The battery of virulence genes is highly strain variable (Shittu et al., 2007). 
The second domain, comprising of ~25% of the staphylococcal genome, is the 
accessory genome. The accessory genome mostly consists of mobile genetic elements 
(MGEs) that encode variety of non-essential components required for growth and 
survival. These elements include pathogenicity islands, bacteriophages, chromosomal 
cassettes, genomic islands, plasmids and transposons. Many of these elements encode 
virulence and antibiotic-resistance determinants that are transferred horizontally 
between strains of clinical importance (Lindsay and Holden, 2004; Shittu et al., 2007). 
There is preliminary evidence to indicate that some of MGEs move among isolates at a 
high frequency whereas others move if only rarely. Although, the transfer mechanisms 
are not fully understood, valuable information has been obtained about how S. aureus 
causes infection from the characterisation and identification of MGEs. Several studies 
suggest that certain virulence and antibiotic-resistance determinants are associated with 
particular strains and types of infection (Lindsay and Holden, 2004).   
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Table 1. 1: The sequenced genomes of S. aureus.   
Strain Source Type Year Size (bp) ORFs Status GeneBank Reference 
NCTC8325 Colindale, UK MSSA 1949 2,821,361 2892 complete CP000253 (Gillaspy et al., 2006)   
COL Colindale, UK HA-MRSA 1961 2,809,422 2612 complete CP000064 (Gill et al., 2005) 
FPR3757 Abscess, US CA-MRSA 2006 2,872,769 2560 complete CP000255 (Diep et al., 2006) 
TCH1516 Sepsis, US CA-MRSA 2007 2,872,915 2654 complete CP000730 (Highlander et al., 2007) 
MW2 Bacteremia,US CA-MRSA 1998 2,820,462 2624 complete CP000033 (Baba et al., 2002) 
MSSA476 Osteomyelitis, UK CA-MSSA 1998 2,799,802 2571 complete BX571857 (Holden et al., 2004) 
M50 Wound, Japan HA-VISA 1997 2,878,529 2696 complete CP000017 (Kuroda et al., 2001) 
Mu3 Pneumonia, Japan HA-VISA 1997 2,880,168 2690 complete CP000324 (Neoh et al., 2008) 
N315 Pharynx, Japan HA-MRSA 1982 2,814,816 2583 complete CP000018 (Kuroda et al., 2001) 
ED98 Chickens, UK MSSA 2009 2,824,404 2661 complete CP001781 (Lowder et al., 2009) 
MRSA252 Bacteremia,UK HA-MRSA 1997 2,902,619 2650 complete BX571856 (Holden et al., 2004) 
EMRSA15 Sanger, UK HA-MRSA 2009 2,832,299 NA complete NA www.Sanger.ac.uk 
JH1 Blood, US HA-VISA 2002 2,906,507 2747 complete CP000736 (Mwangi et al., 2007) 
JH9 Blood, US HA-VISA 2002 2,906,700 2697 complete CP000703 (Mwangi et al., 2007) 
Newman Osteomyelitis, UK MSSA 1952 2,878,897 2614 complete AP009351 (Baba et al., 2008) 
RF122 Bovin, Ireland MSSA 2007 2,742,531 2509 complete AJ938182 (Herron-Olson et al.,2007) 
LGA251 Bovine, Sanger, UK MSSA 2009 2,750,834 NA complete NA www.Sanger.ac.uk 
TW20 Bactermia, Sanger, UK HA-MRSA 2010 3,043,210 2808 complete FN433596 (Holden et al., 2010) 
  
NA= not available  
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1.2.5 Pathogenesis and virulence factors 
  Although one-third of mankind is asymptotically colonised by S. aureus, most are 
asymptomatic. However, under the right conditions this versatile organism is able to 
cause a wide range of infections (Archer, 1998). The nature of those infections depends 
on several factors, such as the pathogenic characteristics of the strain, host susceptibility 
and the route of entry into the host. In addition, S. aureus infections vary in seriousness 
and outcome from minor skin infections such as superficial lesions (furuncles, boils) 
and wound infections, to life-threatening infections such as septicaemia, ostemyelitis, 
acute endocarditis and necrotising pneumonia (Lowy, 1998; Keane, 1992)  
The ability of S. aureus to colonise the host and the capacity of this bacterium to 
exchange and obtain genetic information reflect its success as a versatile pathogen. This 
contributes to the fact that S. aureus strains can express a variety of virulence factors 
(Table 1.2) that play key roles in their spread and proliferation in its human and animal 
hosts. It is noteworthy that a virulence factor can be multifunctional in pathogenesis and 
multiple virulence factors may play the same function (Decker, 2008; Gordon and 
Lowy, 2008) 
The virulence factors of S. aureus can be divided mainly into three clusters: cell 
surface-associated factors including cell surface-bound proteins (the MSCRAMMs 
[microbial
 
surface components recognizing adhesive matrix molecules]) and other 
surface-components (polysaccharide capsule & cell wall peptidoglycan); extracellular 
enzymes including coagulase and staphylokinase, and toxins such as haemolysins, 
leukocidins and toxic shock syndrome toxin (TSST) (Wright and Novick, 2003; 
Novick, 2006). 
    Most S. aureus strains produce a capsular polysaccharide that contributes in 
virulence of S. aureus. The capsule plays vital role in the adhesion of bacterial cells to 
each other and to host tissues and medical equipment. In addition, the capsule inhibits 
phagocytosis and restricts the ability of antibiotics to reach the bacterial cell surface. 
Moreover, other cell wall components (e.g. peptidoglycan and lipoteichoic acid) have a 
role in S. aureus pathogenicity: peptidoglycan, for example, has endotoxin activity that 
stimulates macrophages to release cytokines (Lowy, 1998). Lipoteichoic acid (LTA) is 
thought to plays an important role in septic shock and other detrimental host responses 
(Ferry et al., 2005; Fournier and Philpott, 2005; Novick, 2006).     
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  Staphylococcal surface proteins contribute to the spread and virulence of S. aureus. 
These proteins, which include protein A, fibronectin binding proteins, fibrinogen 
binding proteins and collagen binding proteins are known MSCRAMMs. These proteins 
perform a wide spectrum of functions and many recent studies have shown that these 
surface proteins play essential roles in the ability of these bacteria to colonize host 
tissues (Wright and Novick, 2003; Lowy.1998) by promoting adhesion to the surfaces 
of host cells and tissues. MSCRAMMs are covalently attached to the cell wall by 
sortase enzymes that recognise and cleave the Leu-Pro-X-Thr-Gly (LPXTG) motif 
(Schneewind et al., 1995; Mazmanian et al., 1999). MSCRAMMs can also help the 
organism to evade the innate immune system and increase iron uptake (Foster, 2005). It 
appears that MSCRAMMs play a key role in the colonisation of prosthetic-devices and 
endovascular infections by, for example, assisting in the formation of biofilms. 
Moreover, MSCRAMM protein A is a good example of immune evasion factor that 
binds to the Fc portion of immunoglobulin and subsequently prevents opsonisation 
(Gordon and Lowy, 2008).     
          During infection, S. aureus secretes a wide variety of extracellular enzymes and 
toxins that contribute either directly or indirectly to pathogenesis. Most, if not all S. 
aureus strains produce haemolysins, coagulases, nucleases, protease, lipases, 
hyaluronidase and collegenases (van Belkum, 2007). Coagulase is produced 
exclusively, among the staphylococci, by almost all strains of S. aureus (with the 
exception of a few strains of S. intermedius). Coagulase reacts with blood-prothrombin 
to form a staphylothrombin complex that can convert fibrinogene to fibrin. Although, 
coagulase covers the bacterium with fibrin to reduce its susceptibility to host defences, 
its contribution to pathogenesis is not clear (Lowy, 1998; Wright and Novick, 2003). In 
contrast, staphylokinase disassembles fibrin by its interaction with plasminogen to form 
plasmin (a serine protease) that, by virtue of its ability to digests fibrin clots, allows 
staphylococci to spread into deep host tissue (Bokarewa et al., 2006). Other enzymes 
secreted by S. aureus include proteases such as serine protease V8 and lipases that 
breakdown the bactericidal fatty acids produced by infected cells. Many S. aureus 
strains produce hyaluronidase that can degrade the hyaluronic acid, a component of the 
extracellular matrix of host tissues, and enables the bacterium to spread through host 
tissues. Hyaluronidase is commonly referred as the spreading factor (Hynes and Walton, 
2000; Wright and Novick, 2003). The DNA and RNA of host cells are degraded by 
nucleases. These enzymes almost produced by all staphylococcal strains and cleave the 
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phosphodiester bonds of both single and double stranded DNA and RNA (Wright and 
Novick, 2003). Finally, S. aureus strains can produce β-lactamases that are responsible 
for the resistance of β-lactam antibiotics (Lowy, 1998). 
  S. aureus produces many cytotoxins that are grouped according to their mode of 
action (Lowy, 1998). Haemolysins (alpha, beta, gamma and delta) are porin-like toxins 
that lyse a variety of host cells such as red blood cells (erythrocytes) and platelets. 
Another important pore-forming toxin is Panton-Valentin leukocidin (PVL) that 
structurally resembles alpha toxin. This cytotoxin mostly forms its pores in the outer 
membrane of mitochondria and kills neutrophils and macrophages. Fortunately, <5% of 
S. aureus strains produces PVL and its production is associated with cutaneous 
infections and, more recently, with necrotizing pneumonia (Wright and Novick, 2003, 
van Belkum, 2007; Decker, 2008). S. aureus also secretes enterotoxins (A-E, G-I), toxic 
shock syndrome toxin-1 (TSST-1) and exfoliative toxin (A, B). These toxins are 
responsible for diseases such as food poisoning, toxic shock syndrome and exfoliative 
dermatitis (scalded skin syndrome) (Wright and Novick, 2003). Enterotoxin and TSST 
represent pyrogenic toxin superantigens (PTSgs) and both play a role in derailing and 
over-stimulating components of the immune response (van Belkum, 2007). 
Staphylococcal virulence factors are precisely regulated by a quorum-sensing 
system based on the accessory gene regulator (agr). In order to initiate colonisation of 
tissue sites, MSCRAMMs are expressed during exponential growth phase whereas 
secreted enzymes and toxins are produced later during stationary phase so as to aid the 
spread of the organism (Table 1.2) (Gordon and Lowy, 2008).   
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Table 1.2:   Extracellular proteins of S. aureus including virulence factors.  (Adapted from 
Wright and Novick, 2003; Novick, 2006).    
          Gene Location Product Activity/Function Timing 
S
u
p
er
a
n
ti
g
en
s 
sea Phage Enterotoxin A Food poisoning, TSS xp 
seb SaPI3 Enterotoxin B Food poisoning, TSS pxp 
sec SaPI4 Enterotoxin C Food poisoning, TSS pxp 
sed Plasmid Enterotoxin D Food poisoning, TSS pxp 
eta ETA phage Exfoliatin A Scalded skin syndrome pxp 
etb Plasmid Exfoliatin B Scalded skin syndrome pxp 
tst SaPI1,2,bov1 Toxic shock toxin-1 Toxic shock syndrome pxp 
C
y
to
to
x
in
s hla Chrom α-haemolysin Haemolysin, cytotoxin Pxp 
hlp Chrom β-haemolysin Haemolysin, cytotoxin pxp 
hld Chrom δ-haemolysin Haemolysin, cytotoxin xp 
hlg Chrom γ-haemolysin Haemolysin, cytotoxin pxp 
lukS/F PVL phage P-V leukocidin Leukocidin pxp 
E
n
zy
m
es
  
a
n
d
 o
th
er
 s
e
cr
et
ed
 
SplA-F Chrom Serine protease Putative protease pxp 
sspA Chrom V8protase Spreading factor pxp 
aur Chrom Metalloprotease (aureolysin) Processing enzyme pxp 
sspB Chrom Cysteine protease Processing enzyme  
scp Chrom Staphopain (protease II) Spreading, nutrition pxp 
geh Chrom Glycerol (esterhydrolase) Spreading, nutrition pxp 
Lip Chrom Lipase (butyryl esterase) Spreading, nutrition pxp 
fme Chrom Fatty acid methyl ester Fatty acid esterification pxp 
plc Chrom PI-phospholipase C Degrades membrane lipid PI  pxp 
nuc Chrom Nuclease Nutrition pxp 
hys Chrom Hyaluronidase Spreading factor pxp 
coa Chrom Coagulase Clotting, clot digestion exp 
sak Phage Staphylokinase Plasminogen activator pxp 
S
u
rf
a
ce
 p
ro
te
in
s spa Chrom Protein A Anti-immune, ant-PMN pxp 
cna PT islet Collagen binding protein Collagen binding pxp 
fnbA Chrom Fibronectin BPA Fibronectin binding exp 
finB Chrom Fibronectin BPB Fibronectin binding exp 
clfA Chrom Clumping factor A Fibrinogen binding exp 
clfB Chrom Clumping factor B Fibrinogen binding exp 
hlfB Chrom Lactoferrin BP Lactoferrin binding  
C
a
p
su
la
r 
p
o
ls
a
cc
h
a
ri
d
es
 cap5 Chrom Polysacch. cap.type5 Antiphagocytosis pxp 
 
cap8 
 
Chrom 
 
Polysacch. cap.type8 
 
Antiphagocytosis 
 
pxp 
 
xp = throughout exponential phase. exp = early exponential phase only. Pxp = post-exponential 
phase.  SaPI= Staphylococcus aureus pathogenicity island. 
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1.2.6 Antibiotic resistance    
Since the late 1940s, antibiotics resistance associated with hospital-acquired 
infections has emerged as a major problem worldwide. In this respect it is important to 
distinguish between bacterial strains acquired in hospitals from those acquired in the 
community, since the former are more likely to exhibit a greater range of antibiotic 
resistances than the latter (Zhang et al., 2006). Penicillin resistant strains of S. aureus 
were first detected in the 1940s, shortly after this antibiotic was introduced into clinical 
practice (Chambers and Deleo, 2009). This resistance was due to the production of β-
lactamases that inactivate the antibiotic by hydrolyzing the β-lactam ring. The main 
mechanism of penicillin resistance is via the blaZ-encodes β-lactamases (Rohrer et al., 
2003). The mechanism is illustrated in Figure 1.3.  
      Currently, 90% of clinical S. aureus isolates are penicillin-resistant and resistance is 
particularly prevalent in hospitals. Consequently, new generations of penicillins have 
been developed. The introduction of methicillin in the 1960s was followed rapidly by 
the emergence of methicillin-resistant isolates. Methicillin-resistance is not mediated by 
β-lactamases but by the production of an altered penicillin binding protein (PBP2a) that 
has a low affinity for β-lactam antibiotics (Johnson, 1998; see Section 1.3.2). The 1960s 
also saw the development of non-β-lactam antibiotics such as chloramphenicol, 
erythromycin, streptomycin and tetracycline. Although initially effective against S. 
aureus, nevertheless resistance against them developed rapidly. By 1976, resistance to 
kanamycin and gentamicin was reported (Fig.1.2) and, by the early of 1980s, 
multiresistant S. aureus strains were reportedly responsible for nosocomial outbreaks in 
many countries (Thomas and Archer, 1989). 
Vancomycin and teicoplanin are glycopeptide antibiotics that have been the first 
choice for the treatment serious nosocomial MRSA infections for the last fifteen years. 
Since the emergence of vancomycin-resistant enterococci, fully vancomycin resistant 
strains of S. aureus have been expected. The first vancomycin-intermediate resistant S. 
aureus (VISA) was reported in Japan in 1996. This isolate, designated Mu50, had an 
MIC for vancomycin of 8µg/ml (Hiramatsu et al., 1997). Thereafter, clinical cases from 
which VISA were isolated were reported in 1997 in USA, then France and later in the 
UK. All these reported strains were vancomycin-intermediate S. aureus (VISA) and 
were called glycopeptide-intermediate S. aureus (GISA) (Cui and Hiramatsu, 2003). 
The National Committee for Clinical laboratory standard (NCCLS) suggested the 
definition for vancomycin-resistant terms to avoid any confusion. S. aureus strains that 
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have an minimum inhibitory concentration (MIC) of 4 µg/ml or below of vancomycin 
are defined as vancomycin-sensitive S. aureus (VSSA), those that have an MIC of 
between 8-16 µg/ml as vancomycin-intermediate S. aureus (VISA), and those that have 
an MIC of 32 µg/ml or more as vancomycin-resistant S. aureus (VRSA) (Srinivasan et 
al., 2002). Although, VISA strains have been isolated, they are rare in most countries. 
However, 2002 witnessed the reporting of the first fully vancomycin-resistant S. aureus 
(VRSA) isolate from a renal dialysis patient in Michigan, USA (Fig.1.2) (Bartley, 
2002). This strain had an MIC of >128 µg/ml and carried the vancomycin-resistance 
gene, vanA (Chang et al., 2003; Aires de Sousa and Lencaster, 2004). 
 
     Figure 1.2:  The emergence of antibiotic resistance in S. aureus. VRSA = vancomycin-
resistant S. aureus. VISA = vancomycin-intermediate S. aureus (adapted from 
Chambers and Deleo, 2009). 
 
Vancomycin acts on cell-wall peptidoglycan by binding to the carboxyl-terminal 
D-alanyl-D-alanine residues of peptidoglycan precursor, preventing PBPs from 
accessing to their natural substrate. Vancomycin has to penetrate about 20 layers of 
peptidoglycan to reach the cytoplasmic membrane where the transglycosylation and 
transpeptidation reactions of PBPs take place. In the VISA strains Mu50 and Mu3, 
vancomycin-resistance is associated with a thickening of the cell wall caused by 
excessive activation of peptidoglycan synthesis. The vancomycin molecules are trapped 
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by high levels of free D-alanyl-D-alanine residues due to the much-reduced levels of 
cross-linking (Aires de Sousa and Lencaster, 2004).  
In contrast, full vancomycin-resistance in S. aureus (VRSA) is encoded by three 
determinants, namely VanA, VanB and VanD, normally associated with vancomycin-
resistant enterococci (VRE). Resistance is brought about by the replacement of the 
native D-alanyl-D-alanine (D-Ala-D-Ala) residue of the cross-linking wall peptide with a 
D-alanyl-D-lactate (D-Ala-D-Lac) residue, which has a very low affinity to 
glycopeptides. It is noteworthy that the VanA induces high level of resistance and also 
confers resistance to teicoplanin. The vanA gene cluster is carried on a large resistance 
plasmid (Berger-Bachi, 2002).    
1.3 Methicillin-resistant Staphylococcus aureus (MRSA)  
1.3.1 Emerging methicillin resistance 
Methicillin-resistant S. aureus were first discovered in the UK in 1961 by Jevons 
(1961). In this study, three MRSA strains were reported among 5,440 isolates and 
MRSA infections were initially confined to hospital patients. The first nosocomial 
epidemic of MRSA was reported in 1963, when an MRSA strain was isolated from an 
infant who was treated unsuccessfully with penicillin. The same strain was isolated 
from 37 children in eight wards and from one nurse. Medical centres in several 
European countries (e.g. Denmark, France and Switzerland) described outbreaks of 
MRSA nosocomial infections in the 1960s. The first US MRSA outbreak did not occur 
until 1971 (Chambers, 1988; Keane, 1992). More recently, a number of MRSA 
infections have been shown to be community- rather than hospital-acquired (Chambers, 
1988).  
In the UK, the number of MRSA infections remained limited for several years. 
At the beginning of the 1971, MRSA represented 10% of all S. aureus isolates at the 
general hospital in Birmingham. Interestingly by the mid-1970s, the number of reported 
MRSA cases declined to virtually zero, a decrease was thought to be due to a 
combination the use of aminoglycoside antibiotics and better infection control 
procedures (Griffiths et al., 2004; Johnson et al., 2005; Grundmann et al., 2006). 
However, in the early 1980s, concerns about MRSA were heightened with the 
emergence of gentamicin-resistant MRSA in the UK, Ireland and the USA.  
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In 1982, an epidemic strain of multi-resistant MRSA was reported in Australia, 
and the same strain was discovered in London in connection with a hospital outbreak. 
The staphylococcal reference laboratory of the UK Public Health Laboratory Service 
established a numerical prefix for epidemic MRSA strains and, based on this system, 16 
epidemic strains were identified in England and Wales up to 1995. Nevertheless, only 
three epidemic strains, UK EMRSA-3, UK EMRSA-15 and UK EMRSA-16, were still 
being recorded in the 1990s and EMRSA-15 and EMRSA-16 were behaviourally more 
dynamic. In the meantime, six epidemic MRSA strains have been recorded in some 
central Europe countries (Grundmann et al., 2006). EMRSA15 and EMRSA16 strains 
have spread broadly and are associated with severe infections (Livermore, 2000). 
According to the Centers for Disease Control (CDC) and the National Nosocomial 
Infection Surveillance System (NNISS), the proportion of MRSA in US hospitals 
increased dramatically from 2.4% in 1975 to 29% in 1991 (Graffunder and Venezia, 
2002). In the UK MRSA bacteraemias remained at 3% until 1992 and then rose 
considerably to reach 43% by 2002. Since then, the rate of isolation of MRSA strains 
has increased significantly every year worldwide (Grundmann et al., 2006).   
1.3.2 Mechanism of Methicillin-resistance 
  Methicillin-resistance in staphylococci is due to the acquisition of a large mobile 
DNA element (20 to 100kb in size), the so-called “Staphylococcal cassette chromosome 
mec” (SCCmec) (Rohrer et al., 2003). Currently, eight SCCmec types (I to VIII) have 
been described in details (see Section 1.3.3).  
 β-lactam antibiotics destroy bacteria by inhibiting bacterial cell wall synthesis. The 
antibiotic, an analogue of D-alanyl-D-alanine, covalently attaches to penicillin-binding 
proteins (PBPs). These membrane-anchored proteins catalyse one or more of three 
reactions (transpeptidase, endopeptidase and carboxypeptidase) involved in cell wall 
synthesis. MRSA produces a modified PBP2a that can complete cell wall synthesis 
when the transpeptidation activities of the native PBPs are inactivated by the antibiotic 
(Chambers and Hackbarth, 1992). Resistance is due to the fact that PBP2a has low 
affinity to β-lactams antibiotics. The expression of the mecA gene is controlled by the 
products of the mecRI and mecI genes.  MecRI synthesis is induced upon exposure to β-
lactam antibiotics. As a result, the MecI repressor is inactivated and PBP2a produced 
(Figure 1.3; Lowy, 2003).  
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Figure 1.3:  The mechanisms of β-lactam-resistance in S. aureus. (a) The production of β-
lactamase by blaZ gene in the presence of penicillin, I. The operator region of blaZ, 
blaR1 and blaI is bound by the DNA-binding protein Blal that represses the 
transcription of blaZ, blaR1 and blaI. II- III. The presence of penicillin stimulates 
the transmembrane sensor-transducer BlaR1 to inactivate the Blal repressor. IV-V. 
This process results in the removal of Blal and allowing transcription of blaZ to 
produce β-lactamases that inactivate penicillin by cleaving the β-lactam ring, (b) 
The mechanism of methicillin-resistance by production of PBP2a encoded by mecA 
gene. PBP2a synthesis proceeds similarly to that shown for β-lactamases. MecR1 is 
induced by β-lactam antibiotics and MecR1 inactivates MecI repressor allowing 
PBP2a synthesis (Lowy, 2003). 
 
 1.3.3 Staphylococcal cassette chromosome mec (SCCmec) elements 
The emergence of MRSA is the result of the acquisition of a mecA gene by the 
chromosome of an MSSA strain. The mecA gene is methicillin-resistance determent 
that is carried on a large (21- 67 kb) mobile genetic element called the staphylococcal 
cassette chromosome mec (SCCmec) element. SCCmec integrates into the 
staphylococcal chromosome at a specific-site (att BSCC) at 3‟-end of orfX, close to the 
origin of replication (de Lencaster et al., 2007; Ito et al., 2007). The SCCmec element 
does not resemble other mobile genetic elements such as phages or transposons, but is 
instead more like a pathogenicity island that lacks virulence factors (Short and Enright, 
2007). The origin of SCCmec is still unknown but there is evidence that SCCmec can be 
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horizontally transferred between staphylococcal species, and coagulase-negative 
staphylococci (CNS) are a potential source for SCCmec (Hanssen and Sollid, 2006).   
According to their genetic structure and contents, SCCmec elements are 
categorised into several types and subtypes (IWG-SCC, 2009). Almost all SCCmec 
types shared common characteristics: (1) the elements carry the mec gene complex; (2) 
They contain a cassette chromosome recombinase (ccr) gene complex; (3) SCCmec 
elements integrate at the same site into chromosome (near the origin chromosome of 
replication); (4) They are flanked by incomplete inverted and direct repeats sequences 
that contain integration site sequence (ISS) and located at the integration site of 
chromosome; those repeat sequences are recognised by ccr recombinases during the 
excision and integration of SCCmec (Hanssen and Sollid, 2006; Ito et al., 2007; IWG-
SCC, 2009).  
  SCCmec elements are currently classified into various types and subtypes based 
on a combination of the class of the mec gene complex and the allotype of the ccr gene 
complex. In SCCmec of S. aureus, three classes of the mec gene complex have been 
described: class A has the intact mec regulon (mecA- mecRI - mecI) with insertion 
sequence IS431mec downstream of mecA, whereas classes B and C1/C2 contain mecA 
regulation genes that are truncated by insertion sequence IS431-mecA-mecRI-IS1272 
and IS431- mecA- mecRI- IS431, respectively (Ito et al., 2003; Hanssen and Sollid, 
2006; de Lencaster et al., 2007; IWG-SCC, 2009). Another essential component of 
SCCmec is the ccr gene complex. Two genes (ccrA and ccrB) with four allotypes have 
been identified. Another gene, ccrC, has been identified in only one of the allotypes 
(Fig.1.4). A summary of the classification of ccr genes is showed in Table.1.3. The ccr 
gene complex plays a key role in the integration and excision of SCCmec into the 
conserved orfX locus by encoding the recombinase proteins of the invertase/resolvase 
family (Ito et al., 2003). Although the remaining regions of the SCCmec element carry 
antibiotic-resistance determents, they are called junkyard regions since they harbour the 
non-essential components. Three junkyard regions have been classified (J1-3) and 
variations in these regions are used to define the SCCmec subtypes (de Lencaster et al., 
2007).    
 
 
 
 
 
Chapter 1: Literature Review                                                                                          16 
Table 1.3:  SCCmec types (adapted from IWG-SCC (2009).  
SCCmec types mec gene complex ccr gene complex Size 
I B (IS1272- mecA- mecRI) 1 (A1B1) 34kb 
II A (IS431- mecA, mecRI - mecI) 2 (A2B2) 53-58kb 
III A (IS431- mecA, mecRI - mecI) 3 (A3B3) 67kb 
IV B (IS431- mecA- mecRI - IS1272) 2 (A2B2) 20-25kb 
V C2 (IS431- mecA- mecRI- IS431)
b 
5 (C) 28kb 
VI B (IS431- mecA- mecRI - IS1272) 4 (A4B4) 20-25kb 
VII C1 (IS431- mecA- mecRI- IS431) 5 (C) 28-30kb 
VIII A (mecA, mecRI and mecI) 4 (A4B4) 32kb 
b 
Difference between C1 and C2, the orientation of  IS431upstream of  mecA is reversed 
in C2 mec gene complex. 
 
 
To date, eight SCCmec (I – VIII; Fig. 1.4 and Table 1.3) elements have been 
identified according to the criteria in Table 1.3 (IWG-SCC, 2009). The sizes of SCCmec 
types I, II and III are 34kb, 53-58kb and 67kb respectively whereas type IV is 20-24kb 
and type V is 28kb. SCCmec types VI, VII and VIII are 20-25kb, 28-30kb and 32kb 
respectively (Ito et al., 2004; Rohrer et al., 2003; Oliveira et al., 2002; Plata et al., 
2009). Many antibiotic resistant genes and heavy metal resistance elements are encoded 
by SCCmec types II, III and VIII. These include integrated plasmids (pUB110 and 
pT181) and transposons (Tn554 and IS431). In contrast, types I, IV, V, VI and VII do 
not contain antibiotic resistant genes other than mecA (Grundmann et al, 2006; de 
Lencaster et al, 2007; IWG-SCC, 2009; Plata et al, 2009). 
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Figure 1.4:  Different types of SCCmec verified in MRSA (IWG-SCC, 2009). 
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1.3.4 Epidemiology of MRSA in hospital      
 
    MRSA has become a major nosocomial pathogen and its prevalence continues to 
increase worldwide. MRSA infections usually result in an increase in morbidity and 
mortality rates among hospital patients. According to the National Nosocomial 
Infections Surveillance (NNIS), approximately 80,000 patients per year suffer from 
MRSA infections (Aires de Sousa and de Lencastre, 2004). In addition, hospital-
acquired HA-MRSA strains are generally described as multi-drug resistant (MDR) 
MRSA because of their resistance to many classes of antibiotics such as β-lactam, 
chloramphenicol, erythromycin, streptomycin and tetracycline antibiotics. As a result, 
MRSA infections are difficult and costly to treat. Previous studies have revealed that the 
mortality rate associated with MRSA bacteraemia is higher than that associated with 
MSSA bacteraemia (Cosgrove et al., 2003).    
According to NNIS, between 1998 and 2002 in the USA, about 51.3% of S. aureus 
isolates from the patients in intensive care units (ICUs) were methicillin-resistant 
(NNIS, 2002). The prevalence of MRSA has shown variations between European 
countries. The European antimicrobial surveillance system (EARSS) has reported that 
the proportion of MRSA isolated from blood between 1999 and 2002 was 41-45% in 
the UK (Fig.1.5), Greece, Ireland, Malta and Italy, but less than 1% in Iceland, 
Denmark, Netherlands and Sweden. This disparity was not only observed between 
countries but also sometimes between hospitals within same country (Tiemersma et al., 
2004; Johnson et al., 2005). 
 
   Figure 1.5: The proportion of isolates of Staphylococcus aureus from blood culture that are 
methicillin resistant, England and Wales (Johnson et al., 2005). 
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The most common MRSA nosocomial infections are skin and soft tissue 
infections, bloodstream infections, bone and joint infections, endovascular infections, 
osteomyelitis and meningitis. These infections vary from unit to unit. For example, 
MRSA nosocomial bloodstream and pneumonia infections are most common in ICUs 
(Chang et al., 1997; Cunha, 2005).  
1.3.4a Risk factors associated with nosocomial MRSA              
A good knowledge of the epidemiological characteristics of MRSA is the 
cornerstone of establishing an effective infection control strategy. There are many risk 
factors associated with the emergence of MRSA nosocomial infections. Most of which 
can be attributed to host factors, antibiotic pressure and infection control procedures. 
Those risk factors are older age, male gender, previous hospitalization and exposure to 
antibiotics, length of hospitalization, length of stay in ICU, and underlying disease. In 
addition, pneumonia infections are associated with ventilator therapy, and 
immunosuppressive therapy in ICUs. Invasive devices play role in increasing 
vulnerability to nosocomial infection. Intravascular (IV) catheters are, for example, the 
main risk factor for MRSA bloodstream infection in ICUs (Washio et al., 1997; 
Graffunder and Venezia, 2002). There are other factors that are linked to spread of 
MRSA in hospitals: transferring of patients within or between hospitals, poor 
communication between hospital units, difficulties in isolation MRSA patients and new 
epidemic MRSA strains (Vuopio-Varkila, 2007)  
Those factors contribute not only to therapeutic failure and morbidity but also to 
increased mortality of MRSA among hospitalized patients. According to UK 
Government statistics, the number of deaths due to MRSA has increased dramatically 
from 51 in 1993 to 1,230 in 2008, although, there has been a noticeable decrease in 
MRSA deaths in 2008, compared with 2005, 2006 and 2007 (Fig. 1.6). It is noteworthy 
that colonized and infected patients and healthcare workers are the main reservoir for 
MRSA in hospitals. Moreover, the main road for transmission of MRSA is through the 
hands of health care workers (HCWs) in hospitals (Haddadin et al., 2002). 
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Figure 1.6: Number of death certificates mentioning methicillin resistant Staphylococcus 
aureus in England and Wales (UK Government statistics). 
1.3.5   Epidemiology of MRSA in the community   
             Although MRSA is mainly associated with nosocomial infections, it is 
becoming an increasing problem in the community. In the 1993, community-acquired 
MRSA (CA-MRSA) was first reported in the Western Australia and by end of 1999, 
four deaths were reported among children due to CA-MRSA infections in USA (Aires 
de Sousa and de Lencastre, 2004). CA-MRSA strains differ from nosocomial strains in 
a number of respects. Firstly, CA-MRSA strains are sensitive to non-β-lactams 
antibiotics, for example clindamycin, trimethoprim/sulfamethoxazole and doxycycline. 
Secondly, these strains have genotypes that are distinct from those of nosocomial 
strains. Finally, they have different methicillin-resistance cassettes and often encode 
PVL (Grundmann et al., 2006; Boyle-Vavra and Daum, 2007).  
 There is no standard definition for CA-MRSA and approximately eight 
classification systems have been applied to categorize community-acquired infections 
(Aires de Sousa and de Lencastre, 2004). The CDC defines CA-MRSA as an infection 
with MRSA that lacks the risk factors of HA-MRSA including: the isolation of MRSA 
more than 48 hours after admission, hospitalization history, recent surgery, previous 
isolation of MRSA and presence of an indwelling catheter or a percutaneous device at 
the time of culture (Fridkin et al., 2005; Brasel and Weigelt, 2008). Most common CA-
MRSA infections are bacteraemias, skin and soft tissue infections, septic arthritis, toxic 
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shock syndrome, necrotizing fasciitis and necrotizing pneumonia (Grundmann et al., 
2006). CA-MRSA is also associated with the production of PVL that is encoded by 
phage-mediated lukS-PV and lukF-PV genes. The production of this toxin is associated 
with severe skin and soft tissue infections (Boyle-Vavra and Daum, 2007). The CA-
MRSA infections have been documented among homeless people, homosexuals, 
military recruits, competitive athletes, residents of community-based health-care 
institutions and children in day-care centres (Grundmann et al., 2006). There are several 
risk factors attributed to the acquisition of CA-MRSA such overcrowding, high rates of 
skin infections, frequent use of broad-spectrum antibiotics and close contact with a 
person with these risk factors. It is assumed that health-care institutions are the most 
likely source for CA-MRSA strains since some similarities have been found between 
sporadic nosocomial-MRSA and CA-MRSA infections (Aires de Sousa and de 
Lencastre, 2004).  
1.3.6 Treatment and control of MRSA 
   MRSA strains are resistant to most β-lactam antibiotics and several other 
antimicrobial agents including aminoglycosides, clindamycin, chloramphenicol 
fluoroquinolones and macrolides (Schmitz and Jones, 1997). The glycopeptides have 
emerged as the most effective agents against MRSA. However, the emergence of 
MRSA strains with low sensitivity to vancomycin (VISA), first reported in 1996 and 
thereafter VRSA in 2002, has led to an increasing concern about the use of vancomycin 
as the first choice for the treatment of MRSA infections (Cui and Hiramatsu, 2003).  
The treatment of MRSA infections depends on the site of infection. In some 
cases, such as infected devices and abscess, the remove of these devices and draining of 
abscess are more important than antimicrobial therapy (Cunha, 2005). Recently, new 
guidelines for the prophylaxis and treatment of MRSA infections in the UK have been 
published. These guidelines recommend the use of glycopepides or linezolid as a first 
choice to treat MRSA pneumonia and severe skin and soft tissue infections where the 
risk of bacteraemia is high (Gemmell et al., 2006). Linezolid is recommended for 
treatment of pneumonia since has showed an excellent penetration into lungs (Conte et 
al., 2002). The same choice of glycopepides or linezolid is recommended but with 
longer treatment for uncomplicated bacteraemia. In bone and joint infections 
glycopepides can be used particularly with multiresistant MRSA and/or in combination 
with rifampicin or fusidic acid. Glycopeptide prophylaxis is recommended for patients 
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who require surgery and have a history with MRSA colonisation (Gemmell et al., 
2006). These recommendations take in their account not only the efficacy of the 
antibiotics but also their toxicity, selection of resistant bacteria and cost (Ben-David and 
Rubinstein, 2003) 
   In the UK, the control of MRSA has been given a high priority among health-
care professionals (Haddadin et al., 2002). Although there is, as yet, no consensus 
approach for the control the MRSA infections, three strategies have been proposed for 
this purpose. The “Scutari strategy” is based on the application of basic cleanliness and 
protective procedures. This strategy is also applicable to nursing homes and small 
hospitals. The “Search and Destroy” strategy is applicable to hospitals that do not have 
a major problem with MRSA but have recently experienced epidemic outbreaks. This 
strategy is based on isolation of all infected and colonized patients and associated 
attempts to eradicate MRSA from the environment. The “SALT strategy” 
(Staphylococcus aureus Limitation Technique) is only applicable for non-containable 
infections, and when resources are limited. This method is appropriate for epidemic 
situations in which the incidence of infection is low (Spicer, 1984; Frank, 2003)  
 The majority of studies have reported that the screening of infected and colonised 
patients, the early detection of MRSA, improved hand hygiene and the prudent use of 
antibiotics, are effective control methods for the MRSA infections (Frank, 2003; Hardy 
et al., 2004; Grundmann et al., 2006; Wang and Barrett, 2007). Furthermore, the most 
important step in controlling MRSA outbreaks is the typing of strains to distinguish 
between epidemic and sporadic strains (Frank, 2003) (see Section 1.4). 
1.4 The typing of MRSA 
The ability to type isolates of MRSA is an important tool for understanding the 
epidemiology of MRSA and for developing effective control measures. In the last ten 
years, a variety of typing methodologies have been developed for use in both clinical 
and epidemiological studies (Wilailuckana et al., 2006). In recent years traditional 
typing methods have been augmented with a range of molecular typing methods. These 
include pulsed-field gel electrophoresis (PFGE), plasmid fingerprinting (PF), arbitrarily 
primed polymerase chain reaction (AP-PCR), multiple locus variable number tandem 
repeat (VNTR) analysis (MLVA) and multilocus sequence typing (MLST). For any 
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typing method to be valuable it should have high discriminatory power, be reproducible, 
inexpensive, and easy to use and interpret (Tenover et al., 1997; Weller, 2000; Sabat et 
al., 2003).  
1.4.1 Mechanism of genetic variability of bacterial genome  
The concept behind all microbiological typing methods is that epidemiological 
related strains are descended from a single ancestor. Consequently, the descendents 
share the similar, but not necessarily identical epidemiological characteristics that are 
distinct from those of unrelated strains. Consequently, the analysis of such 
characteristics can be useful for the study of population structures and the evolution of 
bacterial species. The stability of such characteristics within a strain and the general 
diversity of species are vital factors for epidemiological typing (van Leeuwen, 2003).  
The genetic diversity among strains is attributed to several types of mutational 
process including the accumulation of spontaneous or induced point mutations, genetic 
recombination and the acquisition or loss of mobile genetics elements. The latter 
elements, which can confer virulence factors and antibiotic resistance determents, 
include plasmids, bacteriophages and gene islands (Fitzgerald et al., 2001; van 
Leeuwen, 2003). Mutations are caused by three processes: mutagenic agents, including 
environmental factors (e.g. chemicals, radiation and ultraviolet light (UV)), mistakes or 
errors that occur spontaneously during DNA replication without exposure to any 
mutagenic agent and the activity of mobile genetic elements. The UV, for example, can 
form thymine dimers (TT) on the same strand of the DNA. The thymine dimers cannot 
act as a template for DNA polymerases and such dimerization therefore can be lethal by 
preventing of the appropriate functioning of polymerases. Some chemical mutagens 
such as hydroxylamine (NH2OH) can modify cytosine to uracil that pairs with adenine 
instead of guanine while acridine (C13H9N) causes frame-shift mutations by base 
deletion or base addition mutations. The spontaneous mutations can be caused by DNA 
polymerases by mismatched base insertion or slippage errors during DNA replication 
resulting in changes in the base sequence (Atlas, 1997). Three types of replication errors 
have been characterised: (1) Single-base mispairs leading to a base substation, (2) 
single-base bulges leading to a single-base frameshift and (3) multiple-base mismatches 
leading to a sequence substitution. These changes during the DNA replication play 
significant role in bacterial evolution and therefore in bacterial genetic diversities 
(Schumann, 2006).    
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Although, S. aureus clones arise more frequently (about 15-fold) by point 
mutation than by recombination, Robinson and Enright (2004) suggested that large 
chromosomal replacements could influence the long-term evolution of this species (Feil 
et al., 2003; Robinson and Enright, 2004). The SCCmec cassette, for example, is a large 
group of mobile genetic elements whose diversity is the result of extensive 
recombination. The SCCmec contains the mec gene (methicillin-resistance gene) and 
other mobile genetic elements (e.g. transposons, plasmids and insertion sequences). 
SCCmec is horizontally transferred within Staphylococcus species, playing an important 
role in microbial evolution by promoting the genetic diversity (van Leeuwen, 2003).   
Typing methods vary in their ability to monitor and define genetic changes, not 
only between species, but also between strains within a single species. This is reflected 
in differences in the resolving power of the various typing methods. For example, 
MLST is less discriminatory than PFGE for the analysis of S. aureus in hospital 
outbreaks, reflecting the fact that the the evolution of diversity over short time periods is 
more likely to be due the the positive selection pressure for virulence or antibiotic 
resistance genes based on mobile genetics elements genes, than for spontaneous 
mutations in housekeeping genes (Singh et al., 2006; See Section 1.4.3b.iii and 1.4.3d.i 
1.4.2 Phenotyping methods 
Phenotyping methods are used to characterize the products of gene expression in 
order to identify a species or to discriminate between strains. Examples of phenotyping 
methods include biochemical profiles, antibiogramme profiles, bacteriophages 
susceptibilities (phage typing), the presence of surface antigens and protein analysis. 
However, there are limitations in using these methods extensively for typing MRSA 
strains because they are influenced by growth conditions and epigenetic modifications 
(Tenover et al., 1997; van Leeuwen, 2003)       
1.4.2a Phage typing  
S. aureus strains (including MSSA and MRSA) can be differentiated by their 
susceptibility or resistance to lysis by bacteriophages (Wentworth, 1963; van Leeuwen, 
2003). The concept of using bacteriophages for typing bacteria was developed in the 
1940s. For decades, this technique was used as one of the principal typing method for 
differentiating among strains of staphylococci. Phage typing was standardized by the 
International Subcommittee for Typing Staphylococci. Currently, 25 standard phages 
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are used for typing the staphylococcal strains and they have some value for 
investigating MRSA isolates since they have greater discriminatory power than other 
phenotyping methods such as capsular typing and zymotyping. The standard phages are 
used at a routine test dilution (RTD) but strains that show no lysis at RTD are 
subsequently tested at RTD × 100 (Weller, 2000; de Gialluly et al., 2003).   
Although a widely used method, phage typing has important limitations. Many 
isolates are non-typeable by this technique (e.g. 20-30% of MRSA strains, in some 
instances this reaches 75%), its reproducibility is low and the sets of virus stock need to 
be maintained effectively. Phage typing is also affected by the presence of modification 
systems, a form of epigenetic change on the chromosomal DNA that can impact on the 
stability of incoming phage DNA. Consequently, phage typing has been replaced with 
molecular typing methods in many reference laboratories (Khalifa et al., 1989; Weller, 
2000; van Leeuwen, 2003). 
1.4.2b Serotyping          
 Serotyping is the oldest phenotyping method. However, despite its value for 
other bacterial genera, serotyping has not been used extensively for typing of S. aureus 
strains. Serotyping is mainly aimed at revealing diversity among capsular 
polysaccharides and the antigenic properties of enzymes such as coagulase. There are 
about 11 types of S. aureus capsules, although between 85-90% of clinical S. aureus 
isolates belongs to just two types, serotype 5 and serotype 8. The poor discriminatory 
power of the serotyping technique makes it of limited value for epidemiological studies, 
and has generally been replaced by phage typing (Weller, 2000; Witte et al., 2006). 
1.4.2c Antimicrobial susceptibility patterns 
The susceptibility of a bacterium to different antibiotics can be used to compare 
and differentiate MRSA strains. The major advantage of this technique is its cheapness 
and its ability to be used routinely in many clinical laboratories. However, antimicrobial 
susceptibility patterns (antibiogrammes) have low discriminatory power and 
reproducibility and are affected by environmental factors. Moreover, the acquisition or 
loss of resistance plasmids means that unrelated strains can give similar antibiogrammes 
while genetically related strains can gave very different antibiogrammes (Tenover et al., 
1997; Weller, 2000). In the case of MRSA, antimicrobial susceptibility patterns are not 
reliable as a distinctive typing technique although the antibiogramme of an epidemic or 
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endemic clone can be useful for monitoring and treatment purposes (Weller, 2000; van 
Leeuwen, 2003). 
1.4.2d Multilocus enzyme electrophoresis (MLEE)                
 MLEE involves the extraction and analysis of key enzymes from bacterial cells 
by gel electrophoresis. MLEE has been used to type many bacterial species, including S. 
aureus. When MRSA isolates were examined by MLEE it was found to show good 
reproducibility but was only moderately discriminatory (Weller, 2000). About 12 to 20 
enzymes are used, although the discriminatory power of the individual enzymes has not 
been fully assessed. Although MLEE correctly classified related isolates among 
outbreak strains, some unrelated isolates were incorrectly included. MLEE has the 
advantage that it is relatively easy to interpret the generated data, but is time-consuming 
and consequently is not recommended for use in clinical laboratories (Goh et al., 1992; 
Weller, 2000; Tenover et al., 1994). Nevertheless, MLEE can be useful for studying the 
diversity of bacterial populations, for example clonal relatedness and diversity among 
MRSA strains (Witte et al., 2006). 
1.4.3 Genotyping methods 
A variety of typing methods have been developed for the molecular typing of S. 
aureus. For a typing method to be effective it should be inexpensive, have high 
discriminatory power, good reproducibility, and be easy to perform and interpret. In the 
last decade, several molecular techniques have been developed for the typing of 
bacterial strains, including arbitrarily primed polymerase chain reaction (AP-PCR), 
pulsed-field gel electrophoresis (PFGE), plasmid fingerprinting (PF), variable number 
tandem repeat analysis (VNTR) typing, multiple-locus variable-number tandem repeat 
analysis (MLVA), multilocus sequence typing (MLST) and, in the case of MRSA, 
SCCmec typing. These techniques have been used primarily in reference laboratories 
but, with passage of time, are being used in an increasing number of clinical laboratories 
(Sabat et al., 2003; Trindade et al., 2003). Molecular methods have been increasingly 
applied to the epidemiology of nosocomial pathogens such as MRSA (van Leeuwen, 
2003). The aim of any strategy for controlling the incidence of MRSA is to develop a 
thorough knowledge of its epidemiology and molecular typing techniques are ideally 
suited for this purpose because they are not phenotype-dependent (Deurenberg et al., 
2007).     
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1.4.3a  First phase molecular typing (plasmid analysis) 
 Analysis of the plasmid content of staphylococcal strains was introduced in the 
mid-70s (van Leeuwen, 2003). It was the first molecular typing technique to be used to 
investigate the epidemiology of MRSA. Plasmid analysis is based on the extraction of 
plasmids DNA from the bacterial cells and the subsequent determination of their 
number and sizes by gel electrophoresis. This method is easy to perform and its results 
simple to interpreted (Weller, 2000). However, there are limitations to its application for 
epidemiological studies since, as mobile extra-chromosomal DNA elements, plasmids 
can be lost or acquired at a relatively high frequency (Witte et al., 2006). Moreover, in 
the case of S. aureus, the discriminatory power of plasmid analysis is poor (Weller, 
2000; Trindade et al., 2003). 
The discriminatory power and reproducibility of plasmid analysis was improved 
by incorporating a restriction digestion step. This approach can be particularly useful for 
distinguishing plasmids that are genetically distinct despite having similar molecular 
masses. Despite some studies reporting that restriction endonuclease analysis of plasmid 
DNA (REAP) has more discriminatory power than PFGE, other studies have described 
this method as ineffective. A major problem is the lack of stability and reproducibility 
(Weller, 2000; Ttraindade et al., 2003; van Leeuwen, 2003). 
1.4.3b Second-phase molecular typing  
1.4.3b.i Restriction enzyme analysis (REA) 
Restriction endonucleases can digest chromosomal DNA into a large number of 
fragments (5-15 kb) that can be separated by conventional gel electrophoresis. 
Examples of the restriction endonucleases that have been used to analyse the 
chromosomal DNA of MRSA strains include PstI, EcoRI and BglII (Jordens and Hall, 
1988; Trindade et al., 2003). The patterns can be interpreted by comparing the banding 
patterns from different isolates. Despite the fact that all strains of MRSA are potentially 
typeable by REA, the resulting large number of fragments produced can be difficult to 
interpret. The main problem is that fragments larger than 20kb will not be separated by 
conventional gel electrophoresis (Trindade et al., 2003).     
     
Chapter 1: Literature Review                                                                                          28 
1.4.3b.ii Restriction fragment length polymorphism (RFLP) analysis using DNA 
probes (Southern hybridization). 
In the mid-70s Southern hybridization became available for epidemiological 
studies (van Leeuwen, 2003). This method is based on the digestion of the chromosomal 
DNA using restriction endonucleases and the separation of the DNA fragments by gel 
electrophoresis. The bands are then transferred to a nylon membrane and hybridized 
with labelled probes that bind only to specific fragments. The resulting simplified 
banding pattern (Fig. 1.7) facilitates the differentiation bacterial strains (Weller, 2000; 
Trindade et al., 2003). A modified approach is ribotyping, which is based on the 
presence of one or more of rRNA operons on the chromosomes of all bacterial isolates. 
Ribotyping uses a labelled rRNA probe to reveal the restriction fragment pattern of 
DNA encoding rRNA operons. Although this technique is reproducible, its use for 
epidemiological studies declined when it was shown to have only moderate 
discriminatory power (Trindade et al., 2003; Tenover et al., 1997). Despite this 
limitation, this technique remains useful for preliminary screening of large numbers of 
isolates (Trindade et al., 2003).   
   
Figure 1.7: Southern hybridisation. The image on the left indicates the very large number of 
DNA fragments produced by restriction endonuclease. DNA fragments are blotted 
and the hybridized with specific nucleic probes. In the left hand image, tracks A, B 
and C represent independent organisms, A and B are of the same type whereas C is 
a different type (Tenover et al., 1997). 
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1.4.3b. iii Pulsed-field gel electrophoresis (PFGE) 
Bacterial chromosomes are generally between 2000-5000kb in length. The 
resulting patterns of digestion of the chromosomes can most easily be interpreted when 
using restriction endonucleases which generate a relatively few number of large 
fragments i.e. 10-30 fragments of between 10-800kb in length. While small DNA 
fragments can be separated by conventional electrophoresis this technique shows poor 
discriminatory power for large fragments (Weller, 2000). PFGE was introduced in 1984 
by Schwarz and Cantor (1984), who used it to resolve large DNA fragments from 
eukaryotic organisms. This technique was subsequently adapted for use as a high 
resolution molecular typing system to study different bacterial species.  
In conventional electrophoresis the DNA fragments migrate in a straight line 
from the cathode to the anode. Because large molecules adopt a hairpin-like 
configuration, increasing the size of a fragment has little influence on its mobility. In 
contrast, the PFGE apparatus consists of sets of electrodes through which the charge can 
be directed in a short time pulses to force the DNA molecules to re-orientate through the 
gel. Consequently, larger DNA fragments now migrate according to their size (Fig. 1.8) 
and individual fragments become clearly distinguishable (Trindade et al., 2003; 
Tenover et al., 1997; Weller, 2000).  
The PFGE patterns of isolates are derived from genetic events that either change 
the sizes of the fragments between the restriction sites or result in the loss or gain of a 
restriction site. For example, a single genetic event such as a point mutation, or the 
insertion or deletion of DNA, and which leads to the loss or gain of restriction site, can 
result in difference to one to three restriction fragment while two genetic events can lead 
to differences in two to five restriction fragments (Stepan et al., 2004; Singh et al., 
2006). Therefore, PFGE is highly discriminatory for indentifying the relatedness of 
isolates from short time studies (e.g. outbreak within a hospital), but it is not suitable for 
long-term studies of global epidemiology, which require highly discriminatory 
technique that are able to monitor genetic changes that accumulates slowly (Enright et 
al., 2002). 
In theory, all bacterial species are typeable using PFGE despite difficulties in 
extracting their DNA (e.g. C. difficile) (Tenover et al., 1997). Extra precautions are 
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needed during the extraction of the chromosomal DNA to ensure that it remains largely 
intact. Consequently the bacterial cells are embedded in low-melting point agarose 
during the DNA extraction steps in order to avoid the risk of mechanical breakage 
(Trindade et al., 2003). Many studies have been performed to establish a standardised 
PFGE protocol. These studies have achieved success with regard to speed, 
reproducibility and the cost (Murchan et al., 2003).  
PFGE has been used for the study of MRSA and has been compared extensively 
with other methods. A range of restriction endonucleases has been tested but none have 
shown better results than SmaI (Trindade et al., 2003; Weller, 2000). In a comparative 
study between PFGE and PCR-based methods, Stranden et al. (2003) reported that 
while PCR-based methods could not replace PFGE they could complement them. PFGE 
is therefore considered the gold standard for the typing of MRSA since it exhibits high 
discriminatory power and reproducibility. There are, however, some disadvantages that 
have impeded the wider use of PFGE: procedures are time-consuming and results are 
not available for several days. PFGE is also relatively costly. Despite these 
disadvantages, PFGE has been used extensively to investigate outbreaks of pathogens 
(Weller, 2000) 
 
 
Figure 1.8:  PFGE technique. DNA is digested with an infrequent cutting restriction enzyme 
and the resulting large fragment separated by PFGE. The image on the right 
shows a PFGE gel of strains showing different chromosomal DNA fragment 
profiles (Tenover et al., 1997).      
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1.4.3c Third-phase molecular typing: PCR- based technique 
The time-consuming and expensive nature of PFGE has necessitated the 
development of a variety of rapid and less expensive typing method. PCR was 
developed in the mid-80s and become one of the most important biological discoveries 
in the twentieth century. The PCR technique is based on the amplification of a specific 
region the target DNA (Weller, 2000; van Leeuwen, 2003).  
The technique depends on cyclical repetition of three main steps: (i) the 
denaturation phase which take place at temperatures around 95˚C; (ii) the annealing 
phase in which the primer pairs bind to specific regions in the resulting ssDNA - a 
temperature of between 50˚C and 65˚C is used, as determined by the composition of the 
primers; (iii) the temperature is raised to ~70˚C for DNA synthesis. The Taq polymerase 
requires the presence of dNTPs and Mg
2+
. In order to amplify the DNA template 
sufficiently for detection by ethidium bromide staining, 20 – 40 cycles are required: 30 
cycles generated about 1 billion copies of the target which is optimal for the 
thermostable DNA polymerases used in the PCR (Tenover et al., 1997; Trindade et al., 
2003; Harwood and Wipat, 2000).     
          PCR has been used for many years for the detection of pathogens in clinical 
samples but has more recently been adopted as a molecular typing tool. There are four 
main groups of PCR-based techniques that are used to differentiate among the bacterial 
isolates. They include arbitrarily primed PCR (AP-PCR), PCR-restriction fragment 
length polymorphism (PCR-RFLP), repetitive element sequence-based PCR (rep-PCR) 
and PCR-ribotyping. However, PCR-RFLP and PCR-ribotyping methods are no longer 
used for MRSA typing (Tenover et al., 1997; Trindade et al., 2003). 
1.4.3c.i  Arbitrarily primed PCR (AP-PCR) 
AP-PCR is also referred to as random amplified polymorphic DNA (RAPD). 
This technique was introduced by Williams et al. (1990) and by Welsh and McClelland 
(1990) for the analysis of chromosomal DNA using small randomly generated primers 
(about 10 bases). As a result one or more DNA sequences will be amplified and be 
separated by gel electrophoresis. The number and size of the resulting products are used 
for the typing of the isolates. AP-PCR is a rapid and relatively straightforward 
technique. It has a good reproducibility but its discriminatory power is variable, 
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depending on the number of primers used and the nucleotide sequence of the target 
DNA (Tenover et al., 1997; Trindade et al., 2003; Witte et al, 2006). Although, AP-
PCR has been successfully applied in the investigation of the outbreaks, its 
discriminatory power is not as good as that of PFGE. AP-PCR has been used for the 
typing of the MRSA strains and has shown the poor reproducibility. In addition, there is 
still not a standard guideline as to how to interpret the results of AP-PCR (Tenover et 
al., 1997; Weller, 2000).      
1.4.3c.ii  Binary typing (BT) methods  
The binary typing method is a DNA-based typing technique that is considered as 
alternative to MLST but depends on large genetic diversities in DNA content instead of 
allelic profiles. BT is a hybridization typing method that targets specific DNA 
sequences using a set of probes. The determination of a set of candidate probes is the 
most important step in the technique to ensure maximum discriminatory power 
(Srinivasan et al., 2007). In case of S. aureus, van Leeuwen and his co-workers have 
developed a binary typing method, based on 15 DNA probes that target random 
amplified polymorphic DNA (RAPD). In their study, binary typing was found to be a 
reproducible and its discriminatory was as similar to PFGE (van Leeuwen et al., 1996; 
van Leeuwen et al., 1999). However, the typeability of binary typing was lower than 
PFGE in the epidemiological study of Zadoks et al. (2002) on bovine and human S. 
aureus isolates. They also reported that, while binary typing can used in combination 
with PFGE, it could not yet replace it (Zadoks et al., 2002).   
1.4.3c.iii Repetitive element sequence-based PCR (rep-PCR) 
All bacterial chromosomes have repetitive elements sequences. These elements, 
which are scattered throughout the chromosome, have been elucidated in detailed 
studies involving repetitive palindromic (REP) sequences (van Leeuwen, 2003; Stepan 
et al., 2004). These sequences are conserved with most bacteria and can be targeted, via 
PCR, for epidemiological studies (Trindade et al., 2003). This technique has been used 
to differentiate between various bacterial species including S. aureus. For typing of 
MRSA, rep-PCR has been used with a variety of the target sequences, such as Rep 
MP3, InterIS256 and Tn916. Although, there are not repetitive intergenic consensus 
primers for typing S. aureus, one hundred and seventy MRSA strains were studied using 
primer RW3A, derived from the RepMP3 sequence of Mycoplasma (Del Vecchio et al., 
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1995). The results show stability with high reproducibility, even following frequent 
subculturing. Some intergenic repetitive regions in the coagulase (coa) and protein A 
(spa) genes have been proposed to improve the performance of this technique with S. 
aureus (Trindade et al., 2003; Witte et al., 2006). In general, Rep-PCR has good 
discriminatory power and its reproducibility is good compared with other methods such 
as RAPD and PFGE. However, the disadvantage of rep-PCR is that the DNA requires 
an additional purification step that increases the time taken to perform the procedure 
(van der Zee et al., 1999; Weller, 2000; Trindade et al., 2003). 
1.4.3c.iv  Multiple locus Variable Number Tandem repeat analysis (MLVA)  
The genome of S. aureus has several VNTR loci and the majority of those 
repeats are associated with cell surface-bound proteins MSCRAMMs. VNTRs are 
highly variable in both the number of repeat units and by heterogeneity of the sequences 
amongst those units (Moser et al., 2009). This variability in VNTRs might be due to 
slipped-strand mispairing (SSM) events that occur during DNA replication (van 
Belkum, 2008). This feature has been exploited to develop typing method for S. aureus. 
Initially, VNTR was based on single locus such as protein A (spa) typing. VNTR has 
been developed as a typing method, but lacks discriminatory power (Ikawaty et al., 
2008). The first MLVA for S. aureus typing was introduced by Sabat et al. (2003), 
targeting the sdr, ssp, clfA, clfB and spa loci using multiplex PCR. In this study, they 
reported that MLVA is a simple and reproducible method and its discriminatory power 
was comparable with other typing method including PFGE. However, the number of 
strains tested in this study was small (34 strains) and they concluded that MLVA may 
need further evaluation on large number of S. aureus strains. In a comparison study 
conducted by Malachowa and his co-workers, the discriminatory power of MVLA was 
lower but comparable with PFGE and they also suggested additional validation against 
PFGE (Malachowa et al., 2005). Francois et al. (2005) have developed an alternative 
version of MLVA which included the additional loci of finBP, cna and mecA. Although, 
MVLA was rapid and showed adequate reproducibility, it was not able to distinguish 
HA-MRSA lineages (USA100, 200 and 500) from CA-MRSA lineages (USA300, 400, 
1000 and 1100) (Tenover et al., 2007). Nevertheless, evaluation of MLVA has shown it 
to have high discriminatory power and adequate stability. It therefore appears to be very 
useful for the epidemiological investigation of S. aureus outbreaks. In addition, as a 
multiplex PCR-based typing method, MVLA is easy to perform and cost effective, 
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meaning that it is suitable for use in clinical laboratories (Malachowa et al., 2005; 
Luczak-Kadlubowska et al., 2008). Although, MVLA could distinguish between some 
strains with identical PFGE profiles, further analysis is needed to ensure that MVLA is 
suitable for epidemiological analyses (Moser et al., 2009).  
1.4.3c.v  PCR-restriction fragment length polymorphism (PCR-RFLP) 
The products of PCR can be digested at specific sites by restriction endonucleases 
then separated using gel electrophoresis. The coagulase (coa) gene shows a high level of 
disparity when digested with AluI. The discriminatory power of this method is moderate 
but can be improved by increasing the number of restriction endonucleases. Its results 
are similar to that obtained for MLEE, so it is useful for studying populations of 
microorganisms (van Leeuwen, 2003). Many MRSA strains are typeable by this 
technique with reproducible results even after extensive subculturing. Nevertheless, 
unrelated MSSA strains can exhibit the same coagulase gene type. The reproducibility 
of this technique is low comparing with that of PFGE (Weller, 2000). Another target for 
PCR-RFLP is the protein A gene (spa) which can be divided into three fragments using 
RsaI (Frenay et al., 1994). This typing system has two major drawbacks; its 
reproducibility is low and the results cannot be compared directly with those obtained 
by other methods (Hoefnagels-Schuermans et al., 1997; Weller, 2000). However, 
Montesinos et al. (2002) have pointed out that typing techniques based on coa and spa 
genes can provide initial epidemiological information when investigating an outbreak.   
1.4.3d.iv  SCCmec typing  
 SCCmec elements carry the mecA gene that encodes the determinant of ß-lactam 
resistance. SCCmec elements are highly diverse in their structures and genetic 
composition and therefore have been classified into several types and subtypes. This 
technique can be carried out using either uniplex or multiplex PCRs. The classification 
of SCCmec elements by the uniplex PCR method is mainly based on combinations of 
primers to distinguish the allotypes of the ccr and mec gene complexes, as well as the J 
region (Ito et al., 2001; Okuma et al., 2002). This method has a number of limitations 
including its low discriminatory power and the number of individual PCR reactions 
required. Consequently, a multiplex PCR of SCCmec has been developed for a more 
discriminatory and rapid identification, using SCCmec components other than the mec 
and ccr gene complex. SCCmec multiplex PCR typing was introduced by Oliveira and 
Lencastre in 2002 when initially four SCCmec types (I-IV) were identified. In this 
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study, eight loci (A through H) within mec element sequences (as a control) were 
targeted on the basis of published SCCmec element sequences (Table 1.4) (Oliveira and 
Lencastre, 2002; Hanssen and Sollid, 2006). Ito and colleagues have developed an 
alternative multiplex PCR method which targeted mainly the mec and ccr gene complex 
(Table 1.4) (Ito et al., 2001). However, the Oliveira and Lencastre technique lacks 
resolution in the identification of SCCmec type IV variants and a novel SCCmec type V 
(5C) when it omitted the core components (the mec and ccr gene complex) of SCCmec 
(Milheirico et al., 2007). In addition, both methods characterized the SCCmec type in 
the same strain differently (Deurenberg et al., 2007). In order to utilize real-time PCR 
for SCCmec typing, Francois et al. developed an assay to distinguish SCCmec types I-
IV based on the mec and ccr gene complexes (Francois et al., 2004; Deurenberg et al., 
2007). The RT-PCR method is rapid but does not identify any SCCmec subtypes. 
Similarly, a multiplex PCR designed to identify SCCmec types I – V, introduced by 
Boye et al. (2007), was unable to discriminate SCCmec type IV variants.  
More recently, a new nomenclature for SCCmec types has been proposed by 
Chongtrakool et al. (2006) in an attempt to resolve the confusion in the field of SCCmec 
typing and to facilitate the identification and classification of new SCCmec types. This 
nomenclature was based on structural elements of SCCmec, particularly, the sequences 
of the mec gene complex (referred by letter) and ccr genes (referred by number) (e.g. 
SCCmec type 4B means it is defined as a class B mec complex and allotype 4 ccrAB).  
The application of this nomenclature is as follows: SCCmec type 1A (type I), type 2A 
(type II), type 3A (type III), type 2B (type IV) and type 5C (type V) (Chongtrakool et 
al., 2006; Oliveira et al., 2006). 
The International Working group on the Classification of Staphylococcal 
Cassette Chromosome Element (IWG-SCC) has redefined some SCCmec subtypes and 
classified SCCmec into eight types I-VIII with two subtypes of types IV and V (Fig 
1.4). This classification has been established according to the criteria in Table 1.3 
(IWG-SCC, 2009). SCCmec types I, II, III and VIII carry antibiotic resistant genes other 
than mecA and are commonly found in HA-MRSA whereas other types tend not to 
harbour additional antibiotic resistant determents and are most common in CA-MRSA 
(Grundmann et al., 2006; IWG-SSC, 2009).  
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It is worth noting that SCCmec typing is used in combination with MLST (ST) 
to study the epidemiology of MRSA clones. Nowadays, SCCmec typing is considered 
one of the most important epidemiological tools for typing MRSA strains. 
Table 1.4:  The major methods of SCCmec typing (adapted from Deurenberg et al.(2007) and 
IWG-SCC(2009)).  
 Method of Ito et al., Method of Oliveira 
et al., 
IWG-SCC 
SCCmec 
types 
mec gene 
complex 
ccr gene 
genes 
Loci mec gene 
complex 
ccr gene 
genes 
I B A1/B1 A, D B 1(A1B1) 
II A A2/B2 B, C, D A 2(A2B2) 
III A A3/B3 C, E, F A 3(A3B3) 
IV B A2/B2 D B 2(A2B2) 
V C
 
C E C2 5(C) 
VI - - - B 4(A4B4) 
VII - - - C1 5(C) 
VIII - - - A 4(A4B4) 
 
1.4.3d Forth-phase molecular typing:  Sequence typing  
1.4.3d.i Multilocus sequence typing (MLST) 
MLST is a relatively new approach to identifying and monitoring the spread of 
antibiotics resistant pathogens (Enright and Spratt, 1999). This technique, which is 
derived from multilocus enzyme electrophoresis (MLEE), was first introduced by 
Maiden et al. (1998) to resolve certain limitations of MLEE analysis. MLST is an 
excellent technique for investigating MRSA clonality. MLST is based on the analysis of 
seven ~500-bp sequences derived from housekeeping genes. The sequences represent 
distinct alleles and contain sufficient information to define the isolate using an online 
data search tool. The MLST website, http://www.mlst.net, contains information on 21 
bacterial species, including S. aureus. The distinct sequences of each locus are given 
allelic numbers, for example, a Iberian clone of MRSA has the MLST profile “3-3-1-
12-4-4-16” which categorises it as sequence type ST247. Recently the nomenclature 
system has been expanded to include the SCCmec type (e.g MRSA-I) and the Iberian 
clone is now categorised as (ST247-MRSA-I) (Robinson and Enright, 2004; 
Deurenberg et al., 2007). MLST can also be used to establish the evolutionary 
relationship of MRSA strains using the Electronic based upon related sequence types 
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(eBURST) program that groups closely related STs into co-called clonal complexes 
(CC).  
            The first application of MLST to S. aureus was published in 2000 by Enright et 
al. who analysed the target DNA sequences of 155 strains. The housekeeping genes 
used in this study were: carbamate kinase (arcC), shikimate dehydrogenase (aroE), 
glycerol kinase (glpF), gulanylate kinase (gmk), phosphate actyltransferase (pta), 
triosephoshate isomerise (tpi) and acetyl coenzyme A acetyltransferase (yqiL). In their 
study, Enright and colleagues clearly demonstrated the value of MLST with respect to 
the analysis of MRSA and MSSA, generating results that were comparable to PFGE 
(Enright et al., 2000). These seven housekeeping genes are thought to change slowly 
over time. They are also widely distributed around the genome, which decreases the 
impact of recent recombination events (Short and Enright, 2007). Therefore, MLST is a 
very useful technique for the study of evolutionary and population biology of bacterial 
pathogens but, is less discriminatory for the analysis of outbreaks (Cooper and Feil, 
2004). Indeed, MLST provides unambiguous information and is very useful for 
studying the population structures of MRSA (Enright et al., 2002). However, MLST 
technology is costly and requires specialist equipment. It is therefore not used 
extensively for routine epidemiological studies (Trindade et al., 2003).     
1.4.3d.ii Staphylococcal protein A (spa) sequence typing  
Protein A is an important virulence factor of S. aureus. It has five repeating 
analogous α-helical domains (A, B, C, D, and E) which involve in binding the Fc 
portion of immunoglobulin IgG. The gene encoding Protein A (spa) has a hypervariable 
region (polymorphic X region or short sequences repeats (SSR)) that consists of 24bp 
repeats (variations from 21bp and 27bp have been identified) and located upstream of 
the region encoding the cell wall attachment sequences. This high degree of repeats is 
attributed to duplications, deletions and, rarely, to point mutations. The sequence of 
these tandem repeats in the X region has been used as alternative typing method to those 
currently in use. The spa typing approach was first introduced in 1996 as a single-locus 
sequence typing method by Frenay and his colleagues. Its discriminatory power lies 
between MLST and PFGE and has the advantages of being rapid, easy to use and 
interpret and has an established database (Frenay et al., 1996; Shopsin et al., 1999; 
Moodley et al., 2006; Deurenberg et al., 2007). Another advantage is the existence of a 
freely available software package for interpreting the resulting sequences. Although, the 
Chapter 1: Literature Review                                                                                          38 
Ridom StaphType software (Ridom GmbH, Wurzburg, Germany) is commonly used to 
analyse the spa sequences, many laboratories use the central online spa server 
(http://www.spaserver.ridom.de). This database has contributed in the widespread use of 
spa typing. To date, the spa database includes about 6167 spa types that are composed 
of a combination of 355 repeats from 108309 strains. Harmsen et al. (2003) and Koreen 
et al. (2004) have both introduced spa nomenclature systems. However, differences 
between these nomenclatures make comparisons between published spa data difficult 
(Deurenberg et al., 2007). Although, spa typing has many advantages and is widely 
used as a single-locus typing technique, it is susceptible to chromosomal replacements 
that can falsely cluster genetically unrelated strains. Moreover, the cost of sequencing is 
still considered as a limitation of using spa typing extensively in routine clinical 
laboratories (Karynski et al., 2008).      
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1.5. The study aims 
This study focuses on the evaluation of existing molecular epidemiological tools 
to determine limitations that hinder their use as routine tools for studying the 
epidemiology of MRSA isolates in hospitals laboratories.  
Ultimately, this study aimed to develop a novel tool to monitor the spread of 
MRSA that has the same or similar discriminatory power as PFGE but which can be 
performed in a few hours in a routine clinical laboratory.  
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 2 
General Methods and Materials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: General Methods and Materials                                                                           40 
2. General Methods and Materials 
2.1 Chemicals and reagents 
The chemicals and reagents that were used in this study are listed in Appendix A 
with their suppliers. 
2.2 Preparation of buffers, media and solutions 
  Growth media, buffers and solutions are described in detail in Appendix A 
2.3 Growth, storage of strains 
2.3.1 Sources of standard staphylococci strains  
The standard S. aureus strains and two S. epidermidis strains used in these 
studies were obtained from a variety of sources. The strains and their sources are listed 
in Table 2.1.  
Table 2.1: Reference staphylococcal strains which were used in this study. 
Strain Description  Source  
NCTC8325                                Laboratory strain                   NCTC 
EMRSA-15(HO50960412)      UK Epidemic MRSA-15 Prof. Mark Enright 
JH9                                            HA-VISA, USA                     Prof. Herminia de Lencastre 
USA300-FPR3757 CA-MRSA NARSA 
Mu50                                         HA-VISA, Japan                    NARSA 
Mu3 HA-VISA, Japan                    NARSA 
N315 HA-MRSA, Japan                    NARSA 
MRSA252                                 Typical UK EMRSA-16 NARSA 
MSSA476                                  CA-MSSA, UK                      NARSA 
COL Early MRSA, UK                   NARSA 
MW2 Typical USA CA-MRSA         NARSA 
USA1000 CA-MRSA, USA                     NARSA 
USA1100 CA-MRSA, USA                     NARSA 
CA-629 CA-MRSA, USA                     NARSA 
S. epidermidis RP62A               CNS NARSA 
S. epidermidis ATCC12228                 CNS Prof. Jan Maarten van Dijl 
NCTC6571 MSSA Dr. John Perry 
MRSA (585296) PVL + PVL positive Dr. John Perry 
MRSA (602025) PVL- PVL negative  Dr. John Perry 
NARSA=Network on antimicrobial resistance in Staphylococcus aureus. CNS= Coagulase 
negative staphylococci. 
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2.3.2 Sources of clinical MRSA isolates  
           Newcastle upon Tyne Hospitals NHS Foundation Trust‟s Freeman Hospital is 
one of the largest NHS hospitals in the north-east of England. It has 699 inpatient beds. 
In addition to its own clinical samples, it receives clinical samples from General 
Practitioners (GPs) and from other hospitals in the Trust. It has research laboratories in 
addition to clinical laboratories. 
   2.3.3 Storage of MRSA isolates 
Growth of clinical and screening samples for identification was as follows: 
samples were cultured on selective media followed by routine clinical identification. 
Confirmed MRSA strains were grown on fresh blood agar and strains were transferred 
to 20% of glycerol and maintained at -80 ºC for long-term storage. Each MRSA strain 
was allocated a unique identifier (e.g. FMRSA1 refers to the first MRSA received from 
the Freeman hospital; see Section 2.4). Standard strains were received on agar slopes 
and were subcultured on BHI agar followed by BHI broth culture and maintained in 
20% glycerol at -80˚C till required.  
2.3.4 Isolates data  
A total of 406 MRSA isolates were collected from the Freeman Hospital during 
the period from 23
rd
 of October 2006 to 25
th
 November 2006. These isolates were 
isolated from both clinical and screening samples. Clinical information about the 
isolates was recorded in a database – patients were coded to facilitate cross-reference 
between samples, but no patient names were supplied.   
2.4 Identification of MRSA isolates using principle approaches   
The clinical samples were cultured on ATM blood agar or nalidixic acid blood 
agar, while screening samples were cultured on MRSA ID medium. All plates were 
incubated at 37˚C for 48h with the exception of nalidixic acid blood agar that was 
incubated anaerobically for 48h.  
          Green colonies on MRSA ID (Fig. 2.2) were considered to be diagnostic for 
MRSA and were confirmed by Slidex Staph Plus (SSP) latex reagent (bioMerieux UK). 
Colonies on blood agar that resembled staphylococci (Fig. 2.1) were also examined with 
the SSP latex test. Finally, the results were confirmed by an antibiotic susceptibility test 
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(Perry et al., 2003). The MRSA isolates were subcultured on blood agar in order to 
obtain fresh pure cultures. All isolates were maintained as in Section 2.3.3 until 
required.  
    
                         Figure 2.1:  Colonies of a clinical S. aureus isolate on blood agar. 
2.4.1 MRSA ID medium  
MRSA ID (bioMerieux, La Balme Les Grottes, France) is a new chromogenic 
agar medium that has been developed to select and identify MRSA isolates. This 
medium contains a chromogenic enzyme substrate and cefoxitin. It is highly selective 
against non-staphylococci such as enterococci. MRSA isolates grow on this medium 
with green colonies due to their production of -glucosidase (Fig. 2.2). MRSA ID has 
been evaluated by Perry and colleagues and shown to perform better than other 
chromogenic agar media (Perry et al., 2004). 
 
                        Figure 2.2:   MRSA growing with green colonies on MRSA ID medium. 
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2.4.2 Slidex Staph Plus (SSP) latex reagent 
The Slidex Staph Plus (SSP; bioMerieux, La Balme Les Grottes, France) test is 
based on the detection of the S. aureus-specific clumping factor, Protein A. A single 
colony of the test isolate was mixed with a drop of latex reagent on slide. The test is 
positive if agglutination is observed (Fig. 2.3).                                                        
 
                             Figure 2.3: Slidex Staph Plus (SSP) latex agglutination test. 
 
2.4.3 Disc diffusion antibiotic susceptibility test  
          A single colony of the test isolate was mixed thoroughly with 2ml sterile water 
and the suspension adjusted to 0.5 against a McFarland standard. 200µl of suspension 
were transferred to 2ml sterile water and the suspension spread on Columbia medium 
using a sterile cotton-wool swab. Antibiotic discs were placed on the dried inoculated 
plate that was incubated at 35-37ºC for 18-20h. MRSA isolates should be resistant to 
cefoxitin with an inhibition zone of diameter ≤21mm (Andrews et al., 2007).     
2.5 Molecular diagnostic methods 
2.5.1 Bacterial growth  
Bacterial isolates stored at -80˚C were thawed and 20µl cultured on brain-heart 
infusion (BHI) agar or nutrient agar (Appendix A) overnight at 37˚C.  The following 
day a single colony was suspended in 10ml BHI broth and incubated overnight at 37˚C, 
with shaking at 200 rpm.     
2.5.2 Extraction of chromosomal DNA from MRSA  
 2.5.2a  Extraction of the DNA by lysostaphin treatment using the DNeasy kit 
(QIAGEN). 
Six millilitres of overnight culture was transferred to four 1.5ml microcentrifuge 
tubes and centrifuged for 3 min at 13000g. The supernatants were discarded and the 
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pellets resuspended in 180µl lysis buffer (Appendix A) lacking lysozyme but with 10µl 
lysostaphin [1mg/ml]. The suspension was incubated at 37ºC for 30 min and then 25µl 
of proteinase K and 200 µl AL buffer were added and the mixture incubated at 56ºC for 
30 min. 200 µl of ethanol (100%) was added and mixed thoroughly. The mixture was 
transferred into a DNeasy Mini spin column placed in a 2ml collection tube and 
centrifuged for 1 min at 8000g. The collection tube with flow-through was removed and 
replaced with a new collection tube. 500 µl of AW1buffer was added and the tube 
centrifuged for 1 min at 8000g and the flow-through discarded. 500 µl of AW2 buffer 
was added and centrifuged for 2 min at 13,000g and the flow-through again discarded. 
Finally, the DNeasy Mini spin column was placed in a 1.5ml microcentrifuge tube and 
200µl of AE buffer was added onto DNeasy membrane, incubated 1 min at room 
temperature and centrifuged for 1 min at 8,000g. This step was repeated in a new 1.5ml 
microcentrifuge tube and the DNA stored at -20ºC.  
2.5.2b Extraction of the chromosomal DNA by cell mechanical breakage using a 
DNeasy kit (QIAGEN) 
           Six millilitres of culture grown overnight in 10ml of BHI broth at 37ºC were 
transferred into four 1.5ml microcentrifuge tubes and centrifuged for 3 min at 13000g. 
The supernatants were discarded and the pellets combined by resuspending in 550µl 
lysis buffer lacking lysozyme. 500µl of glass beads was added in a 2ml screw cap tube 
and the mixture was shaken in a Mikro dismembrator (Braun, Germany) for 5 min at 
2600rpm. After shaking the mixture was centrifuged for 10 min at 13000g and 180µl of 
supernatant transferred to 1.5ml microcentrifuge tube. 25µl of proteinase K, and 200 µl 
AL buffer were added to the supernatant and incubated at 56ºC for 30 min, Finally, 200 
µl of ethanol (100%) was added and mixed thoroughly. The mixture was transferred to a 
DNeasy Mini spin column placed in a 2ml collection tube and centrifuged for 1 min at 
8000g. Then final steps in Section 2.5.2a were followed to yield the DNA.  
2.5.2c Rapid Extraction of chromosomal DNA using the boiling method 
        A colony from an overnight culture on BHI agar was transferred to 20µl of sterile 
milli-Q water in a microcentrifuge tube and mixed thoroughly. The cell suspension was 
boiled at 100ºC for 10 minutes then centrifuged at 13,000g for 5 min. 5 µl of the 
resulting supernatant was used in a diagnostic PCR reaction. 
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2.5.3 Polymerase Chain Reaction (PCR)  
In order to amplify regions of the DNA the PCR technique was used. 
Oligonucleotide primers for amplifying specific MRSA genes were designed according 
to the following parameters: G/C between 50-60%, the 3'-end had a G or C and more 
three adjacent nucleotide repeats (e.g. AAAA or TTTT) were avoided. Oligonucleotide 
primers were obtained from MWG Biotech GmbH. Lyophilised primers were 
rehydrated by addition of sterile milli-Q water to a concentration of 100µM and stored 
at -20ºC. 
          PCR reactions were performed as indicated in Table 2.2, and according to the 
reaction conditions in Table 2.3.  The sequences of primers used in this study are listed 
in Table 2.3 
Table 2.2 : Components of PCR reaction mixture.  
Components Volume per 50 µl reaction (µl) 
Milli-Q Water 25 
DNA polymerase buffer (10x) 5 
Forward primer (20mM) 5 
Reverse primer (20mM) 5 
dNTP (10mM) 1 
MgCl2 (25mM) 3 
Template DNA (~200ng/ µl) 5 
Taq polymerase (5U/µl) 1 
 
 
Table 2.3:  PCR reaction conditions  
             Genes 
steps 
mecA coa PVL 
ºC min cycles ºC min cycles ºC min cycles 
Denaturing                                                            
Denaturing                                     
Annealing                                                                                
Extension                                                                                                
Final Extension 
95         5            1 
94         0.5        
55 0.5 40
72          1 
72          5            1 
95         3            1 
94        0.41        
52 0.66    30 
72 1
72          5           1 
95         10           1 
95        0.16         
52        0.08       35 
72         0.3 
72          5           1 
 ºC = temperature. min = time (minute)    
2.5.3a Detection of the mecA methicillin-resistance gene 
         EMRSA-15 was used as a mecA positive control and S. aureus NCTC 6571 as a 
mecA negative control. The primer pairs designed by Murakami et al. (1991) were used 
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to amplify a 532-bp region of mecA. The PCR reaction was performed as in Table 2.2 
according to reaction condition in Table 2.3 
2.5.3b Detection of coagulase (coa) gene 
The presence of the coa gene was determined using the primers of Walker et al. 
(1998). These primers were used to amplify a 830bp region of the coa gene according to 
the conditions in Tables 2.2 and 2.3. DNA from S. aureus NCTC 6571 was used as a 
coa positive control and S. epidermidis was used as a coa negative control. 
2.5.3c Detection of the Panton-Valentin leukocidin (lukS-PV) gene 
De novo primers were designed to target a 443bp region of the lukS-PV gene. 
The sequences of this gene were obtained from the National Centre for Biotechnology 
Information (NCBI) database. The PCR reaction was performed as in Table 2.2 
according to reaction conditions in Table 2.3. PVL+ and PVL- MRSA strains were used 
as controls. 
Table 2.4: Sequences of primers used in this study  
Primer           Sequence (5’- 3’) Reference 
mecA-for 
mecA-rev 
AAAATCGATGGTAAAGGTTGGC 
AGTTCTGCAGTACCGGATTTGC 
Murakami et al., 1991 
coa-for 
coa-rev 
GAACAAAGCGGCCCATCATTA 
TAAGAAATATGCTCCGATTGTCG 
Walker et al., 1998 
lukS-PV -for 
lukS-PV -rev 
GCTGCAACATTGTCGTTAGG 
CCATTACCTCCTGTTGATGG 
This study 
arcC- for 
arcC- rev 
aroE- for 
aroE- rev 
glpF- for 
glpF- rev 
gmk- for 
gmk- rev 
pta- for 
pta- rev 
tpi- for 
tpi- rev 
yqiL- for 
yqiL- rev 
TTGATTCACCAGCGCGTATTGTC 
AGGTATCTGCTTCAATCAGCG 
ATCGGAAATCCTATTTCACATTC 
GGTGTTGTATTAATAACGATATC 
CTAGGAACTGCAATCTTAATCC 
TGGTAAAATCGCATGTCCAATTC 
ATCGTTTTATCGGGACCATC 
TCATTAACTACAACGTAATCGTA 
GTTAAAATCGTATTACCTGAAGG 
GACCCTTTTGTTGAAAAGCTTAA 
TCGTTCATTCTGAACGTCGTGAA 
TTTGCACCTTCTAACAATTGTAC 
CAGCATACAGGACACCTATTGGC 
CGTTGAGGAATCGATACTGGAAC 
Enright et al., 2000 
 
carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol kinase (glpF), 
gulanylate kinase (gmk), phosphate actyltransferase (pta), triosephoshate isomerise (tpi) 
and acetyl coenzyme A acetyltransferase (yqiL). 
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2.5.4  Agarose Gel Electrophoresis 
About 5 – 10 µl of PCR product was combined with loading buffer and loaded 
on 0.8-1.5% agarose gel containing ethidium bromide (0.5μg/ml). Electrophoresis was 
carried out in 1xTBE buffer (Appendix A) at 100V for 30 to 45 min. PCR products 
were sized against molecular size markers (100bp-1kb) (Appendix B), their bands 
visualized under UV-light and documented using a gel documentation system.    
2.6 Molecular typing of MRSA isolates 
2.6.1 Pulsed field gel electrophoresis (PFGE)  
2.6.1a Preparation of agarose-embedded bacterial DNA 
            Chromosomal DNA was prepared in agarose plugs using the CHEF Genomic 
DNA Plug Kits (Bio-Rad) according to the manufacturer‟s instructions excepting for the 
addition of lysostaphin prior to mixing the cells with low melting agarose. 2% of clean-
cut agarose (Bio-Rad) was prepared and was equilibrated at 50ºC. An overnight culture 
in 10 ml LB was diluted and grown to an OD600 of between 0.8 and 1.0. Three 
millilitres of culture were transferred into two 1.5ml microcentrifuge tubes and 
centrifuged for 3 min at 13000g. The pellets were resuspended in 1ml TN buffer 
(Appendix A) and the suspension centrifuged at 13,000g for 3 min. The pellets were 
resuspended in 300µl cell suspension buffer, equilibrated at 50ºC, and 4µl of 
lysostaphin (1mg/ml in 100mM NaCl pH 4.5) added immediately then 300µl of 2% of 
clean-cut agarose. The cell suspension was mixed gently and the mixture was 
transferred to a CHEF plug moulds (100µl the agarose/cell suspension per mould) and 
were left to solidify. Solid agarose plugs were incubated for 2 h at 37ºC in 2.5ml lysis 
buffer containing 100µl lysozyme. The lysis buffer was removed and the plugs were 
rinsed with sterile deionised water. 2ml of proteinase K buffer containing 100μl 
proteinase K was added and incubated overnight at 50ºC. The plugs were washed four 
times (1 h each time) in wash buffer (1ml for each plug) at room temperature with 
gentle agitation. In the second wash, 60 µl of 100mM phenylmethanesulfonyl fluoride 
(1mM PMSF) (Appendix A) was added to the wash buffer/plugs. The plugs were stored 
in 1x wash buffer at 4ºC for up to six months. 
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 2.6.1b Digestion of bacterial DNA for PFGE analysis 
             Prior to digestion, a single plug was washed in 1ml of 0.1x wash buffer for 1h, 
followed by 1 ml of 1X restriction endonuclease buffer 4 (New England Biolabs) for 1h 
with gentle agitation. The plug was cut in half and slices transferred to 300µl of fresh 
restriction buffer containing 3µl (50-60U) of the restriction endonuclease SmaI 
(CCC↓GGG) (New England BioLab). The slices were incubated overnight at 25ºC. 
After digestion, the slices were placed in 1ml 1x wash buffer for 30 min and were 
equilibrated in 0.5x TBE buffer. The plugs were melted at 65ºC for 10 minutes in a 
water bath and were inserted by pipette into the wells of a 21 x 14 cm 1% agarose gel 
(0.5x TBE buffer) for pulse-field electrophoresis. 
2.6.1c  Pulse-field gel electrophoresis analysis 
 Restriction fragments of chromosomal DNA were separated in a 1% agarose gel 
using a Contour-Clamped homogeneous electric field (CHEF)-DRII apparatus (Bio-
Rad), at field strength of 200V for 24h with initial and final switching times of 5s and 
60s respectively. The buffer temperature was kept under 14ºC. A lambda ladder (Bio-
Rad) and strain NCTC8325 (Appendix B) were used as molecular size markers. After 
electrophoresis, the gel was stained in ethidium bromide (1µg/µl) for 30-45 min and 
distained in distilled water for 2 hours. The gel was photographed under UV light. 
2.6.1d Data analysis of PFGE 
Gel images were saved as TIFF files for analysis by fingerprinting software 
(BioNumerics v3.50, Applied Maths). The analysis of PFGE patterns was based on 
band differences and a clustering dendrogram was generated by the unweighted-pair 
group method with arithmetic mean (UPGMA) using the Dice similarity coefficient.   
2.6.2 Multilocus sequence typing (MLST) 
2.6.2a PCR amplification with MLST primers  
Seven primer pairs in Table 2.4 were used to amplify internal fragments (about 
500bp) of seven housekeeping genes according to Enright et al. (2000). The targeted 
genes were: carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol kinase 
(glpF), guanylate kinase (gmk), phosphate actyltransferase (pta), triosephoshate 
isomerise (tpi) and acetyl coenzyme A acetyltransferase (yqiL). The PCRs were 
performed as described as in Table 2.2 using the following reaction conditions: initial 
denaturation at 95ºC for 5min followed by 30 cycles of denaturation at 95ºC for 1 min, 
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annealing at 55ºC for 1min, extension at 72ºC for 1 min with a final extension step at 
72ºC for 5 min. 5 µl of PCR reaction was run on 1% agarose gel to confirm the presence 
of the PCR products.   
2.6.2b Purification of PCR products of MLST 
2.6.2b.i Purification of PCR products using the PEG method  
The PCR products were purified as described by Enright et al. (2000) as 
following: 40µl of PCR products were precipitated with 40 µl of 20% (w/v) 
polyethylene glycol (PEG6000) in 2.5M NaCl (Appendix A) and recovered by 
centrifuging for 15 min at 13,000g. The precipitate was resuspended in cold 70% 
ethanol and centrifuged for 10 min at 13000g. The ethanol was carefully removed and 
the precipitate resuspended in 10µl of 1xTE buffer (Appendix A). The PCR products 
were stored at -20ºC until required for sequencing.  
2.6.2b.ii Purification of PCR products using QIAquick PCR purification kit 
Five volumes of PB buffer were added to one volume of PCR reaction and 
mixed thoroughly. The entire mixture was transferred to a QIAquick spin column 
placed in 2ml collection tube and centrifuged for 1 min at 13,000g. The flow-through 
was discarded and QIAquick spin column was placed back in the same collection tube. 
About 0.75ml of PE wash buffer was added to the QIAquick column and centrifuged for 
1 min at 13,000g. The flow-through was discarded and QIAquick column was placed 
back in the same collection tube. The column was centrifuged once more to remove 
residual ethanol. The QIAquick column was placed in a clean 1.5ml microcentrifuge 
tube and 30µl of elution buffer EB or ddH2O (pH 7.0-8.5) was added to the centre of 
QIAquick column membrane and centrifuged for 1 min at 13,000g. The PCR products 
were stored at -20ºC until required for sequencing.  
 2.6.2c Sequencing and analysis of MLST data 
The concentration of DNA was adjusted (see 2.6.3) and the products were sent 
for sequencing (MWG Biotech, Germany). Allelic profiles and sequence type (ST) were 
identified using the MLST database through website (http://www.mlst.net).      
2.6.3 Quantification of DNA  
 The concentration of DNA was determined using the NanoDrop (ND-1000) 
system (NanoDrop Technologies). 1µl of DNA sample was pipette directly onto the 
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measurement surface and the 260/280 and 260/230 nm ration was calculated to evaluate 
the DNA purity.       
2.6.4  Identification of SCCmec types using multiplex PCR    
Multiplex PCR was carried out to determine the SCCmec types according to 
Boye et al. (2007) using a set of four primer pairs (Table 2.5). The multiplex PCR was 
performed according to the following reaction conditions: initial denaturation at 94ºC 
for 4 min followed by 30 cycles of 30 sec at 94ºC, 30 sec at 55ºC and 60 sec at 72ºC 
with final extension at 72ºC for 4 min. About 8 µl of multiplex PCR products was 
loaded on 1.5% agarose gel containing ethidium bromide (0.5μg/ml) and was 
electrophoresed in 1xTBE buffer (Appendix A) at 90V for 60 to 80 min.      
  
Table 2. 5:  Primers used in the multiplex SCCmec PCR and the resulting gel band          
patterns of SCCmec types I–V (Boye et al., 2007). 
Name Primer sequence (5'→3') Length 
(bp) 
SCCmec type 
I II III IV V 
ccrA2-B-for ATTGCCTTGATAATAGCCTTCT 937   
  
X 
  
  
  
X 
  
  
  ccrA2-B-rev TAAAGGCATCAATGCACAAACACT 
ccrC-for CGTCTATTACAAGATGTTAAGGATAAT 518   
  
  
 
X 
 
  
 
X 
 ccrC-rev CCTTTATAGACTGGATTATTCAAAATAT 
IS1272-for GCCACTCATAACATATGGAA 415 X 
  
  
 
  
  
X 
  
  
  IS1272-rev CATCCGAGTGAAACCCAAA 
mecA-IS431-
for 
TATACCAAACCCGACAACTAC 359 
 
  
  
  
  
  
  
  
  
X 
  
mecA-IS431-
rev 
CGGCTACAGTGATAACATCC 
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3. Analysis of clinical MRSA isolates using existing molecular typing 
methods 
 
3.1 Introduction  
Since the emergence of penicillin-resistant S. aureus strains in the 1940s (Kirby, 
1944) and the subsequent emergence of methicillin-resistant S. aureus (MRSA) in 1961 
(Jevons, 1961), MRSA has become the main concern for both patients and health care 
professionals. The ability of these bacteria to resist many available antibiotics, including 
the drug of last resort, vancomycin, has led some to predict a return to the pre-antibiotic 
era in relation to the treatment of infections. Since morbidity and mortality rates 
associated with MRSA infection have increased, high priority has been given to the 
control of MRSA in many healthcare settings. The National Nosocomial Infections 
Surveillance (NNIS) System of the Centers for Disease Control and Prevention (CDC), 
reports that approximately 80,000 patients/year worldwide acquire MRSA infections 
(Aires de Sousa and Lencastre, 2004).  In the UK, mortality associated with MRSA has 
increased dramatically from 51 reported cases in 1993 to 1, 230 in 2008, although this 
in part represents improved reporting procedures.  
A good understanding of the epidemiology of MRSA is the cornerstone of the 
control and subsequently elimination of infection. During the last century, 
microbiologists have introduced many epidemiological tools to differentiate between S. 
aureus strains. Initially, those tools relied on phenotypic features including phage typing 
and serotyping. In the last two decades, however, with the advent of advanced 
molecular typing methods such as PFGE, MLST and SCCmec typing, the 
epidemiological field has witnessed a rapid development (Weller, 2000; Ito et al., 
2001).  
PFGE profiling basically relies on the digestion of whole chromosomal DNA 
with restriction endonucleases (SmaI in case of MRSA) that generate a relatively few 
number of large fragments. Because the generated fragments are large in size they can 
only be separated by pulsed-field gel electrophoresis (Schwartz and Cantor, 1984). 
PFGE has been used extensively for the typing of many bacterial species and it is now 
described as a gold standard technique for typing MRSA (Schmitz et al., 1998) since it 
shows high discriminatory power and reproducibility. In recent years, PFGE has been 
supported by more rapid methods, such as multi-locus sequence typing (MLST), a 
sequence-based technique which provides unambiguous results. MLST relies on single 
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nucleotide variations (each variant is called an allele and is represented by a unique 
identifier) in seven housekeeping genes of S. aureus (Enright et al., 2000).  
However, there are limitations that restrict the routine use of PFGE and MLST 
in many hospitals‟ laboratories: both methods are time-consuming, expensive, require 
specific expertise and specialist equipment (Abele-Horn et al., 2006; Sabat et al, 2006). 
In addition, the reproducibility of PFGE between laboratories is sometimes challenging 
(van Belkum et al., 1998) and the ability of MLST to discriminate outbreak isolates is 
limited (Hardy et al., 2006).   
3.2 Aims  
The aims of this part of the study were: 
1. Initially, to use established genotyping typing tools to study the epidemiological 
characteristics of MRSA isolates isolated in local hospitals (Newcastle upon 
Tyne). 
2. Ultimately, to evaluate the most popular molecular typing methods and 
determine the limitations that restrict their routine use in hospital clinical 
microbiology laboratories.      
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3.3 Results 
3.3.1 Analysis of MRSA data 
3.3.1a MRSA patients 
 MRSA strains were isolated from 286 patients throughout the period of collection. 176 
(61.5%) patients were male and 110 (38.5%) female. 219 (76.5%) patients were from 
the Freeman Hospital while the remaining 67 patients (23.5%) were from other 
hospitals or primary care centres in Newcastle upon Tyne. 
3.3.1a.i  Patient age groups 
The patient ages ranged from 11 to 100 years with a mean of patient age of 68 years. 
44.5% of patients were older than 75 years while only 5.6% were under 30 years (Fig. 
3.1) 
 
               Figure 3.1: The age distribution of MRSA patients.  
 
3.3.1a.ii  Infected and colonized patients  
The isolation of MRSA from colonised sites (nose, throat and perineum) of patients 
with no signs of infection were considered to be “colonized patients” while the isolation 
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of MRSA from wound, blood, urine and respiratory tract were considered to be 
“infected patients”.  
In this study, 57.7% of patients were colonised by MRSA isolates without symptoms 
while 42.3% were infected. Seventy percent of colonised patients were older than 60 
years whereas only 7% under 30 years. Similarly, 73% of infected patients were older 
than 60 years while only 4% were under 30 years. These data confirm the susceptibility 
of older individuals to both infection and colonisation, as observed previously by others 
(Morgan et al., 1999, 2000; Hori et al., 2002; Gemmell et al., 2006).  
3.3.1a.iii The distribution of patients between hospital units 
Fifty-nine percent of MRSA patients were in general medical (24%), urology (23%) and 
surgical (12%) units whereas only 1% were in orthopaedics and musculoskeletal units 
(Fig. 3.2). 84% of urology and 73.5% of general medical patients were colonised 
whereas the percentages of infected patients in these units were 16% and 26.5%, 
respectively. In critical care and surgical units 70% and 54% of patients, respectively, 
were infected (Fig. 3.2). 
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Figure 3.2:  The distribution of infected and colonised patients in units of the Freeman Hospital. ENT: Ear, Nose & Throat Unit. CC: critical care unit.  FOP: 
Freeman out patient. FMDU: Freeman Melville day unit. FEAS: Freeman admission suite. 
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 3.3.1b MRSA isolates  
  Four hundred and six MRSA strains were isolated from clinical and screening 
samples. 325 (80%) strains were isolated from patients at the Freeman Hospital whilst 
81 (20%) strains were isolated from patients at other hospitals or primary healthcare 
centre in Newcastle upon Tyne. 267 (66%) of MRSA strains were isolated from 
screening samples (nose, throat and perineum) while the remaining 139 (34%) were 
from clinical samples: 27% from wounds, 3% from blood, 3% from respiratory tract and 
1% from urine samples (Fig. 3.3a). In the case of the MRSA strains isolated from 
patients at the Freeman Hospital, 21% were from the general medical unit, 20% from 
urology and 13% from surgery. Only 1% of strains were isolated from the orthopaedics 
and musculoskeletal units (Fig. 3.3b). 
 
 
Figure 3.3:  A) The isolation sites of MRSA isolates.  B) Distribution of MRSA isolates in the 
Freeman Hospital units. NPT: nose, perineum and throat. ENT: Ear, Nose & 
Throat Unit. CC: critical care unit. FOP: Freeman out patient. FMDU: Freeman 
Melville day unit. FEAS: Freeman admission suite.  
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3.3.2 Molecular diagnostic methods. 
3.3.2a Extraction of chromosomal DNA for PCR analysis. 
  Two protocols were evaluated for the extraction of chromosomal DNA from 
MRSA isolates – mechanical disruption and enzymatic digestion. As shown in Figure 
3.4, the quantity of DNA extracted by mechanical disruption with the Mikro 
dismembrator was significantly better than that extracted following digestion with 
lysostaphin. The concentration of DNA in the Mikro dismembrator method was 
between 200 to 400 ng/µl whereas the concentration was between 60 to 190 ng/µl in 
case of the digestion with lysostaphin. Consequently, mechanical disruption was used to 
extract DNA from the twenty test isolates used for the evaluation for the PCR and 
MLST analyses.  
        For diagnostic PCR, the extraction of DNA by the rapid boiling method was tested 
and showed excellent results. This method was applied to all isolates examined (n=76) 
for the diagnostic PCR detection of the gene encoding the PVL virulence factor.    
    
                     
      Figure 3.4:  Extraction of DNA from MRSA isolates using various protocols. Lane 1: 
Mikro dismembrators. Lanes 2 & 3: lysostaphin treatment. MW: 1kb DNA 
molecular size ladder. 
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3.3.2b Identification of MRSA isolates by PCR  
All MRSA isolates were initially identified at the Freeman Hospital using conventional 
bacteriological approaches including MRSA ID media, Slidex Staph Plus (SSP) and an 
antibiotic susceptibility test. Thereafter, mecA and coa genes were used as targets of 
PCR in order to confirm the identity of MRSA isolates using various primer pairs. PCR 
was also used to determine the presence of genes encoding the staphylococcal virulence 
factor PVL.   
3.3.2b.i Detection of the mecA gene.  
PCR was used to amplify a 533bp fragment of the mecA gene from twenty MRSA 
isolates and an amplicon of the expected size was amplified from each of the isolates. 
The results of twelve representatives of 20 isolates are shown in Figure 3.5. The test 
strains were isolated from non-infected patients during routine screening (nose, throat 
and perineum) with the exception of MRSA3 and MRSA13, which were isolated from 
the wounds of patients. 70% of these patients were older than 75 years (Table 3.1).  
 
        Figure 3.5:  PCR products of the mecA gene for MRSA from isolates 9 to 20, (+) = 
MRSA (585296); (-) = MSSA NCTC6571. MW =1kb DNA molecular size 
marker. 
 
3.3.2b.ii Detection of coa gene  
The same twenty MRSA isolates as above (Section 3.3.2b.i) were analysed for the 
presence of a 830bp fragment amplified from the coa gene. All of the isolates tested 
positive and Figure 3.6 shows twelve representative isolates. Interestingly, MRSA12 
produced a shorter PCR product, which might be due to deletion in targeted region of 
coa (Figure 3.6, Table3.1).  
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           Figure 3.6:  PCR products of coa gene for MRSA isolates from 1 to 12. (+) = MSSA 
NCTC6571; (-) = S. epidermidis 1kb: DNA molecular size ladder.  
 
3.3.2c Detection of the gene encoding the PVL virulence factor in MRSA isolates 
Seventy-six MRSA isolates were examined for the presence of the gene encoding PVL. 
The primers targeted a 443bp fragment of lukS gene. 90% of the tested strains were 
isolated from screening samples whereas only 10% were from wounds. None of these 
isolates were PVL-positive (Fig. 3.7). 
   
Figure 3.7:  PCR of PVL gene for isolates from 65 to 76. (+) = MRSA (585296) PVL (-) = 
MRSA (602025) PVL-.  1kb: DNA molecular size marker. 
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Table 3.1: Isolation sites and PCR results of the first twenty MRSA isolates  
Isolates     age of patient    sites of isolation     coa gene      mecA gene      PVL gene 
FMRSA 1           85                      NPT                        +                     +                     - 
FMRSA 2           83                      NPT                        +                     +                     - 
FMRSA 3           72                   Wound                       +                     +                     - 
FMRSA 4           25                     NPT                         +                     +                     - 
FMRSA 5           93                     NPT                         +                     +                     - 
FMRSA 6           78                     NPT                         +                     +                     - 
FMRSA 7          100                    NPT                         +                     +                     - 
FMRSA 8            82                    NPT                         +                     +                     - 
FMRSA 9            87                    NPT                         +                     +                     - 
FMRSA 10          60                    NPT                         +                     +                     - 
FMRSA 11          82                    NPT                         +                     +                     - 
FMRSA 12          84                    NPT                         +                     +                     - 
FMRSA 13          51                  Wound                       +                     +                     - 
FMRSA 14          80                   NPT                          +                     +                     - 
FMRSA 15          96                   NPT                          +                     +                     - 
FMRSA16           84                   NPT                          +                     +                     - 
FMRSA 17          92                   NPT                          +                     +                     - 
FMRSA 18          31                   NPT                          +                     +                     - 
FMRSA 19          73                   NPT                          +                     +                     - 
FMRSA 20          85                   NPT                          +                     +                     - 
FMRSA= Freeman Hospital MRSA isolate.     + = Positive    - =Negative       NPT = 
(nose, throat or perineum). 
 
3.3.3 Molecular typing of MRSA isolates  
3.3.3a  Pulsed-field gel electrophoresis (PFGE).   
PFGE has been described as the gold standard for MRSA typing. This technique 
requires considerable expertise and some considerable effort was spent to optimize this 
technique. DNA was extracted into agarose plugs to reduce mechanical shearing of the 
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chromosomal DNA. SmaI endonuclease was used to digest the chromosomal DNA 
since this generated in the region of 20 fragments. Plugs were prepared for twenty 
MRSA isolates as indicated above (2.6.1). Initially, the DNA was digested with 20U of 
SmaI according to Wang et al. (2002). However, as shown in Figure 3.8, the DNA was 
incompletely digested and there was evidence of smearing.  
 
Figure 3.8:  The plugs of six MRSA isolates were digested with 20U of SmaI. Lanes 1 to 6: 
duplicate MRSA isolates. C: S. aureus NCTC657. L: 2.5kb molecular size 
marker. 
 
     Two plugs of a MRSA isolate were digested with different concentrations of SmaI 
(50U and 60U) and were separated under similar conditions excepting that the ramping 
time varied from 5s - 60s (Fig. 3.9). Sixty units of SmaI showed the best performance. 
Chapter 3: Analysis of clinical MRSA using existing molecular typing methods        62 
 
Figure 3.9:  Digestion of MRSA plugs with two concentrations of SmaI endonuclease. 
Samples A1 and A2 were digested with 60U, while samples B1 and B2 were 
digested with 50U.  L: 2.5kb Molecular size marker.   
      
       The DNA plugs of twenty isolates were digested with 60U SmaI. The number of 
fragments produced by SmaI was between 10-15, with lengths varying from 
approximately 3kb to 700kb. These fragments were clearly distinguishable and 
comparable (Fig. 3.10).   
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Figure 3.10:  PFGE types of SmaI restriction digest of MRSA isolates. C = S. aureus NCTC 
6571 (non-MRSA).  M2= FMRSA2.   M3= FMRSA3 etc.   L= Molecular size 
marker (lambda ladder).    
 
The PFGE restriction fragments were interpreted according to Wang et al. (2002), as 
follows: i) strains that were identical with respect to the size and number of bands 
generated were deemed as the same type and were ascribed an alphabetical letter (i.e. A, 
B, C etc). ii) Strains which have up to three different bands were considered a subtype 
were given different numbers, (i.e. A2, A3 A4 etc), according to the number of different 
bands. iii) Strains with more than three different bands were deemed to be of a distinct 
type and given other letter. 
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         The UPGMA dendrogram (Fig. 3.11) shows the SmaI-PFGE patterns and the 
genetic relationship of 20 MRSA isolates. It is clear that most of these MRSA isolates 
are closely related and only three PFGE types (A, B and C) were identified. Type A was 
predominate (n=18; 90%) while the remaining PFGE types (B, C) were only 
represented by one isolate each. Within Type A, eight subtypes (A1- A8) were found. 
Type A profiles had high similarity (more than 85%) to EMRSA-15 while Types B and 
C showed 80% similarity to EMRSA-15. Fifty percent of Type A isolates were isolated 
from the urology and general medical units at the Freeman Hospital while the remaining 
isolates were isolated from a variety of units at the Freeman Hospital and local 
healthcare centres (Table 3.3). The Type B isolate was isolated from elderly patient (87 
years) in the geriatric care unit at the Freeman Hospital, while the Type C isolate was 
isolated from an elderly patient (96 years) at the Walkergate Hospital in Newcastle.   
 
Figure 3.11:  The UPGMA dendrogram of SmaI-PFGE patterns based on Dice similarity 
coefficient, illustrating the relationships among the 20 clinical MRSA isolates.  
ST= sequence type. ND= not determined 
. 
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3.3.3b Multilocus sequence typing (MLST) 
 
Initial MLST experiments with the reference strain S. aureus NCTC8325 
correctly identified this strain as sequence type (ST) 8 (3-3-1-1-4-4-3), confirming the 
accuracy of our protocol. Five representative MRSA isolates (FMRSA1, 2, 5, 9 and 15) 
of the twenty PFGE-typed MRSA isolates (Fig. 3.11) showed that these isolates had 
identical sequence types, namely ST22 (7-6-1-5-8-8-6) (Fig.3.12 and Table 3.2).  
 
   Figure 3.12: The various fragments of the seven target housekeeping genes amplified from 
two clinical MRSA (FMRSA1 and FMRSA2) isolates. arcC : carbamate 
kinase; aroE :shikimate dehydrogenase; glpF : glycerol kinase;  gmk 
:gulanylate kinase; pta : phosphate actyltransferase; tpi : triosephoshate 
isomerise; yqiL : acetyl coenzyme A acetyltransferase. MW =1kb DNA 
molecular size marker.   
 
Table 3.2:  The sequence types and allelic profiles of the five clinical MRSA with the 
reference strain S. aureus NCTC8325. 
Allele Number of MRSA strains 
Locus NCTC8325 FMRSA1 FMRSA2 FMRSA5 FMRSA9 FMRSA15 
arcC 3 7 7 7 7 7 
aroE 3 6 6 6 6 6 
glpF 1 1 1 1 1 1 
gmk 1 5 5 5 5 5 
pta 4 8 8 8 8 8 
tpi 4 8 8 8 8 8 
yqiL 3 6 6 6 6 6 
ST 8 22 22 22 22 22 
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3.3.3c Staphylococcus cassette chromosome mec (SCCmec) typing  
          A multiplex PCR was used to identify the SCCmec type of twenty PFGE-typed 
MRSA isolates according to the method of Boye et al.2007. All twenty isolates were 
found to harbour SCCmec-IV and Figure 3.13 shows SCCmec-IV of 10 representatives 
MRSA isolates with control strains.   
 
Figure 3.13: Representative multiplex PCR analyses of of 10 clinical MRSA isolates, 
previously typed by PFGE, to identify their SCCmec type.  Control strains with 
known SCCmec were also analysed. 
3.4  Discussion 
MRSA is one of the most important nosocomial pathogens. Morbidity and 
mortality associated with these strains increases annually throughout the world. 
Analyses of the epidemiology of MRSA can assist in their control and contribute 
significantly to reducing the spread of MRSA infections. Typing is an effective means 
of aiding control since it allows epidemic and sporadic strains to be distinguished and 
potential sources of infection to be identified (Hryniewicz, 1999).  
The Freeman Hospital is one of the largest hospitals in north-east England and 
was chosen as the main location of our studies. More than four hundred MRSA isolates 
were collected from 286 colonized and infected patients. Sixty-six percent of these 
isolates were isolated from screening samples (nose, perineum and throat) whereas 34% 
were isolated from clinical samples (wound, blood, urine and respiratory samples). 
About 30% of the general population is colonised by S. aureus and in some 
cases this can reach 80% (Perla et al., 2007). In this study, more than 57% percent of 
patients were asymptomatic carriers of MRSA whereas 43% were infected patients. The 
Chapter 3: Analysis of clinical MRSA using existing molecular typing methods        67 
present findings are consistent with other research indicating that the proportion of 
patients colonised by MRSA has increased remarkably from 4.5% in 1990 to 34.9% in 
1994 at Fujiwara Memorial Hospital, Japan (Kayaba et al., 1997). The MRSA 
colonization among hospital patients reached 46% (in Brazil) and 49% (USA) in studies 
conducted by Korn et al. (2001) and Robicsek et al.(2009), respectively.  
Colonized and infected patients are considered to be the main reservoir of 
MRSA in hospitals. Increasing age is a significant risk factor associated with MRSA 
and the majority of previous studies have reported that colonization is highest in 
patients older than 75 years (Morgan et al., 1999, 2000). For example, a study on 
patients at the Nottingham University Hospital (Hori et al., 2002) found that 70% of 
patients colonized by MRSA are more than 75 years of age. These findings are in 
agreement with our observation that 73% and 70% respectively of infected and 
colonized patients were older than sixty years.  
With regard to the clinical samples, wounds were the commonest source of 
MRSA, coming mainly from the general medical, urology and surgical units. This is in 
line with other work that has shown that MRSA is the most common wound infection 
pathogen (Giacometti et al., 2000). In addition, general medical, urology and surgical 
units are the busiest units in the Freeman Hospital and consequently have the highest 
turnover of patients. 
Carrier or colonized patients out-numbered infected patients in the general 
medical and urology units, but the reverse was the case in the surgical, ENT and critical 
care units. This might be explained by the frequent surgical interventions in surgical and 
ENT units as well as the increased use of medical devices and the presence of immuno-
compromised patients in the critical care unit.  
MRSA typing is a crucial step in controlling the spread of bacterial infections 
since it aids the identification of the sources of nosocomial strains and facilitates the 
monitoring of their distribution. The ideal typing technique should have high 
discriminatory power and reproducibility. Traditional phenotyping techniques for 
MRSA have included phage and serotyping. Although often providing useful 
information, they lack sufficient discriminatory power to allow them to be implemented 
for detailed epidemiological studies (Weller, 2000; van Leeuwen.2003).     
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Recently, molecular typing methods have been developed and used extensively 
to study the epidemiology of MRSA. Their high discriminatory power and 
reproducibility means that they are generally superior to phenotyping techniques. Many 
of molecular methods depend on PCR-based technology and, for diagnostic purposes, a 
number of targets have been developed (e.g. mecA and coa genes). In addition, PCR is 
also used to determine the presence of specific staphylococcal virulence factors such as 
PVL.  
Twenty MRSA isolates were tested for the presence of mecA genes, which 
encode a homologue of penicillin-binding protein 2 (PBP2a), and all of the isolates 
were positive. Although, some methicillin-susceptible strains have non-expressed or 
non-functional mecA genes, the presence of mecA is considered as an indicator for the 
identification of MRSA. Such strains are called pre-MRSA (Lewis and Dyke, 2000; 
Brown et al., 2005). However, because some coagulase-negative staphylococci carry 
mecA, an additional confirmatory test, involving the coa gene, was necessary to confirm 
that they were methicillin resistant S. aureus (Hussain et al., 2000; Brown et al., 2005). 
All of the putative MRSA isolates were confirmed by the presence of the coa gene.  
 The PVL is pore-forming exotoxin (Kaneko and Kamio, 2004) that is produced 
by some community-acquired MRSA (CA-MRSA) strains that can cause aggressive 
infections involving leukocyte destruction (Chamber, 2005). Such strains can lead to 
death within 72 h. The production of PVL is often associated with community-acquired 
skin, soft tissue and pneumonia infections. Lina and colleagues (1999) have reported 
that PVL production was detected in 93% of furunculosis and 85% of strains 
responsible for pneumonia in community-acquired S. aureus but rarely in hospital 
infection strains (Lina et al., 1999). In the current study, 76 MRSA isolates were tested 
for the presence of the PVL-encoding gene and none were found to be PVL-positive. 
This result may be explained by the fact that < 5% of S. aureus isolates produce PVL 
toxin (Lina et al., 1999; Holmes et al., 2005).  
PFGE is generally regarded as the gold standard technique for typing of 
bacterial species, including MRSA. It is highly discriminatory and reproducibility, but 
is time-consuming and expensive to carry out. In the case of MRSA, several restriction 
endonucleases have been evaluated but SmaI has been shown to give the best 
performance. In this study PFGE was used to type twenty clinical isolates of MRSA. 
All of the tested isolates were typeable by PFGE and its discriminatory power was high, 
with excellent reproducibility with regard to PFGE profiles of isolates but the quality of 
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gels was variable. Almost all of the MRSA isolates were closely related with a high 
percentage of similarity (Fig. 3.11). Three types (A, B and C) of SmaI macrorestriction 
profiles were distinguished with Type A predominating (Fig. 3.11). Eight subtypes were 
found within Type A and the majority of Type A profiles were highly similar (by more 
than 85%) to that of the UK epidemic strain 15 (EMRS-15). The genodiversity and 
prevalence of EMRSA-15 was observed in Nottingham hospitals, which showed that 
80% of MRSA isolates were classical EMRSA-15, whereas genotypic variants of 
EMRSA-15 comprised 72% of Nottingham community-based patients (Jonas et al., 
2002). A recent study (Monnet et al., 2004) has shown that EMRSA-15 is the most 
common type of MRSA in UK hospitals, with MRSA-16 a distant second. In addition, 
EMRSA-15 now predominates among MRSA clones in the north of the UK. In a 
Scottish surveillance study of 486 isolates of MRSA, conducted by Wilson and 
colleagues from January to December 2009, about 81% of the isolates were EMRSA-15 
and only 10% EMRSA-16 (Wilson et al., 2010).  
Multi-locus sequence typing (MLST) is an excellent epidemiological tool for 
typing isolates of MRSA (Maiden et al., 1998). MLST relies on the assignment of the 
nucleotide sequences of specific alleles and, unlike PFGE, provides unambiguous data 
sets (Enright and Spratt, 1999). MLST was used in the current study to analyse the 
sequences of internal fragments (450-500 bp) of seven housekeeping genes. Initial 
experiments were carried out on a reference strain, namely S. aureus NCTC 8325. 
These confirmed the accuracy of our protocol as being >99.8%. MLST analysis of 
representative isolates of the twenty PFGE-typed MRSA isolates shows that they were 
members of sequence type 22 (ST22) (Table 3.2).  
              SCCmec typing is one of the most important tools for typing MRSA and is 
considered to be complementary to MLST. To date, eight SCCmec types have been 
identified based on the characteristics of mec and ccr complex (IWG-SSC, 2009). 
Multiplex PCR was used for identification of SCCmec type on twenty PFGE-typed 
MRSA isolates and this showed that all of these isolates harboured SCCmec type IV.  
Therefore, the sequence and SCCmec type of the 20 PFGE-analysed MRSA isolates 
was ST22-SCCmec-IV (Table 3.3) which is consistent with them being variants of 
EMRSA-15.  
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Table 3.3: Sources of MRSA isolates, PFGE, MLST and SCCmec type. 
Isolates no. Patient’s 
age 
Site of 
isolation 
Unit of isolation PFGE MLST/SCCmec 
FMRSA1 85 NPT GP (out patient) A3 ST22/IV 
FMRSA 2 83 NPT urology A1 ST22/IV 
FMRSA 3 72 Wound urology A2 ND/IV 
FMRSA 4 25 NPT urology A1 ND /IV 
FMRSA 5 93 NPT general medical A5 ST22/IV 
FMRSA 6 78 NPT GP (out patient) A8 ND /IV 
FMRSA 7 100 NPT general medical A7 ND /IV 
FMRSA 8 82 NPT general medical A2 ND /IV 
FMRSA 9 87 NPT geriatric centre C1 ST22/IV 
FMRSA 10 60 NPT FH (out-patient) A1 ND /IV 
FMRSA 11 82 NPT urology A2 ND /IV 
FMRSA 12 84 NPT GP (out patient) A3 ND /IV 
FMRSA 13 51 NPT wound admission A1 ND /IV 
FMRSA 14 80 NPT cardiothoracic A6 ND /IV 
FMRSA 15 96 NPT WGH ward 3 B1 ST22/IV 
FMRSA 16 84 NPT RVI surgery A1 ND /IV 
FMRSA 17 92 NPT urology A2 ND /IV 
FMRSA 18 31 NPT GP (out patient) A2 ND /IV 
FMRSA 19 73 NPT general medical A6 ND /IV 
FMRSA 20 85 NPT general medical A4 ND /IV 
 
NPT = (nose, throat and perineum), FH = Freeman Hospital, GP = General practitioner, 
RVI = Royal Victoria Infirmary, WGH = Walkergate Hospital. ND= not determined  
 
In summary, PFGE has been used extensively to investigate outbreaks of 
pathogens and is still considered as the gold standard technique for typing MRSA 
strains, despite the fact that it is time-consuming, relatively costly and the results, at 
best, are not available for several days. In contrast, MLST is useful for studying of S. 
aureus evolution and tracking the global spread of MRSA, but its discriminatory power 
is limited with respect to the investigation of local outbreaks. MLST is also time-
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consuming and costly, and beyond the internal resources of most clinical laboratories, 
resulting in a dependence on outside agencies. Hence, the development of a new typing 
technique is urgently required. Such a technique should have high discriminatory power 
and reproducibility that is close to or exceeding that of PFGE, but should be rapid and 
suitable for use in all routine clinical laboratories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 4 
A novel multiplex PCR epidemiological technology for the typing of strains 
of Staphylococcus aureus 
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4. A novel multiplex PCR epidemiological technology for the typing of 
strains of Staphylococcus aureus  
 
4.1 Introduction 
Since its emergence in the UK more than 40 years ago, MRSA has become an 
important nosocomial pathogen, and morbidity and mortality rates associated with this 
pathogen have increased markedly in recent years worldwide. MRSA accounts for 50% 
or more of S. aureus isolates in some countries. In the UK this is between 41% - 45%, 
which is higher than several other European countries (e.g. < 3% in the Netherland and 
Iceland) (Aires de Sousa and de Lencastre, 2004; Johnson et al., 2005). Although a 
consensus has yet to be reached as to the most effective means for controlling MRSA, 
the majority of studies indicate that the early detection of colonised and infected 
patients by aggressive screening and improved hand hygiene are both effective (Frank, 
2003; Hardy et al., 2004; Grundmann et al., 2006).  
  A major issue is to identify the sources of MRSA infections once an outbreak 
has been detected and to monitor the epidemic spread of the strains involved. This 
requires the use of reliable typing techniques for monitoring both epidemic and sporadic 
outbreaks. The ability to monitor the epidemiology of an outbreak not only leads to the 
potential identification of its source, but can also reduce the likelihood of subsequent 
infections. For decades, the discrimination between strains of S. aureus has relied on 
phenotypic characters such as phage typing. However, the rapid development of 
molecular approaches during the last twenty years provides the opportunity to explore 
the unique genetic characteristics of individual strains of S. aureus (van Leeumen, 
2003). Consequently, many molecular techniques have been introduced for studying the 
epidemiology of MRSA, including Pulsed-Field Gel Electrophoresis (PFGE), Multi-
locus Sequence Typing (MLST), SCCmec type and multiple locus variable number 
tandem repeat (VNTR) analysis (MLVA). PFGE and MLST are the most widely used 
typing techniques with the former regarded as the gold standard due to its high 
discriminatory power and reproducibility (Enright et al., 2000; Weller, 2000; Sabat et 
al., 2003). However, technical limitations restrict the use of PFGE and MLST in the 
majority of routine hospital laboratories.  
Currently, more than eighteen S. aureus genomes have been completely 
sequenced which allows researchers to explore in detail the genomes of this versatile 
pathogen. The similarities between the core genomes of S. aureus are very high with 
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between 97.7% and 99.8% nucleotide identity. The observed differences are largely due 
to the single nucleotide polymorphisms (SNPs) (Lindsay and Holden, 2006).  
In this study, SNP variations between S. aureus genomes in and around SmaI-
restriction sites (CCCGGG) were exploited to develop a genotyping technique that 
combines the high discriminatory power and reproducibility of PFGE, with the 
simplicity of a multiplex PCR-based technique that can be performed in a routine 
clinical laboratory.  
4.2 Aim 
The main aim of this study was to develop a novel multiplex PCR epidemiological tool 
to monitor the spread of MSSA and MRSA that has the same or similar discriminatory 
power as PFGE, but which can be performed in a few hours using technology that is 
available in routine clinical microbiology laboratories.  
4.3 Methodology  
 4.3.1 Principles of a novel SmaI-multiplex PCR  
        We set out to generate a new typing system based around the output from PFGE 
analysis of SmaI (CCC↓GGG) macrorestriction fragments (10-30 fragments of between 
10-800kb in length). However, instead of the time-consuming DNA extraction and 
digestion technique associated with PFGE, we devised a multiplex PCR technique 
based on SNPs and rapidly extracted chromosomal DNA.  
4.3.2 Genomic analysis tools 
The DNA sequences of the following eighteen S. aureus strains were obtained 
from the European Bioinformatics Institute (EMBL-EBI) 
http://www.ebi.ac.uk/genomes/ bacteria.html and The Sanger Institute 
http://www.sanger.ac.uk: NCTC8325, MRSA252, MSSA476, COL, RF122, JH1, JH9, 
N315, Mu3, Mu50, MW2, Newman, USA300FPR3757, USA300TCH1516, ED98, 
LGA251, TW20 and EMRSA-15. All of the sequences were analysed using a genome 
cutting website at http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi. The SmaI 
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restriction sites for all of the strains were mapped on to their respective chromosomes 
and the sizes and locations of the SmaI fragments determined.  
4.3.3 Alignment and comparison of SmaI-syntenic regions 
  SmaI-syntenic regions analysis was carried out to determine the restriction 
patterns of each strain. Briefly, the strains with the largest number of SmaI restriction 
sites were used to develop a matrix showing the presence and absence of individual 
restriction sites across of the sequenced genomes. The resulting SmaI restriction sites 
were divided into two types based on their discriminatory power. Type I contains six 
groups of SmaI sites that were the most discriminatory while Type II contains four 
groups of SmaI sites with medium discriminatory properties, but which were designed 
to discriminate between specific strains. 
4.3.4 Primer design  
The ten restriction sites that were the most discriminatory between strains were 
identified and ten primer pairs (Table 4.1) designed according to the parameters in 
figure 4.1. All 10 primer pairs were designed to generate a set of uniquely sized 
fragments that could be both easily identified by gel electrophoresis and related to 
specific SmaI sites on the genome. The first phase primers were designed manually to 
for use in two multiplex PCR reactions. The second phase primers were designed using 
the visual OMP
TM 
(Oligonucleotide Modelling Platform) software (see Appendix C for 
the procedure of primers design using visual OMP
TM 
software).  
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 Figure 4. 1:  The principle behind the design of primer pairs. The forward primer terminates at or within the SmaI site and the primer pairs generate  
a set of uniquely sized fragments that can be easily identified by gel electrophoresis. 
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Table 4.1: Oligonucleotide primers of a novel SmaI-multiplex PCR that used in this study.  
 Group 
no. 
Primer Oligonucleotide sequences (5’-3’) GC 
(%) 
Tm 
°C 
Amplicon 
size 
1 SmaI-1_F ATATTTTCCAATCGCCCGGG        50 57.3 814bp 
SmaI-1_R ACTTCCTAATGCTAAAAGTCCG  41 56.5 
2 SmaI-2_F TAATGCAGAAGACCCGGG            56 56.0 1100bp 
SmaI-2_R CTAATGTCATGTTATCAGCACC      41 56.5 
3 SmaI-3_F ACCTGGTGATCCCGGG 64 57.6  299bp 
SmaI-3_R  TCAACGCTGTGCGAATCCTT 50 57.3 
4 SmaI-4_F GTTTGTAGGCCTATTCCCG 52.6 56.7 600bp 
SmaI-4_R CAAGTACGTATGAAATGTCTGG 41 56.5 
5 
 
SmaI-5_F GAAAATGCGCCCCGGG 68.8 56.9 variable 
SmaI-5_R CGTTAGTCATAGCTAATATGC 38.1 54.0 
6 SmaI-6_F TGATCCTGAATTCCCGGG 55.6 56.0 525bp 
SmaI-6_R GGAATAAATGCTGCAGTCGT 45 55.3 
7 SmaI-7_F TGATTTTTTTGACCCGGGGG 50 57.3 378bp 
SmaI-7_R  CACATCAAGTATAGATGCGT 40 53.2 
8 SmaI-8_F GGCAGTGCACCCGGG       80 58.8 930bp 
SmaI-8_R GCAAACTGAGGTTGAAGGAC     50 57.3 
9 SmaI-9_F CCTTGTTTATTAGATCCCGGG            48 58.0 712bp 
SmaI-9_R GCAGCGACTTGGTATGAAAAAC     45 58.5 
10 SmaI-10_F CGCGAAAAGTATTATTTCCCG 43 55.9 248bp 
SmaI-10_R CAATCCAGCGTATATCCGTA 45 55.3 
 Group 
no. 
Primer Oligonucleotide sequences (5’- 3’) GC 
(%) 
Tm 
°C 
Amplicon 
size 
1 SmaI-1_F 
SmaI-1 _F2 
TTCATATTTTCCAATCGCCCG 
TTCATATTTTTCAATCGCCCG       
42.9 
38.1 
55.9 
54.0 
169bp 
SmaI-1 _R CTATAATTCCCTATTTTGACATCTTC 30.8 56.9 
2 SmaI-2 _F GCAGGTAATGCAGAAGACCCG 57.1 61.8 263bp 
SmaI-2 _R CATTAGTTCCGTATGTAATCTTATC  32 56.4 
3 SmaI-3 _F GACCTGGTGATCCCG  61.1 58.2 101bp 
SmaI-3 _R GGTAATTCTGTGCCACTATTAGC 43.5 58.9 
4 SmaI-4 _F TTGTAGGCCTATTCCCG 53 58.6 124bp 
SmaI-4_R CAGTAATCTTAACTTCAATTGTGTCACC 35.7 60.7 
5 
 
SmaI-5 _ F GAACGAAAATGCGCCCCG  61.1 58.2  variable 
SmaI-5 _R AGAAAACGTATTTCTTTATCTTTTCG 26.9 55.3 
6 SmaI-6 _F GAACTGGTGATCCTGAATTCCCG 52 62.4 220bp 
SmaI-6 _R GTCGAACGTGGACCAAAAGGC 57 61.8 
7 SmaI-7_F CGCTTTTGATTTTTTTGACCCG 40.9 56.5 146bp 
SmaI-7_R CATCCGGAGTTTGCTCATGAC 52.4 59.8 
8 SmaI-8_F AGCAGGCAGTGCACCCG 70.6 60.0 319bp 
SmaI-8_R CGATTTATGAGGTATGAAGGAAC 39.1 57.1 
9 SmaI-9_F CGGCCTTGTTTATTAGATCCCG 50 60.3 292bp 
SmaI-9_R CTAAAAAGTATGTTAGGCACGTG 39.1 57.1 
10 SmaI-10_F CGCGAAAAGTATTATTTCCCG 42.9 55.9 82 bp 
SmaI-10_R CTTCTTTTACTTCTCTTAACAGCG 37.5 57.6 
mecA mecA_F GTGGAATTGGCCAATACAGGAAC 48 60.6 502bp 
mecA_R GATGGCAAAGATATTCAACTAAC 35 55.3 
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4.3.5 Standard staphylococci strains  
In this study many well characterised S. aureus strains and two S. epidermidis 
strains were obtained from various sources. Sequenced S. aureus strains USA300-
FPR3757, MSSA476, MRSA252, MW2, COL, N315, Mu3, Mu50 and sequenced S. 
epidermidis RP62A, as well as control community-MRSA strains USA1000, USA1100 
and CA-629, were obtained from the network on antimicrobial resistance in 
Staphylococcus aureus (NARSA) programme, USA. EMRSA-15 (sequenced strain 
H050960412) was kindly provided by Prof. Mark Enright, Imperial College, London, 
UK. The sequenced S. epidermidis strain ATCC12228 was provided by Prof. Jan 
Maarten van Dijl, University of Groningen, the Netherlands whereas strain JH9 was 
provided by Prof. Herminia de Lencastre, Instituto de Tecnologia Química e Biológica, 
Portugal. NCTC8325 strain was obtained from the National Collection of Type Cultures 
(NCTC), London, UK. The PVL+ MRSA strain 585296 was provided by Dr. John Perry 
from the Freeman Hospital, Newcastle upon Tyne, UK.  
4.3.6 DNA extraction  
4.3.6a Extraction of the chromosomal DNA by cell mechanical breakage  
The DNA of all strains was extracted using the cell mechanical breakage method 
(Section 2.5.2b).  
4.3.6b Rapid Extraction of chromosomal DNA using only boiling method 
 The DNA was extracted according to the boiling method (Section 2.5.2c) 
4.3.6c Rapid Extraction of chromosomal DNA using boiling with lysostaphin 
method. 
Two colonies from an overnight culture was transferred into 20µl of sterile milli-Q 
water contains 3µl lysostaphin [1mg/ml] in a microcentrifuge tube and mixed 
thoroughly. The cell suspension was incubated at 37ºC for 15 - 20 min, heated to 100ºC 
for 10 min and then centrifuged at 13,000g for 5 minutes. Three microlitres of the 
resulting supernatant were used in the multiplex PCR reaction. 
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4.3.7 PCR amplification  
4.3.7a Uniplex PCR 
The 10 pairs of primers were initially tested using conventional PCR (i.e. uniplex 
reactions) to determine their amplification specificity and discriminatory power. The 
reaction conditions were as follows: 5 min at 94 ˚C initial denaturation, followed by 30 
cycles of 94˚C for 1 min, 52 - 50˚C for 1 min and 72˚C for 1 min, with final extension 
at 72˚C for 5 min.  
4.3.7b Multiplex PCR 
The optimization of multiplex PCR involved two main phases:  
Phase I: All primer pairs were manually designed to be used in a multiplex PCR. 
Initially, three pairs of primers (SmaI-groups 4, 5 & 6) were tested in the same reaction 
conditions as those used for the uniplex PCR on DNA from three unrelated S. aureus 
strains, namely NCTC8325, EMRSA-15 and MRSA-PVL+.  Multiplex PCRs were then 
carried out on the same set of DNA using six primer pairs (SmaI-groups 10, 3, 5, 6, 4 & 
7), but with modifications to the reaction conditions, as outlined in Tables 4.2 and 4.3. 
An additional four primer pairs (SmaI-groups 1, 8, 9 & 2), designed to distinguish 
specific EMRSA strains, were tested in a multiplex PCR under the same reaction 
conditions as used in phase I (Table 4.2).   
Phase II: In order to use all primers in a single 10x multiplex PCR reaction instead of 
two separate (6x and 4x) reactions, the primers were redesigned and optimised with the 
visual OMP
TM 
6.0v
 
(Oligonucleotide Modeling Platform) DNA Software in 
collaboration with Biogene LTD, UK. The optimization included secondary structure, 
homology, annealing temperature and assay conditions. The sizes of fragments 
generated by the new primer set were between 69bp to 406bp.  
Multiplex PCR components and condition 
A series of PCR reactions were carried out to identify optimal conditions for the 
multiplex PCR. This included varying the primer concentrations and the other 
components of the PCR reagents. The optimal PCR reaction conditions and components 
are outlined in Tables 4.2 and 4.3.    
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Table 4.2:  PCR reaction conditions  
 
Steps  
Multiplex PCR PhaseI Multiplex PCR PhaseII 
ºC min Cycles ºC min Cycles 
Initial Denaturing                                                            
Denaturing                                     
Annealing                                                                                
Extension                                                                                                
Final Extension 
95 5 1
94             1       
52 1 30
68 2
68             5               1 
96             2              1 
96             0.75      
56             0.75        35 
72    0.75 
72             2               1 
 
Table 4.3: Components of PCR reaction mixture.  
           Components     Volume per 50 µl reaction (µl) 
uniplex PCR Multiplex PCR 
PhaseI 
Multiplex PCR 
PhaseII 
Milli-Q Water                                                                                       
DNA polymerase buffer (10x)                                                                
Forward primer (20mM)                                                                         
Reverse primer (20mM)                                                                         
BSA (100x)                                                                                                  
dNTP (10mM)                                                                                        
MgCl (25mM)                                                                                                     
Template DNA (200ng/ µl)                                                                                       
Taq polymerase  (5U/µl)                                                                                     
28
5 
5 
5
-
1
3
2
1
Variable
5 
Variable 
Variable
4 
1.5 
4
3
1.5
29 
5 
2 µl each 
2 µl each 
4 
1 
3 
3
1 
 
4.3.8 Gel electrophoresis  
For uniplex PCR and phase I multiplex PCR, the resulting amplicons were 
separated on 1 - 1.5% agarose (in 1x TBE with 0.5µg/ml ethidium bromide) at 90V for 
50 – 130 min, then visualized using a gel documentation system.     
   In the phase II multiplex PCR, a higher percentage of low melting point agarose 
(LMP) (4% in 1xTBE) was used to resolve the smaller fragments (between 69bp to 
500bp) at 110V for 3 h. The 4% gel was stained for 15 min in one litre of multiplex 
staining solution buffer (0.5μg/ml in 1xTBE), destained in ddH2O for 15 min and then 
visualized with a gel documentation system. 
4.3.9 PFGE 
  PFGE was carried out according to the protocol in Section 2.6.1 with the 
following modifications: 70 µl lysostaphin (1mg/ml) was added to lysis buffer and the 
running time increased by 2 to 26 h.  
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4.3.10 Data analysis of SmaI-multiplex PCR and PFGE 
Gel images were saved as a TIFF file and analysed using the BioNumerics v3.50 
(Applied Maths) software. The analysis of multiplex PCR and PFGE gels was based on 
band differences and a clustering dendrogram was generated by the unweighted-pair 
group method with arithmetic mean (UPGMA) using the Dice similarity coefficient.   
4.3.11 MLST  
MLST was performed according to the protocol of Enright et al. (2000) as described in 
Section 2.6.2a. PCR products for sequencing were purified using QIAquick PCR 
purification kit (QIAgen) according to manufacturer‟s instructions (see Section 
2.6.2b.ii). The concentration of DNA was determined using the NanoDrop (ND-1000) 
system (NanoDrop Technologies) and the products were sent for sequencing (MWG 
Biotech, Germany). Nucleotide sequences were compared with the MLST database 
through website (http://www.mlst.net) for assignment of allelic profiles and sequence 
type (ST).   
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4.4 Results 
4.4.1 SmaI-Multiplex PCR  
   In this study we developed a novel multiplex PCR method that can be adapted 
for use in any routine microbiology laboratory to monitor the relations between MSSA 
and MRSA strains isolated in the clinical settings. The primers were designed around 
SmaI restrictions sites so that they can be related to PFGE electropherograms.  
4.4.2 Genomic analysis  
All currently sequenced genomes of S. aureus strains were subject to a 
bioinformatical analysis to determine the gene neighbourhoods that contain SmaI 
restriction sites. This analysis revealed that the number of SmaI restriction sites varied 
from 24 to 29 among the sequenced S. aureus strains (Table 4.4). 
Table 4.4:   Number of SmaI restriction sites among sequenced S. aureus strains.    
 S.aureus strains SCCmec 
type 
 Genome size 
(bp) 
Number of  SmaI-
restrictions sites  
M
R
S
A
 
COL I 2,809,422 27 
USA300FPR3757 IV 2,872,769 26 
USA300TCH1516 IV 2,872,915 26 
Mu50 (VISA) II 2,878,529 25 
Mu3 (VISA) II 2,880,168 26 
N315 II 2,814,816 25 
JH1 (VISA) II 2,906,507 26 
JH9 (VISA) II 2,906,700 28 
MW2 IV 2,820,462 28 
MRSA252 II 2,902,619 26 
EMRSA-15 IV 2,832,299 24 
TW20 (0582) III 3,043,210 29 
M
S
S
A
 
NCTC8325 MSSA 2,821,361 25 
RF122 MSSA 2,742,531 27 
MSSA476 MSSA 2,799,802 28 
Newman MSSA 2,878,897 26 
ED98 MSSA 2,824,404 26 
LGA251 MSSA 2,750,834 25 
 
Using a restriction site that was invariant in all the strains, the locations of all 
other SmaI restriction sites were mapped in relation to each other (Fig 4.2). 
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    Figure 4.2: SmaI restriction fragments of the DNA of S. aureus strains 
 
4.4.3 Alignment and comparison of SmaI restriction sites between strains 
Alignment of the gene neighbourhoods for the syntenic regions of SmaI-sites showed 
that more than fifty SmaI-groups were identified within the S. aureus genomes. S. 
aureus has five to six copies of the rRNA operons, and each operon contains about two 
SmaI sites (Green and Vold, 1993; Wada et al, 1993). The gene neighbourhoods located 
within the ribosomal RNA (rRNA) genes were excluded due to the high similarity of 
the sequences within rRNA that would generate unforeseen PCR products.  
             A matrix of gene neighbourhoods of SmaI restrictions sites was constructed to 
show the presence (Blue) and absence (Red) of distinct restriction sites. This matrix 
ultimately provides a reproducible diagnostic profile for each strain. More than 30 SmaI 
groups were identified to be variable between strains and the ten most discriminatory 
SmaI groups were selected for analysis (Table 4.5).   
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 Table 4. 5:  A matrix of gene neighbourhoods of SmaI restrictions sites of sequenced S. aureus strains.  
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          Once alignments of the gene neighbourhood were established, primers were 
designed. Forward primer contained the SmaI site at its 3‟ end and the reverse primer 
was designed from a conserved region between 100 – 412bp downstream of the target 
SmaI site (Fig. 4.1 and 4.3). Visual OMP
TM 
DNA software was used to design all primer 
pairs to be compatible in a single 10x multiplex PCR reaction. Visual OMP
TM 
facilitates 
the design of primers that conform to predetermined parameters, including the optimal 
length of the primers and PCR products, isothermal melting temperature, and the 
avoidance of primer dimers and secondary structures.            
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Figure 4.3:  DNA sequences of the gene neighbourhood of SmaI-group7 for seven S. aureus strains. The yellow highlighted sequences are 
 the conserved regions that were used for the design of the selected primers. The red highlighted sequences indicate variable regions  
that were avoided in the designed primers.      
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4.4.4 Identified the locations of high discriminatory SmaI restriction sites on 
the S. aureus genome         
 The location of each gene neighbourhood was determined on the S. aureus genome and 
the locations of those discriminatory sites were distributed throughout the entire genome 
(Fig. 4.4). In addition, all PCR amplicons of SmaI-groups were found to be located 
within a single gene with the exception of SmaI-groups 7 and 5. The SmaI-group 7 
amplicon was located at 5‟-end and 3‟-end of two genes encoding hypothetical phage 
proteins whereas SmaI-group 5 is located in an intergenic region (IGR) downstream of 
the dipeptidase (pepV) gene (Fig. 4.4). The SmaI-group 2 amplicon is located within a 
paralogous gene encoding a Ser-Asp rich fibrinogen-binding bone sialoprotein-binding 
protein (sdrD) while SmaI-group 9 is located on genes encoding nitrate reductase alpha 
chain (narG). The amplicons of SmaI-groups 3 and 8 are located within genes encoding 
conserved hypothetical proteins and SmaI-group 4 is located within the polynucleotide 
phosphorylase/polyadenylase gene (pnpA). SmaI-groups 1 and 6 are located within 
genes encoding capsular polysaccharide synthesis enzyme (cap8J) and serine protease 
(splC), respectively (Table 4.6 and Fig. 4.4). Once the primer pair for SmaI-group 5 
were designed and tested, it immediately became clear that it generated fragments of 
different sizes: 408bp in COL and Newman, 351bp in NCTC8325, 238bp in USA300, ~ 
180bp Mu50, Mu3, N315, MW2, MSSA476, and only 65bp in JH9 and JH1 (Table 4.6). 
The reason for this will be discussed later.  
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 Figure 4.4:  The positions and distribution of high discriminatory SmaI-restriction sites on 
the S. aureus genome. Blue rectangles (indicated by black arrows) refer to PCR 
amplicons of SmaI-groups. Mb= Megabase pair. 
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Table 4.6:  The SmaI gene neighbourhoods and their locus tags on the S. aureus genomes.  
 
 
SmaI-
group no. 
Strain PCR 
products 
size (bp) 
Gene name/ neighbourhood – (Locus tag) Primer 1  
(include SmaI) 
(L Coordinate) 
Primer 2 
 
(R Coordinate) 
1 252 169 capsular polysaccharide synthesis enzyme (cap8J)- (SAR0160) 178612 178781 
2 15 263 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein (SdrD) – 
(SAEMRSA15_04890) 
583628 583896 
3 8325 101 conserved hypothetical protein – (SAOUHSC_01174) 1124335 1124436 
4 252 120 Polynucleotide phosphorylase/polyadenylase (pnpA) – (SAR1250) 1310202 1310321 
5 
 
 
 
 
 
a COL 408 241 bp at 5' of dipeptidase (PepV) – ( SACOL1801) 
272 bp at 3' of  hypothetical protein 
1850334 1850741 
b 8325 351 241 bp at 5' of dipeptidase (PepV) – ( SAOUHSC_01868) 
272 bp at 3' of  hypothetical protein 
1776375 1776726 
c USA300 238 241 bp at 5' of dipeptidase (PepV) – (SAUSA300_1697) 
272 bp at 3' of  hypothetical protein 
1872815 1873053 
d Mu50 179 241 bp at 5' of dipeptidase (PepV) – (SAV1751) 
139 bp at 3' of  hypothetical protein 
1881973 1882151 
e JH9 65 241 bp at 5' of dipeptidase (PepV) – (SaurJH9_1806) 
139 bp at 3' of  hypothetical protein 
1927295 1927359 
6 8325 220 serine protease (SplC) – ( SAOUHSC_01939) 1845160 1845380 
7 252 146 79 bp at 5' of hypothetical phage protein – (SAR2065a) 
117 bp at 3' of hypothetical phage protein- (SAR2066) 
2150906 2151052 
8 252 319 hypothetical protein 2385802 2386121 
9 252 292 nitrate reductase alpha chain (narG)- (SAR2486) 2558309 2558601 
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4.4.5 Designing primers of SmaI restriction sites for multiplex PCR  
  Primer pairs groups of SmaI were chosen according to their discriminatory 
power and divided into two types. Type I consisted of SmaI-groups 3, 4, 5, 6, 7 & 10 
and Type II of SmaI-groups 1, 2, 8 & 9.  Type II SmaI-groups were particularly targeted 
to differentiate the UK epidemic strains EMRSA-15 and EMRSA-16.  
4.4.6 Identification of validity of primer pairs in uniplex PCR  
In the second stage of development, the amplification specificity and 
discriminatory power of primer pairs (SmaI-groups-4, 5 & 6) were examined by uniplex 
PCR on three unrelated S. aureus strains (NCTC8325, EMRSA-15 and MRSA-PVL+). 
The data showed that strains NCTC8325 and MRSA-PVL+ generated amplicons for all 
three primer pairs while EMRSA-15 only generated an amplicon for the group-4 primer 
pair. Interestingly, the length of the PCR fragment generated from the group 5 primer 
pair was found variable (142-bp as compared to the expected 425-bp in the case of 
NCTC8325) (Fig. 4.5). This observation could potentially add to its discriminatory 
power of the technique and the resulting fragment was designated group-5a. 
          
          Figure 4.5:  PCR amplified products generated from three primer pairs SmaI-group-4, 5 
& 6 of S. aureus NCTC8325, EMRSA-15 and MRSA-PVL+. MW= 
molecular size marker.   
 
The variable PCR products that were generated by SmaI-group 5 were due to the 
presence of a variable number of Staphylococcus aureus repeat (STAR) elements in the 
intergenic region between dipeptidase (PepV) and a hypothetical protein encoding gene 
(Fig.4.6) 
Chapter 4: Development of a novel multiplex-PCR typing technique                         90 
 
 
Figure 4. 6:  SmaI-group 5 primers that amplify variable PCR products due to repeated STAR sequences in an intergenic region in different  
strains. R1= repeated sequence 1. 
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4.4.7 Multiplex PCR 
4.4.7a Combined multiplex PCR against individual strains  
Multiplex PCR was initially performed with the first six primer pairs of SmaI- 
groups 3, 4, 5, 6, 7 &10. In this experiment four unrelated strains (NCTC8325, 
EMRSA-15, EMRSA-16 and MRSA-PVL+) were typed and showed three distinct 
profiles, allowing two of the strains to be distinguished from each other. However, 
EMRSA-15 and EMRSA-16 had identical profiles. Consequently, at this stage, the first 
set of primers was not able to distinguish between the most predominant UK epidemic 
clones, namely EMRSA-15 and EMRSA-16 (Fig. 4.7). 
      
         Figure 4.7:  Multiplex PCR using six primer pairs against strains (NCTC8325, 
EMRSA-15, EMRSA-16 and MRSA-PVL+). Strains showed different 
profiles except that it was not possible to distinguish between EMRSA-15 
and EMRSA-16.  bp = base pairs 
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4.4.7b Initial determination of the discriminatory power against clinical MRSA 
isolates 
     A number of clinical MRSA isolates isolated from the Freeman Hospital (Newcastle 
upon Tyne) were typed by multiplex PCR using all six Type I primer pairs. All of these 
MRSA isolates showed the same profiles as EMRSA-15 and EMRSA-16 (Fig. 4.8). 
 
Figure 4.8:  SmaI profiles of five clinical isolates using multiplex PCR for all six primer pairs. 
M1= MRSA1. MW= molecular size marker.   
 
In an attempt to distinguish two clones of EMRSA-15 and EMRSA-16, four new 
primer pairs were designed and tested using conventional PCR. Distinctive profiles 
were found to distinguish between these strains (Fig. 4.9).  
 
Figure 4.9:  Evaluation of PCR primer pairs designed to differentiate between EMRSA-15 
and EMRSA-16. A: Analysis by conventional PCR. B: Prospective profiles 
expected for a multiplex PCR typing using all 10 primer pairs. MW= molecular 
size marker. bp = base pairs. 
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The four new primer pairs were tested against EMRSA-15 and EMRSA-16 in a 
multiplex reaction and they distinguished clearly between these two clones (Fig. 4.10). 
               
Figure 4. 10:  SmaI-Multiplex PCR profiles of EMRSA-15 and EMRSA-16 using four new 
primer pairs 
4.4.7c Optimization of a novel SmaI-multiplex PCR typing technique  
Having confirmed that the primer selection strategy was effective, the visual 
OMP
TM 
(Oligonucleotide Modelling Platform) software was used to redesign and 
optimise the primers for use in a single 10x multiplex PCR reaction instead of two (6x 
and 4x) multiplex PCR reactions. The sizes of PCR products ranged from ~ 69bp to 
412bp and the software optimized the secondary structure, homology, annealing 
temperature and assay conditions. 
Initially, the ten newly designed primer pairs were multiplexed with two 
different multiplex PCR master mixes against five unrelated S. aureus strains (NCTC 
8325, EMRSA-15, MRSA252, NCTC 6571 and a PVL-positive MRSA). The master 
mix that was prepared in this study showed the best performance and the PCR 
amplicons were sharp and clear whereas the performance of Biogene master mix was 
poor and some PCR products were either weak or missing (Fig. 4.11). 
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Figure 4.11:  SmaI-multiplex PCR profile of five S. aureus strains (NCTC 8325, EMRSA-
15, MRSA252, NCTC 6571 and a PVL-positive MRSA) using 10 new primer 
pairs that redesigned using OMP
TM 
(Oligonucleotide Modelling Platform) 
software. All primers were tested on two different multiplex PCR master mixes, 
one was prepared in this study (left) and another provided by Biogene LTD, UK 
(right).  
In order to determine the optimal annealing temperature for the multiplex PCR, 
the ten redesigned primer pairs were tested on four S. aureus strains at different 
annealing temperatures and their performance was generally excellent. An annealing 
temperature in the region of 56˚C to 57˚C was found to be optimal. However, the primer 
pairs of SmaI-groups 4, 3 and 10 amplified PCR products for strains NCTC8325, 
EMRSA-15 and MRSA252, respectively, that were not predicted (Fig. 4.12).  
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Figure 4.12: SmaI-multiplex PCR profiles of four unrelated S. aureus strains using all ten 
redesigned primers in single multiplex PCR reaction at different annealing 
temperatures. X = PCR products that were not predicted by the bioinformatical 
analysis. 
 
The unexpected products were due to SNPs in restriction the SmaI sites 
themselves in which the nucleotide at position 4, which is a “G”, was replaced with an 
“A” in the case of groups 4 and 10 (CCCAGG) and “T” in the case of group 3 
(CCTGGG). It was clear that, although the forward primers should not have annealed to 
these SNPs, the stringency was not sufficient to avoid their annealing under the 
condition used in the multiplex reaction. In an attempt to avoid these false positive 
reactions, the forward primers for groups 3, 4 and 10 were redesigned to avoid false-
positive PCR amplicons by reducing their melting temperatures. The multiplex was 
repeated on ten of the sequenced S. aureus strains using all ten primer pairs, but 
including the new forward primers for groups 3, 4 and 10. The new primers for groups 4 
(product size 124bp) and 3 (product size 101bp) produced the expected products with 
no false positives (Fig. 8). However, the primers from group 10 (82bp) still generated an 
amplicon from most of the strains, indicating that the forward primer still lacked 
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specificity. Significantly, each of the strains showed a distinct profile, although it was 
not possible to distinguish between three closely related hospital strains, namely Mu50, 
Mu3 and N315, and two closely related community strains, MSSA476 and MW2. In 
general, the specificity of the primers was excellent excepting for the group 10 primers 
(product size 82bp), indicated by the red arrow in Figure 4.13. This primer pair 
generated a false positive amplicon from strains MSSA476, MW2, Mu50, Mu3, N315, 
MRSA252 and EMRSA15. In addition, the PCR products of SmaI groups 2, 4 and 5 
(variable length) were weak in some strains as indicated by yellow arrows in Figure 
4.13. 
 
Figure 4.13: SmaI multiplex PCR profiles of nine sequenced S. aureus strains and a PVL-
positive MRSA strain with all ten redesigned primer pairs. The red arrow refers 
to the false positive PCR products of SmaI-group 10 and the yellow arrows refer 
to weak PCR products of SmaI groups 2, 4 and 5 (variable length) in some 
strains. MW= molecular size markers.  
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In order to assess the problem of SmaI-group10 primers, the sequences around 
SmaI-site of six strains that generated false positive results were aligned with two 
strains that were expected to generate amplicons. This confirmed that the only 
difference between these strains was the SNP SmaI restriction site (CCCAGG) 
associated with the forward primer (Fig. 4.14).   
Attempts to redesign a primer to differentiate between these strains using SmaI-
group10 were unsuccessful and consequently the SmaI-group-10 primer pair was 
replaced by a primer pair based on the methicillin-resistance gene (mecA). This new 
primer actually increased the discriminatory power of the multiplex typing technique by 
allowing community strains MSSA476 and MW2 to be discriminated (Fig. 4.15). 
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Figure 4.14: SmaI-group 10 sequences of two S. aureus (8325 and COL) with SNP in SmaI-site of other strains (red rectangle).  
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 Figure 4.15: The SmaI-profiles of thirteen reference S. aureus strains with all ten primer 
pairs groups after replacing the SmaI-group 10 primer pair with a mecA primer 
pair. The yellow box indentifies the profiles of two closely related community 
strains, MSSA476 and MW2, that were not previous distinguishable. MW= 
molecular size markers.  
4.4.8 Validating the novel typing method with rapidly extracted DNA   
The above studies were carried out on purified chromosomal DNA, isolated as 
described in Section 2.5.2b. To confirm the validity of a new method with rapidly 
extracted DNA, a necessary prerequisite for use in a routine clinical laboratory, four 
strains (NCTC 8325, EMRSA-15, MRSA252 and a PVL-positive MRSA) were tested 
using DNA extracted from a colony removed from an agar plate by boiling with or 
without a short pre-treatment with lysostaphin. As shown in Figure 4.16, the 
performance of the primer pairs was excellent when the DNA was extracted by 
pretreating the cells with lysostaphin prior to boiling. In the absence of lysostaphin 
pretreatment, some of the expected PCR products were either very faint or missing 
altogether (yellow arrows). In this experiment the specificity of the assay was assessed 
using two sequenced coagulase-negative staphylococci (CNS) strains (methicillin 
resistant S. epidermidis RP62A and methicillin sensitive S. epidermidis 12228). With 
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the exception of the mecA primer pair, the multiplex primers were shown to be specific 
S. aureus since no other PCR products were generated from either of the CNS (Fig. 
4.16). 
    
Figure 4.16: SmaI-Multiplex PCR profiles of four unrelated S. aureus strains (NCTC 8325, 
EMRSA-15, MRSA252 and a PVL-positive MRSA) using DNA extracted by 
only boiling with or without lysostaphin pretreatment. The yellow arrows refer 
to missed bands. On the right of the gel two sequenced S. epidermidis strains 
were tested to determine specificity of SmaI-Multiplex PCR assay. 
  
As the final optimization step, new primers for SmaI-groups 2, 4 and 5 (variable 
lengths) were redesigned to improve their performance and amplicon band sharpness on 
the gel. The mecA primer pair was also redesigned to generate ~500bp of mecA instead 
of 82bp. The impact of these new primers is given in Section 4.4.9. 
4.4.9 The typeability, discriminatory power and reproducibility of a novel 
SmaI-multiplex PCR technique  
In this experiment fourteen reference strains (11 sequenced strains and 3 well 
known CA-MRSA strains) were typed by the SmaI-multiplex PCR with all ten primer 
pairs (including mecA). The reference strains used were: NCTC8325, MRSA252, 
MSSA476, COL, JH9, N315, Mu3, Mu50, MW2, USA300FPR3757, EMRSA-15, 
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USA1000, USA1100 and CA-629. Chromosomal DNA was added at a final 
concentration of 10ng/μl and the PCR reaction conditions were the same as those used 
for the phase II optimization. Firstly, it can be seen (Fig. 4.17) that the performance of 
new primer pairs for SmaI-groups 2, 4 and 5 (yellow arrows) was clearly an 
improvement and their products were distinct and sharp in all strains.  
All of the reference strains were typeable and the discriminatory power of the 
new method was both excellent and reproducible (more than 3 times with same 
profiles). The strains had distinct profiles with the exception of the closely related 
hospital strains Mu50, Mu3 and N315 that had identical profiles. The developed 
technique also distinguished between closely related community MSSA strains 
MSSA476 and MW2, community MRSA strains USA1000, USA1100 and CA-629 and 
to hospital-acquired MRSA strains EMRSA-15 and MRSA252 (EMRSA-16) (Fig. 
4.17). 
  
Figure 4.17: The SmaI-multiplex PCR profiles of eleven reference S. aureus strains and three 
unrelated community-MRSA strains with all ten primer pairs groups as the last 
step of optimization of a novel typing technique. Yellow arrows refer to 
redesigned primers to enhance their performance. MW 50bp = 50 base pair 
molecular size markers. (Representative gel of 3 times repeating experiments).  
 
Chapter 4: Development of a novel multiplex-PCR typing technique                         102 
4.4.10 PFGE, MLST and SCCmec type of reference S. aureus strains  
PFGE was performed for all those strains typed by SmaI-multiplex PCR (Fig. 
4.17) except strains Mu3 and CA-629. As can be seen from Figure 4.18, all strains 
showed distinguishable SmaI-PFGE patterns including closely related strains Mu50 and 
N315 that showed identical SmaI-multiplex PCR. Strains COL and USA300 showed 
closely related PFGE patterns and in the same situation with MSSA476 and MW2, and 
JH9, N315, and Mu50. EMRSA-15, MRSA252, USA1000 and USA1100 have slightly 
close SmaI-PFGE profiles (Fig. 4.18).  
 
Figure 4.18: SmaI-PFGE patterns of ten reference S. aureus strains and three unrelated 
community-MRSA strains that were typed by SmaI-multiplex PCR in Figure 
4.17.  MW= molecular size marker (lambda ladder). Kb= kilo base.      
 
All reference strains have known sequence types (STs) and SCCmec types 
except ST of CA-629 that was identified in this study. Nine STs were found among 
those fourteen S. aureus strains. The four strains (JH9, N315, Mu50 and Mu3) have an 
identical MLST type and SCCmec type: ST5-SCCmec-II. The very closely related 
strains MSSA476 and MW2 also have the same MLST type: ST1. Strains NCTC8325 
and USA300 have ST8 whereas COL strain has ST250-SCCmec-I. MRSA252 
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(EMRSA-16) and CA-MRSA USA1100 harbour closely related STs: ST36-SCCmec-II 
and ST30-SCCmec-IV respectively. Also closely related ST59-SCCmec-IV and ST87-
SCCmec-V were possessed by CA-MRSA USA1000 and CA-629 respectively while 
EMRSA-15 has ST22-SCCmec-IV.   
4.4.11 Analysis and comparison of a novel SmaI-multiplex PCR results with 
PFGE and MLST data 
In order to determine and evaluate the discriminatory power of the novel SmaI-
multiplex PCR typing method, an analysis was carried out on 14 S. aureus reference 
strains to compare the performances of the PCR, PFGE and sequence typing. The 
fourteen reference strains used in the comparative study were: NCTC8325, MRSA252, 
MSSA476, COL, JH9, N315, Mu3, Mu50, MW2, USA300FPR3757, EMRSA-15, 
USA1000, USA1100 and CA-629. (Strains Mu3 and CA-629 were not used in the 
PFGE). 
In general, the results were comparable the results for the SmaI-multiplex PCR, 
PFGE and MLST are summarised in Table 4.7. The banding patterns of SmaI-multiplex 
PCR and PFGE were analysed using the fingerprinting analysis software BioNumerics 
v3.50 (Applied maths) whereas the neighbour-joining tree of MLST was constructed 
using the allelic profiles and STs of 14 S. aureus reference strains.  
The UPGMA dendrograms of the novel SmaI-multiplex PCR and PFGE profiles 
clustered the reference strains into the same four groups, although there were slight 
differences in the relationships between groups (Fig. 4.19). SmaI-multiplex PCR 
grouped NCTC8325, USA300 and COL in one contiguous cluster as PFGE (Fig. 4.19, 
yellow box) and each one has unique profile, though, strains NCTC8325 and USA300 
shared same MLST allelic profile ST8 (3- 3- 1- 1- 4- 4- 3) and COL has close sequence 
type ST250 (3- 3- 1- 1- 4- 4- 16).  
 
 
 
 
 
Chapter 4: Development of a novel multiplex-PCR typing technique                         104 
 
Figure 4. 19: The UPGMA dendrogram of SmaI-multiplex PCR and SmaI-PFGE patterns based on Dice similarity coefficient and the neighbour-
joining tree of MLST illustrating the genetic relationship among 14 reference S. aureus strains. CC= clonal complex.
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Two community-acquired strains, MSSA476 and MRSA-MW2, belong to the 
MLST allelic profile (ST1: 1-1-1-1-1-1-1), but had different SmaI-multiplex PCR 
profiles and were clustered together by SmaI-multiplex PCR (75% similarity) and PFGE 
(80% similarity) (Fig. 4.19, blue box). 
 Strains Mu50, Mu3 and N315 had the same MLST (ST5: 1-4-1-4-12-1-10) and 
SmaI-multiplex PCR profiles, while JH9, which was also a member of the ST5, was 
closely related to those strains and within same SmaI-multiplex PCR cluster. All four of 
these strains had the same SCCmec type, namely type II (Table 4.7). PFGE grouped 
Mu50, N315 and JH9 in one cluster and the similarity between Mu50 and N315 was 
65% while JH9 showed 55% similarity to Mu50 and N315 (Fig. 4.19, red box). Mu3 
was not analysed by PFGE. 
SmaI-multiplex PCR clearly distinguished between the most common UK 
hospital epidemic strains EMRSA-15, MRSA252 (EMRSA-16) and also between USA 
community acquired MRSA strains CA-MRSA USA1000, USA1100 and CA-629. 
Those strains were grouped in single clusters by SmaI-multiplex PCR and PFGE, with 
each strain exhibiting a unique profile. CA-MRSA strains USA1000 and CA-629 have 
close but different SmaI-multiplex PCR profiles with 90% similarity and have 
sequence/mecA types ST59/SCCmec-IV and ST87/SCCmec-V, respectively.  
MRSA252 (EMRSA-16), with sequence/mecA types ST36/SCCmec-II, and USA1100, 
with have sequence/mecA types ST30/SCCmec-IV), were 85% related by SmaI-
multiplex PCR. EMRSA-15 (ST22/SCCmec-IV) exhibited a unique SmaI-multiplex 
PCR profile with a 70% similarity to the MRSA252, USA1100, USA1000 and CA-629 
cluster (Fig. 4.19, green box). 
The results show that, in terms of discriminatory power, the order was PFGE> 
SmaI multiplex PCR>MLST. However, in terms of ease of use, the order was SmaI 
multiplex PCR>MLST>PFGE. 
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Table 4. 7: Typing data obtained by SmaI-multiplex PCR, PFGE, MLST and SCCmec analyses for14 reference S. aureus strains. 
 
ST= sequence type.    CC= clonal complex.
Strain PFGE  SmaI- multiplex PCR type MLST SCCmec type 
SmaI-Type SmaI-profile 
MecA- 1 - 2- 3-  4-  5  - 6-  7-  8-  9 
ST Allelic profile Clonal Complex 
NCTC8325 A 1 0-0-0-1-0-1b-1-0-0-0 ST8 3- 3- 1-1- 4- 4-3 CC8 MSSA 
COL B 2 1-0-0-1-0-1a-1-0-0-0 ST250 3-3-1-1-4- 4 -16 CC8 SCCmecI 
USA300-FPR3757 C 3 1-0-0-1-0-1c-1-1-0-0 ST8 3- 3- 1-1- 4- 4- 3 CC8 SCCmecIV 
MSSA476 D1 4 0-1-0-1-1-1d-1-0-0-0 ST1 1-1-1-1-1-1-1 CC1 MSSA 
MW2 D2 5 1-1-0-1-1-1d-1-0-0-0 ST1 1-1-1-1-1-1-1 CC1 SCCmecIV 
Mu50 E 6 1-0-0-0-1-1d-1-0-0-0 ST5 1-4-1-4-12-1-10 CC5 SCCmecII 
Mu3 ND 6 1-0-0-0-1-1d-1-0-0-0 ST5 1-4-1-4-12-1-10 CC5 SCCmecII 
N315 E1 6 1-0-0-0-1-1d-1-0-0-0 ST5 1-4-1-4-12-1-10 CC5 SCCmecII 
JH9 E2 7 1-0-0-0-1-1e-1-0-0-0 ST5 1-4-1-4-12-1-10 CC5 SCCmecII 
EMRSA-15 F 8 1-0-1-0-1-0-1-1-0-1 ST22 7-6-1-5-8-8-6 CC22 SCCmecIV 
MRSA252 G 9 1-1-0-0-1-0-0-1-1-1 ST36 2-2-2-2-3-3-2 CC30 SCCmecII 
USA1100 J 10 1-1-1-0-1-0-0-0-1-1 ST30 2-2-2-2-6-3-2 CC30 SCCmecIV 
CA-629 I 11 1-1-0-0-1-0-0-1-0-1 ST87 19-23-15-2-41-20-15 CC59 SCCmecV 
USA1000 H 12 1-1-0-0-1-0-0-0-1-0 ST59 19-23-15-2-19-20-15 CC59 SCCmecIV 
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4.5 Discussion  
Since their emergence in the early 1980s, EMRSA-15 and EMRSA-16 have 
become the most common and prevalent hospital epidemic MRSA clones in the UK. 
More recently, community acquired MRSA strains have become more prevalent and 
their infections are no longer confined to the community but have started to replace HA-
MRSA in some health care settings (D‟Agata et al., 2009). Understanding the 
transmission behaviour of those clones and distinguishing between them and their 
variants have emerged as major challenges for health care institutions. A wide variety of 
molecular techniques are currently used to type MRSA strains. These include PFGE, 
MLST, spa and SCCmec typing. PFGE is, by far, the most discriminatory of these, but 
has been supported in recent year by more rapid methods, such as multi-locus sequence 
typing.  
Because PFGE and MLST require a high level of expertise and specialist 
equipment, and are technically demanding, they are usually beyond the resources of 
most routine clinical microbiology laboratories. In the UK, for example, potential 
outbreak strains are sent for typing to the Health Protection Agency (HPA) at Colindale, 
London, where it can take up to 4 weeks to process the samples and provide the 
supplying laboratory with the required epidemiology data. Hence, the development of a 
new typing technique is urgently required. Such a technique should have high 
discriminatory power and reproducibility that is similar to that of PFGE, but should be 
rapid and suitable for use in all routine clinical laboratories.  
S. aureus is an ideal species in which to develop novel molecular 
epidemiological approaches. Eighteen S. aureus genomes have been completely 
sequenced and eleven are currently in progress. The availability of this large body of 
sequence information has allowed researchers to investigate in detail variations between 
the genomes of this versatile pathogen. Due to high similarity (97.7%-99.8% nucleotide 
identity) in core genomes of S. aureus strains, SNPs are one of the most effective ways 
of discriminating between individual strains (Lindsay and Holden, 2006).        
This study was targeted at the development of a new typing tool that approaches 
the discriminatory power of PFGE, but is based on multiplex PCR and rapidly prepared 
chromosomal DNA. Similar to PFGE, this new tool is based around SNPs in SmaI 
restriction sites by incorporating discriminatory SmaI sites at the 3‟ end of the forward 
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primer. The presence of a PCR product should therefore reflect the presence or the 
absence of SNPs in specific SmaI restriction sites in the bacterial chromosomal DNA, 
with the size of the resulting products identifying the targeted SmaI site. The DNA 
sequences of eighteen S. aureus strains NCTC8325, MRSA252, MSSA476, COL, 
RF122, JH1, JH9, N315, Mu3, Mu50, MW2, Newman, USA300FPR3757, 
USA300TCH1516, ED98, LGA251, TW20 and EMRSA-15 were therefore used in a 
bioinformatical analysis to determine the number and location of their SmaI restriction 
sites. The number of SmaI restriction sites per genome was between 24 to 29 sites.   
In the second phase of this analysis, a comparative analysis was carried out to 
determine the gene neighbourhoods for the syntenic regions of the SmaI-sites for all the 
sequenced strains. The gene neighbourhoods were grouped in a matrix that was used to 
determine their discriminatory power. Discriminatory SmaI-sites were chosen and their 
resolving power analysed in two stages. The first stage involved the evaluation of the 
six primer pairs with first a uniplex PCR and then multiplex PCR to differentiate 
between strains NCTC8325, EMRSA-15, EMRSA-16 and MRSA-PVL+. These primer 
pairs showed clear specificity and the test strains were, in most cases, distinguishable 
with unique profiles. However, EMRSA-16 and EMRSA-15 exhibited the same profile 
and SmaI-group 5 primers produced products of variable length. Subsequent analysis 
revealed that the latter was due to the presence of variable numbers of Staphylococcus 
aureus repeat (STAR) elements between the group 5 forward and reverse primers.  
STAR elements are CG-rich repeat sequences located in an intergenic region of the S. 
aureus genome (Cramton et al., 2000). The presence of the STAR elements increased 
the discriminatory power of the SmaI-multiplex method.   
In the third stage of development, four new SmaI-groups were selected and 
primers were designed to differentiate between the most common UK epidemic strains 
EMRSA-15 and EMRSA-16. As a result, both strains showed distinctive profiles and 
could be distinguished from each other and from other strains.   
The discriminatory SmaI-sites were found to be located throughout the entire S. 
aureus genome (Fig. 4.4). The breadth of this distribution means that the SmaI-sites 
reflect variations of whole genome rather than relying on variations within a single gene 
(e.g. spa typing) or even seven genes (e.g. MLST).  
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Once the second optimization phase had been confirmed, in collaboration with 
Biogene LTD, UK, all ten primer pairs were redesigned for use in a single multiplex 
PCR reaction. This was done using Biogene proprietary Visual OMP
TM
 
(Oligonucleotide Modeling Platform) DNA analysis software. The primer redesign and 
optimization included secondary structure, homology, annealing temperature and assay 
conditions. The ten PCR fragments were sized between ~ 69bp to 412bp.   
The redesigned primers were multiplexed in a single multiplex PCR with two 
different multiplex PCR master mixes (one prepared in current study and the Biogene 
master mix) against five S. aureus strains (NCTC 8325, EMRSA-15, MRSA252, NCTC 
6571 and a PVL-positive MRSA). Significantly, the master mix that prepared in this 
study showed the best performance (Fig. 4.11). Moreover, the discriminatory power and 
optimal annealing temperature of the redesigned primers were initially determined 
against four unrelated S. aureus strains NCTC8325, MRSA-PVL+, EMRSA-15 and 
MRSA252. These primers showed a clear discrimination between the strains, with an 
optimal annealing temperature of 56˚C. SmaI-groups 3, 4 and 10 generated false-
positive amplicons in some strains (Fig. 4.12). In the case of groups 3 and 4, these were 
subsequently shown to be due to the presence of syntenic SmaI sites with SNPs; 
CCCTGG in the case of group 3 and CCCAGG in the case of group 4. SNPs were also 
found in their reverse primers. In the case of group 10 primers, the presence of a 
syntenic SmaI sites with a SNP was discovered; CCCAGG. Since these SmaI groups 
were highly discriminatory, and excluding them would decrease the discriminatory of a 
developed technique, the Visual OMP software was used in an attempt to redesign new 
primers for these sites. In the case of groups 3 and 4 this was successful and PCR 
products were amplified from the expected strains. However, it was not possible to 
design a primer pair for SmaI group 10.  
The redesigned primer pairs 3 and 4 were used to replace the existing primers 
for these groups and a primer pair for the mecA gene was introduced into the multiplex 
reaction. Analysis of nine sequenced S. aureus strains gave distinct profiles for each 
strain with exception for hospital strains Mu50, Mu3 and N315 (Fig. 4.15).  
The second advance was the development of a rapid DNA extraction protocol 
for the multiplex PCR. The extraction protocol takes 25 minutes and includes just two 
steps, the treatment of bacterial cells from one or two colonies with lysostaphin 
followed by boiling in water. The DNA extraction method was evaluated on four 
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unrelated S. aureus strains in comparison with DNA extracted only by boiling and 
purified DNA. The DNA extracted by lysostaphin pretreatment and boiling generated 
profiles that were as clear as those generated with purified DNA. In the case of DNA 
extracted by boiling alone, some of the expected PCR products were very faint or 
missed altogether (yellow arrows, Fig. 4.16).  
The typeability, discriminatory power and reproducibility of a novel SmaI-
multiplex PCR were validated on fourteen reference strains. Eleven of them are 
sequenced strains (NCTC8325, MRSA252, MSSA476, COL, JH9, N315, Mu3, Mu50, 
MW2, USA300FPR3757 and EMRSA-15) and three are well known community-
MRSA (USA1000, USA1100 and CA-629). In general, all strains were typeable with 
high discriminatory power. All strains tested appeared distinguishable with distinct 
profile with the exception of very closely related HA-VISA strains Mu50, Mu3 and 
N315 that, as expected, showed the same profile (Fig. 4.17). These strains share the 
same sequence (ST5) and SCCmec (II) types and showed close a relationship in a 
molecular evolutionary genetics analysis (MEGA) study (Highlander et al., 2007).  
In order to compare the discriminatory power of
 
a novel SmaI-multiplex PCR 
method with the most popular typing methods, all of the standard S. aureus strains 
(except Mu3 and CA-629) that were tested by SmaI-multiplex PCR were further 
subjected to PFGE analysis. Those strains have well-known MLST and SCCmec types. 
Since the multiplex is based on the similar principles to that of PFGE, the BioNumerics 
fingerprint analysis software was used to compare the outcomes from the SmaI-
multiplex PCR profiles and SmaI-PFGE patterns. The UPGMA dendrogram of SmaI-
multiplex PCR and PFGE, and neighbour-joining tree of MLST showed that the 
correlation between the three typing method was excellent (Fig. 4.19). The 
discriminatory power of a novel SmaI-multiplex PCR seemed to be between PFGE and 
MLST. The cluster analysis showed that the SmaI-multiplex PCR grouped strains into 
the same four clusters as PFGE and almost matched that of the MLST types as well 
(Fig. 4. 19). For example, the clonal complex (CC8) strains NCTC8325, USA300 and 
COL were grouped in one tight cluster by both SmaI-multiplex PCR and PFGE. Strains 
NCTC8325, USA300 showed different SmaI-multiplex PCR profiles though both have 
identical MLST type (ST8). In addition, the HA-MRSA COL strain showed a unique 
SmaI-multiplex PCR profile, albeit on that was relatively close to USA300. COL has 
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ST250, which is a single locus variant (SLV) of ST8 at the yqiL locus and both STs 
belong to same clonal complex (CC8) (Lindsay and Holden, 2006).  
Interestingly, two community-acquired strains, MSSA476 and MRSA-MW2, 
have very close but distinguishable SmaI-multiplex PCR and PFGE profiles. In the case 
of SmaI-multiplex PCR, both showed identical profiles with the exception of a fragment 
generated from the mecA gene. In a comparative study, all orthologous gene pairs in the 
core genomes of MW2 and MSSA476 showed 99.8% of nucleotide identity (Lindsay 
and Holden, 2006). These strains also share an identical sequence type (ST1).  
Although, HA-MRSA N315 and vancomycin-intermediate-resistant strains 
Mu50, Mu3 and JH9 are closely related and share same sequence type ST5 and 
SCCmec-II, SmaI-multiplex PCR discriminated JH9 from strains Mu50, Mu3, and N315 
(Fig. 4.19, red box). This cluster of strains (Mu50, Mu3, N315 and JH9) was closely 
related to the MW2 and MSSA476 cluster (60% of similarity) and both clusters belong 
to the closely related sequence types, ST5 and ST1 respectively (Holden et al., 2004).  
In the UK, the hospital epidemic clones EMRSA-15 and ERSA-16 are 
responsible for more than 95% (60.2 and 35.4%, respectively) of S. aureus bacteraemia 
(Johnson et al., 2001) and this percentage increased since 2007 to 85 and 9%, 
respectively (Ellington et al., 2010). Moreover, CA-MRSA has been involved in 
hospital-acquired MRSA, and in USA, for example, CA-MRSA USA300 was 
responsible for 33% of hospital-acquired MRSA infections in a study conducted by 
Huang et al. (2006). This makes the distinction between the most prevalent HA-MRSA 
and CA-MRSA an issue in many healthcare settings.  
In this study, the developed SmaI-multiplex PCR discriminated between the 
most common UK hospital epidemic strains EMRSA-15, MRSA252 (EMRSA-16, also 
called USA200) and also between well known USA community-acquired MRSA 
strains: USA1100, USA1000 and CA-629. Although, those strains were grouped in 
single tight cluster, each strain showed unique SmaI-multiplex PCR, MLST and PFGE 
profiles (Fig. 4.19, green box). 
 CA-MRSA strains, USA1000 and CA-629 showed closely related but 
distinguishable SmaI-multiplex PCR profiles and sequence types (ST59 and ST87, 
respectively). The ST87 is an SLV of ST59 at the pta locus and both clones belong to 
same clonal complex (CC59) (Table 4.7) (Coombs et al., 2010). Similarly, MRSA252 
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(EMRSA-16) (ST36) and USA1100 (ST30) showed closely related SmaI-multiplex 
PCR profiles. ST36 is also an SLV of ST30 at the pta locus and both sequence types 
represent the same clonal complex (CC30) (Table 4.7). EMRSA-15 (ST22/SCCmecIV) 
was slightly divergent with a unique SmaI-multiplex PCR profile but it showed about 
70% similarity to cluster of MRSA252, USA1100, USA1000 and CA-629  (Fig. 4.19, 
green box).  
We proposed a simple nomenclatural system for a novel SmaI-multiplex PCR 
profiles based on the presence and absent of all nine SmaI-sites according to their order 
on the genome (i.e. mecA-1 to SmaI-9). For example, SmaI-multiplex PCR type 2 of the 
COL strain, was given the SmaI-profile 1-0-0-1-0-1a-1-0-0-0, with the binary numbers 
(1 = present, 0 = absent) referring to the presence or absence of an amplicon at a 
specific allele. The letter on the group 5 refers to the length of the variable PCR 
products generated by SmaI-group 5 primer pair (Table 4.7). 
In conclusion, a novel PCR-based typing technique, which is relatively rapid, 
reproducible and discriminatory, has been developed for use in routine clinical 
microbiology laboratories. The technique is more discriminatory than MLST and has 
the potential to be as discriminatory as PFGE. It does not require expertise and uses 
standard clinical laboratory apparatus (PCR machine and agarose gel electrophoresis). 
The required DNA is extracted from lysostaphin-treated boiled colonies and the results 
are available within 4-6h. This technique could to be adapted for real-time multiplex 
PCR assay to reduce the processing time to <60 minutes and for the data to be 
processed automatically. 
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5. Evaluation of the discriminatory power of the SmaI-multiplex PCR 
typing technique against MSSA and MRSA obtained during 
potential outbreaks 
 
5.1 Introduction  
An outbreak of an infectious agent is defined as the occurrence two or more 
cases of infection caused by the same microorganism, or an unexpectedly large number 
of cases of infection that exceeds that normally observed (van Leeuwen, 2003). MRSA 
outbreaks occur frequently in hospitals units, with intensive care units (ICUs), neonatal 
units, surgical units and burn units and ICUs the most often affected. ICUs in particular, 
are a principal source of multi-drug resistant MRSA outbreaks (Albrich et al., 1999; 
Embil et al., 2001; Song et al., 2010).  
Colonised and infected individuals, whether patients or healthcare workers, are 
considered to be the main reservoir for MRSA, with the nose being the most common 
site of colonisation. Furthermore, direct contact by hand is the main route for the spread 
of MRSA among patients, with healthcare workers playing a key role in the 
dissemination of these bacteria. In addition, in many cases where an outbreak has been 
investigated in detail, a combination of the hospital environment and insufficient 
cleaning have been identified as major risk factors which contributed to the outbreak 
(Embil et al., 2001). 
During the 1960s-1970s, the incidence of MRSA outbreaks was low and due to 
sporadic strains. However, the prevalence of MRSA increased during the 1980s and 
many epidemic outbreaks were reported during this period (Hryniewicz, 1999). Most 
hospital outbreaks were confined to what are now recognised as HA-MRSA, however, 
more recently both CA-MRSA and high virulence HA-MRSA (PVL+) have been 
reported in some outbreaks (Taneike et al., 2006). In the UK, epidemic clones EMRSA-
15 and EMRSA-16 are responsible for most hospital outbreaks. Both clones have a high 
tendency to spread and the differentiation between these and other clones is important in 
monitoring this spread.  
The purpose of any epidemiology study, such as the investigation of individual 
outbreaks, is to identify the potential source(s) of infection and to monitor 
dissemination. The early identification of an outbreak, making use of a rapid, precise 
and simple MRSA typing technique, could lead to prompt and effective precautions that 
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avoid the further spread of the infection. The choice of an epidemiological tool basically 
depends on the purpose of the analysis (short and long term) and the availability of the 
necessary expertise, and resources. Due to their increased accuracy, molecular typing 
methods (e.g. PFGE, MLST and SCCmec) have tended to replace more traditional 
phenotyping methods (e.g. phage typing) (Singh et al., 2006). However, both PFGE and 
MLST are technically demanding and expensive and they are not used routinely in most 
hospital clinical laboratories in the UK. Therefore, potential outbreak strains are sent to 
a reference laboratory (e.g. HPA, at Colindale, London) for analysis. This makes the 
investigation and monitoring of MRSA outbreaks difficult which, in turn limits, the 
effective decision making of the infection control team. 
  SmaI-multiplex PCR typing is based on single nucleotide polymorphism (SNP) 
in SmaI restriction sites, the same sites that are used in the PFGE analysis of MRSA 
strains. When used against sequences strains, the technique was shown to be 
reproducible and to exhibit good discriminatory power. It was also easy to perform and 
interpret, and results are available with 4-6 hours. SmaI-multiplex PCR was more 
discriminatory than MLST but less than PFGE against reference S. aureus strains. For 
the analysis of potential outbreaks, a molecular typing method should be able to 
differentiate between outbreak and sporadic strains. Therefore, the discriminatory power 
of the SmaI-multiplex PCR typing technique was investigated on isolates obtained from 
potential outbreaks in local hospitals.  
5.2 Study Aims  
The aim of the studies in this chapter was to evaluate the discriminatory power 
of the SmaI-multiplex PCR typing technique against MSSA and MRSA obtained during 
potential outbreaks in NHS Trust Hospitals in the North East of England. The resulting 
epidemiology data was provided to the infection control teams within 4-6 hours of 
receipt at the Medical School. Each analysis included known types of UK Epidemic-
MRSA strains that were obtained from the Health Protection Agency (HPA).   
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5.3 Methods 
5.3.1 Sources of strains  
5.3.1a Isolates of outbreaks  
Isolates from seven suspected outbreaks (in total 59 MSSA and MRSA isolates) were 
received over a period of four months. The strains were isolated from three major NHS 
Trust Hospitals in North East of England, the Freeman Hospital (FH), the Royal 
Victoria infirmary (RVI) and the Newcastle General Hospital (NGH). In each case the 
outbreaks were defined as such by clinicians, infection control teams and the 
microbiological laboratory. The vast majority of the strains were isolated from 
hospitalised patients, while a few were isolated from members of staff and the 
environment.   
5.3.1b Health Protection Agency (HPA) strains  
Twenty-four epidemic MRSA strains with known PFGE types were received from HPA 
to be examined by the SmaI-multiplex PCR typing method.    
5.3.1c Other clinical MRSA isolates 
See Section 2.3.2 
5.3.1d S. aureus control strains 
See Section 2.3.1  
5.3.2 Bacterial growth  
Bacterial isolates received on blood agar plates were tested directly by the SmaI-
multiplex PCR technique whereas those received on agar slopes were subcultured on 
brain-heart infusion (BHI) agar prior to typing. In order to keep stocks for further tests, 
a single colony of each isolate was suspended in 10ml BHI broth and incubated 
overnight at 37˚C, with shaking at 200 rpm and stored in 20% of glycerol at -80˚C till 
required. 
5.3.3 Extraction of chromosomal DNA from MRSA  
5.3.3a  Extraction of the DNA by lysostaphin treatment using the DNeasy kit 
(QIAGEN). 
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See Section 2.5.2a  
5.3.3b Extraction of the chromosomal DNA by cell mechanical breakage using a 
DNeasy kit (QIAGEN) 
  See Section 2.5.2b   
5.3.3c Rapid Extraction of chromosomal DNA using boiling with lysostaphin 
method. 
See Section 4.3.6c 
5.3.4 Molecular identification   
5.3.4a Multiplex PCR diagnostic assay for detection mecA, coa and PVL 
A multiplex PCR diagnostic assay was designed to detect two diagnostic genes, mecA 
and coa, and the PVL virulence factor. The presence of the coa gene was used to 
confirm the isolate was S. aureus whereas the mecA was used to confirm the isolate was 
methicillin-resistant. The presence of the PVL virulence factor was used to identify 
leukocidin (PVL) producers.    
5.3.4a.i Primer design  
The sequences of all three genes were obtained from NCBI website and the primer pairs 
were designed according to following parameters: length 18-30-mers, %GC 35-55, Tm 
50-65˚C. The design of the coa and mecA primer pairs was based on regions that were 
highly conserved across several versions of these genes while that of PVL primer pair 
included a portion of the two genes, lukF-PV and lukS-PV, that encode PVL. The 
designed also ensured that the various primer pairs generated different sizes of PCR 
fragments (coa 248bp, mecA 346bp, and PVL 448bp) so they could be discriminated by 
agarose gel electrophoresis. Oligonucleotides were obtained from MWG Biotech GmbH 
and rehydrated by the addition of sterile milli-Q water to a concentration of 100µM and 
stored at -20ºC. The sequences of primers are listed in Table 5.1. 
 
 
 
 
Chapter 5: Evaluation of the SmaI-multiplex PCR against S.aureus outbreaks         117 
Table 5. 1: Primers of three diagnostic genes ( mecA and coa and PVL) which used in 
multiplex PCR diagnostic assay that designed in this study. 
Primer Sequences   Tm Length of 
PCR product 
coa-For   
coa-Rev  
5‟-GAAGAGAAGAAAGTTGAAGAACC- 3‟  
5‟-CTTAAAGATGGTCTGTTTTGTTCC- 3‟ 
57.1˚C 
57.6˚C 
248bp 
mecA-For    
mecA-Rev   
5'-GCAATCGCTAAAGAACTAAGTA-3' 
5'-TGACACGATAGCCATCTTC-3' 
54.7˚C 
54.5˚C 
346bp 
lukS/F-For    
lukS/F-Rev    
5‟- GGCTCAGGAGATACAAGTG-3' 
5‟- GTTTCCAGCAGCTTTGAGTA-3' 
56.7˚C 
55.3˚C 
448bp 
Tm = melting temperature   
                   
5.3.4a.ii PCR amplification  
The presence of all three genes (coa, mecA and PVL) was tested in a multiplex PCR 
against all MSSA and MRSA isolates. Each PCR reaction (50µl) contained 200 µM of 
dNTP; 5 µl of 10x reaction buffer; 1.5 mM of MgCl2; 4 µl of 100x BSA; 0.8 µM of 
PVL primers; 0.4µM of mecA, 0.3 µM of coa; 1 µl of 5 U/µl Taq Polymerase 
(Fermentas, Germany); 3 µl of DNA template. PCR amplification was carried according 
to the reaction conditions: 2 min at 96˚C initial denaturation, followed by 35 cycles of 
96˚C for 40sec, 56˚C for 40 sec and 72˚C for 40 sec, with a final extension at 72˚C for 2 
min.  
5.3.5 Agarose electrophoresis   
Six microlitres samples were loaded on 1.6% agarose containing 0.5µg/µl ethiduim 
bromide. The gel was electrophoresed in 1x TBE buffer at 110V for 100 min. A 100bp 
ladder was used as a molecular size marker. DNA bands were visualised under UV 
light.   
5.3.6 Molecular typing  
5.3.6a. SmaI-multiplex PCR typing technique  
  SmaI-multiplex PCR typing was carried out for all isolates according to the method in 
Section 4.3.7b phase II, using primers in Table 4.1. DNA was extracted by the rapid 
extraction method (boiling with lysostaphin) as described in Section 4.3.6c 
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5.3.6a.i Data analysis of SmaI-multiplex PCR typing 
Gel images were saved as TIFF file to be analysed by the fingerprinting analysis 
software, BioNumerics v3.50 (Applied Maths). The analysis of SmaI-multiplex PCR 
typing was based on band differences and a clustering dendrogram was generated by the 
unweighted-pair group method with arithmetic mean (UPGMA), using the Dice 
similarity coefficient. 
5.3.6b  PFGE 
PFGE was carried out according to the protocol in Section 2.6.1, and PFGE profiles 
were analysed as described in Section 4.3.10    
5.3.6c MLST  
MLST was performed according to the protocol in Section 2.6.2. PCR products were 
purified using the QIAquick PCR purification kit (QIAgen), as described in Section 
2.6.2b.ii. The concentration of DNA was adjusted (see Section 2.6.3) and the products 
were sent for sequencing (MWG Biotech, Germany). Nucleotide sequences were 
compared with the MLST database through website (http://www.mlst.net) for 
assignment of allelic profiles and sequence type (ST).      
5.3.6d SCCmec typing 
SCCmec types were verified according to the method in Section 2.6.4 
5.4 Results 
5.4.1 Molecular epidemiology of multiple MSSA and MRSA outbreaks using 
SmaI-multiplex PCR typing. 
Seven outbreaks were reported in different NHS Trust Hospitals in north east of 
England and about 60 MSSA and MRSA strains were isolated from these outbreaks. 
Seven isolates from a single outbreak were carbon dioxide (CO2) dependent methicillin 
resistant Staphylococcus aureus (MRSA). The isolates of each outbreak were typed by 
SmaI-multiplex PCR typing and the epidemiology data was sending to the infection 
control office at the Freeman Hospital on the same day. 
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5.4.1a Outbreak A    
 In June 2008, we received six MRSA isolates that were isolated from different 
patients on the regional liver unit (RLU) at the Freeman Hospital. One of these isolates, 
isolated from a screening sample (nasal swab) of a liver transplant recipient, showed 
small poorly growing green colonies on chromogenic MRSA media (chrom ID MRSA, 
bioMerieux) after 24 hours aerobic incubation. This isolate repeatedly failed to grow 
after 24-48 hours aerobic incubation on blood agar for susceptibility testing. However, 
this isolate grew heavily when subcultured on blood agar and incubated for overnight at 
37˚C in 5% CO2. A further five CO2-dependent MRSA isolates were found among 
patients and a member of staff at the same unit. These isolates had unusual growth 
characteristics in that they require an increased level of carbon dioxide (5%) for growth 
and were also resistant to erythromycin, clindamycin, moxifloxacin and trimethoprim. 
A seventh case of a CO2-dependent MRSA was reported in a patient in the same unit 
and sent to us later.  
5.4.1a.i Molecular diagnosis 
The presence of coa, mecA and PVL genes was examined by diagnostic PCR which 
showed that all isolates were positive for coa and mecA but negative for PVL. 
5.4.1a.ii Molecular typing using SmaI-multiplex PCR typing. 
All CO2-dependent MRSA isolates were tested by SmaI-multiplex PCR typing and this 
revealed that the isolates were indistinguishable from EMRSA-15 (Fig.5.1).  
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Figure 5. 1: The UPGMA dendrogram of SmaI-multiplex PCR and SmaI-PFGE patterns 
based on Dice similarity coefficient, illustrating the genetic relationship among 
outbreak of seven CO2-dependent MRSA isolates. 
 
5.4.1a.ii Molecular typing using PFGE, MLST and SCCmec typing 
All seven CO2-dependent MRSA isolates were typed using PFGE and the data 
confirmed that, with exception isolate 823613, the isolates had profiles that were 
identical to EMRSA-15. The PFGE profile of isolate 823613 differed only with respect 
to one band and is therefore a variant of EMRSA-15 (Fig.5.1). 
The results of MLST and SCCmec typing, listed in Table 5.2, revealed that all of the 
CO2-dependent MRSA isolates were ST22-SCCmec-IV, to the same as EMRSA-15. 
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Table 5. 2:  Molecular epidemiology of carbon dioxide (CO2)-dependent MRSA strains isolated from a liver unit outbreak. 
MRSA strains 
no. 
SmaI-Multiplex 
PCR epidemiology 
Diagnostic PCR Multilocus sequence typing (MLST) SCCmec 
type    
PFGE  
Coa  mecA  PVL  Sequence Type Allelic profile 
817028Q EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
822972D EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
823008B EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
823613T EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A2 
830208V EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
854354W EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
919780R EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
EMRSA-15 EMRSA-15 + + - ST22 7-6-1-5-8-8-6 IV A1 
MRSA252 
(EMRSA-16) 
EMRSA-16 + + - ST36 2-2-2-2-3-3-2 II EMRSA-16 
S.aureus 
NCTC8325 
NCTC8325 + - - ST8 3-3-1-1-4-4-3 - NCTC8325 
type 
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5.4.1b Outbreak B 
On 28
th
 of August 2009, three S. aureus isolates from a small outbreak at the Freeman 
Hospital. Those isolates were isolated from post-operative wounds of three patients in 
the cardio surgery unit (Table 5.3). 
Table 5. 3:  Isolation sites and hospital units of the outbreak B isolates. 
Ref. no Isolates  Source Site of isolation Hospital unit 
241094X                    MSSA patient Post-operative wound           Freeman cardio surgery 
243759Q                     MSSA patient Post-operative wound           Freeman cardio surgery 
2445552 MSSA patient Post-operative wound           Freeman cardio surgery 
 
5.4.1b.i Molecular diagnosis 
The diagnostic PCR for the presence mecA, coa and PVL confirmed that all isolates 
were MSSA and one isolate (243759Q) was PVL positive (Fig.5.2, labelled red). 
 
Figure 5. 2: Diagnostic PCR for the presence of mecA, coa and PVL against an outbreak of 
three MSSA isolates.    
 
5.4.1b.ii Molecular typing using a novel SmaI-multiplex PCR typing. 
The three outbreak MSSA isolates were characterized using the SmaI-multiplex PCR. 
The results revealed that the three isolates displayed distinct but unrelated profiles (Fig. 
5.3). Interestingly, MSSA isolate 2445552 exhibited a close relationship to the 
genotypic profile of MSSA NCTC 6571 (Oxford strain) and MRSA252 (EMRSA-16), 
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while the profile of MSSA isolate 243759Q was similar to that of EMRSA-15. The 
profile of MSSA isolate 241094X was unique and appears to be related to CA-MSSA 
strains. 
 
              Figure 5.3: SmaI-multiplex PCR profiles of the outbreak B isolates.  
 
5.4.1c Outbreak C 
On 2
nd
 of September 2009, two clusters of 17 S. aureus outbreak isolates were received 
from the Freeman Hospital. Cluster 1 consisted of eleven isolates that were isolated 
from the screening of patients and members of staff in a surgical ward (F5) at the 
Freeman Hospital. Cluster 2 contained isolates from six patients in the baby care unit of 
the RVI (Table 5.4). Cluster 2 isolates were also isolated from screening samples except 
isolate 246957K which was isolated from blood. The clinical laboratory at the Freeman 
Hospital identified them as MRSA isolates except for isolate 246957K, which showed a 
weak positive reaction in the penicillin binding protein latex test but was methicillin 
sensitive. The ward F5 patient from which isolate 148858X was isolated had been 
treated to eradicate MRSA colonization while the infant patient with isolate 063369Y 
had a previous history of hospitalization.  
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Table 5. 4: Isolation sites and hospital units of the outbreak C isolates. 
Ref. no Isolates  Source Site of isolation Hospital unit 
140842D                             MRSA Staff Screening sample       Freeman surgical ward (F5) 
148858X MRSA Patient Screening sample       Freeman surgical ward (F5) 
149683F MRSA Patient Screening sample       Freeman surgical ward (F5) 
149740A MRSA Staff Screening sample       Freeman surgical ward (F5) 
149941G MRSA Patient Screening sample       Freeman surgical ward (F5) 
155309B MRSA Patient Screening sample       Freeman surgical ward (F5) 
166824J MRSA Patient Screening sample       Freeman surgical ward (F5) 
180028B MRSA Patient Screening sample       Freeman surgical ward (F5) 
182548B MRSA Patient Screening sample       Freeman surgical ward (F5) 
182836N MRSA Patient Screening sample       Freeman surgical ward (F5) 
187132W MRSA Patient Screening sample       Freeman surgical ward (F5) 
063369Y MRSA Infant patient      Screening sample       RVI Baby care unit (R35) 
081157C MRSA Infant patient      Screening sample       RVI Baby care unit (R35) 
231520G MRSA Infant patient      Screening sample       RVI Baby care unit (R35) 
234723Y MRSA Infant patient      Screening sample       RVI Baby care unit (R35) 
237320L MRSA Infant patient      Screening sample       RVI Baby care unit (R35) 
246957K MSSA Infant patient      Blood RVI Baby care unit (R35) 
RVI= Royal Victoria Infirmary 
5.4.1c.i Molecular diagnosis 
The presence of the coa gene in all the isolates was confirmed by diagnostic PCR. 
Outbreaks isolates were mecA positive with exception isolate 246957K, which was 
mecA negative. None of seventeen isolates was PVL positive.  
5.4.1c.ii Molecular characterization of an outbreak C using a novel SmaI-multiplex 
PCR. 
All isolates were typed by SmaI-multiplex PCR and 11 isolates showed a profile that 
was identical to that of EMRSA-15 (Fig. 5.4, labelled yellow). In addition, isolate 
149941G (Fig. 5.4, labelled orange) appears to be a variant of EMRSA-15 that has not 
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been seen before. Isolates 148858X and 155309B (Fig. 5.4, labelled red) showed 
identical profiles to that of MW2 (CA-MRSA) and are therefore likely to be community 
associated.  
Isolates 063369Y and 081157C (Fig. 5.4, labelled white), have unique profiles 
and were unrelated to any of the profiles we have encountered previously. However, 
their profiles are closer to those of community associated rather than hospital acquired 
MRSA strains. Isolate 246957K (Fig 5.4, labelled green) appears to be an MSSA isolate 
and its profile is also unique and shows no relationship with other isolates that we have 
analysed.   
 
 
Figure 5.4: SmaI-multiplex PCR profiles of the two clusters of outbreak C isolates that were 
isolated from wards at two local hospitals.  
 
5.4.1d Outbreak D 
On 14
th
 of September 2009, thirteen MRSA isolates were isolated from an outbreak that 
included eight patients, three members of staff and two environment isolates. The 
isolates were isolated from medical ward R23 at the RVI and all were screening samples 
(Table 5.5). There was a concern that a member of staff (with MRSA 252348L) who 
works between two RVI wards, the baby care unit R35, which had outbreak C, and 
medical ward R23, may have been a potential source of the outbreak.   
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Table 5. 5: Isolation sites and hospital units of the outbreak D isolates. 
Ref. no Isolate  Source Site of isolation Hospital unit 
248193                           MRSA Enviroment Enviroment sample         medical ward (R23) 
248188 MRSA Enviroment Enviroment sample         medical ward (R23) 
248585 MRSA Patient Screening sample medical ward (R23) 
248596 MRSA Patient Screening sample medical ward (R23) 
248600 MRSA Patient Screening sample medical ward (R23) 
248602 MRSA Patient Screening sample medical ward (R23) 
248607 MRSA Patient Screening sample medical ward (R23) 
248610 MRSA Patient Screening sample medical ward (R23) 
248615 MRSA Patient Screening sample medical ward (R23) 
248618 MRSA Patient Screening sample medical ward (R23) 
251299 MRSA Staff Screening sample medical ward (R23) 
252060 MRSA Staff Screening sample medical ward (R23) 
252348 MRSA Staff Screening sample medical wards R23 
&R35 
   
5.4.1d.i Molecular diagnostic PCR. 
All isolates from outbreak D were coa positive and PVL negative (Fig. 5.5) 
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Figure 5.5: Diagnostic PCR for the presence of coa, mecA and PVL in thirteen MRSA strains 
isolated from outbreak D.  
 
5.4.1d.ii Molecular characterization of an outbreak using SmaI-multiplex PCR 
 The epidemiological characteristics of the MRSA isolates from outbreak D were 
analysed by SmaI-multiplex PCR, which revealed that all of the isolates showed an 
identical profile to that of EMRSA-15 (Fig. 5.6).    
     
      Figure 5. 6:  SmaI-multiplex PCR profiles of 13 MRSA isolated from the outbreak D. 
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5.4.1e Outbreak E 
On 21
st
 of September 2009 a small outbreak of four MSSA isolates were received for 
epidemiological investigation. All of the isolates were isolated from child patients in 
ward R23 at the RVI and were isolated from infection sites (Table 5.6). The isolates 
were received as blood agar cultures with the exception of isolate 251510, which 
received as swab sample. 
Table 5.6:  Isolation sites and hospital units of the outbreak E isolates. 
Ref. no Isolate  Source Site of isolation Hospital unit 
251510 MSSA Child patient Infection site Medical ward (R23) 
257076 MSSA Child patient Blood Medical ward (R23 
262547 MSSA Child patient Catheter tip or neck line    Medical ward (R23 
263437 MSSA Child patient Infected skin Medical ward (R23 
 
5.4.1e.i  Molecular diagnostic PCR. 
Initially, an attempt was made to test isolate 251510 directly from the received swab by 
diagnostic PCR but no signals were detected. Consequently an overnight culture of 
swab was prepared and the diagnostic PCR carried out on the resulting colonies. All 
four isolates were coa positive and mecA negative.  
5.4.1e.ii  Molecular typing of an outbreak using SmaI-multiplex PCR. 
SmaI-multiplex PCR profile analysis revealed that the four MSSA were distinguishable 
from each other and each showed unique profiles (Fig. 5.7). The profiles of isolate 
MSSA 262547 was more similar to HA-MSSA strains while the profiles of the 
remaining isolates were more similar to CA-MSSA.    
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                    Figure 5.7:  SmaI-multiplex PCR profiles of outbreak E MSSA strains isolated from 
child patients in ward R23 of the RVI. 
 
5.4.1f Outbreak F 
On the 8
th
 of October 2009 an outbreak of eleven S. aureus isolates was received for 
epidemiologically analysis. The isolates were isolated from the post-operative wounds 
of 10 patients in the cardiology ward at the Freeman Hospital. The isolates were 
supplied on blood agar plates and, interestingly, isolate 246870Y showed two colony 
morphology types; yellow and greyish-white (Fig. 5.8). Two additional MRSA isolates 
were also received from two patients at the Newcastle General Hospital (NGH) (Table 
5.7).  
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          Figure 5.8:  MSSA isolate (246870Y) with two types of colonies, (Yellow (left) and 
greyish-white (right) on blood agar. 
   
Table 5.7:   Isolation sites and hospital units of the outbreak F isolates. 
Ref. no Isolate  Source Site of isolation Hospital unit 
246870Y MSSA Patient Post-operative wound Freeman cardio surgery 
249168X MSSA Patient Post-operative wound Freeman cardio surgery 
260348K MSSA Patient Post-operative wound Freeman cardio surgery 
256500X MSSA Patient Post-operative wound Freeman cardio surgery 
257012H MSSA Patient Post-operative wound Freeman cardio surgery 
275089D MSSA Patient Post-operative wound Freeman cardio surgery 
248756Y MSSA Patient Post-operative wound Freeman cardio surgery 
273140Y MSSA Patient Post-operative wound Freeman cardio surgery 
269537M MSSA Patient Tissue Freeman cardio surgery 
277064Q MRSA Patient Screening sample NGH-Neurology 
a
275462Y MRSA Patient Tissue NGH-Orthopaedic       
    NGH: Newcastle General Hospital. a: MRSA isolate with an unusual antibiogram. 
 
5.4.1f.i Molecular typing of an outbreak using SmaI-multiplex PCR. 
Before epidemiological typing, the outbreak F isolates were tested for the 
presence of coa and mecA. All isolates were coa positive and mecA negative. The two 
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strains isolated from the NGH as MRSA isolates 277064Q and 275462Y were, as 
expected, mecA positive. 
SmaI-multiplex PCR typing established that the colony variants (yellow and 
greyish-white) of isolate 246870Y (Fig.5.8) had identical profiles and this profile was 
indistinguishable from that of isolate 260348K and was smilar to that of isolate 
249168X. isolates 256500X, 257012H and 275089D had identical profiles that were 
identical MSSA strain, NCTC6571 (Oxford strain) and very similar to EMRSA-16, 
indicating that they could be examples of hospital-acquired MSSA (Figs. 5.9/10). 
Isolates 248596Y and 273140Y each showed unique profiles that were similar in some 
respects to the profiles of EMRSA-15 and EMRSA-16, even though they were MSSA 
isolates. MSSA 269537M showed a distinct profile that was closely related to MSSA 
strain NCTC8325. The sole MRSA isolate, 277064Q, had a unique profile that was not 
related to either EMRSA15 or 16 (Fig.5.9). 
 
 
Figure 5.9: SmaI-multiplex PCR profiles of 10 MSSA and one MRSA isolated from 
outbreak F.   
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5.4.1f.ii  Molecular typing of an MRSA with unusual antibiogram using SmaI-
multiplex PCR. 
An MRSA isolate with an unusual antibiogram, 275462Y, was isolated at the Newcastle 
General Hospital from a tissue sample of a patient with chronic oestomyelitis. This 
isolate showed resistance to tetracycline, rifampicin, fusidic acid, erythromycin, 
clindamycin, trimethoprim, cloxacillin, gentamicin and moxifloxacin. This isolate was 
tested by SmaI-multiplex PCR and a showed profile that had not been seen before (Fig. 
5.10, labelled yellow). 
                           
 
                                  Figure 5.10: SmaI-multiplex PCR profile of MRSA isolate 
275462Y that showed unusual antibiogram 
 
   
MLST and SCCmec typing showed that isolate 275462Y was ST239-SCCmec-
III (Fig. 5.11), which is known as a Brazilian or Hungarian clone.  
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                     Figure 5.11:  SCCmec type-III of MRSA isolate 275462Y. Control 
strains with known SCCmec types were also included.  
 
5.4.1g Outbreak G 
On 8
th
 of December 2009 four MSSA isolates were isolated from an outbreak in the 
intensive treatment unit (ITU) at Newcastle General Hospital (Table 5.8). These isolates 
were isolated from patients on the same ward and all isolates were recovered within the 
same time frame. 
Table 5.8:  Isolation sites and hospital units of the outbreak G isolates. 
Ref. no Isolate  Source Site of isolation Hospital unit 
328492 MSSA Patient sputum NGH- Intensive treatment unit (ITU) 
328533 MSSA Patient sputum NGH- Intensive treatment unit (ITU) 
328534 MSSA Patient sputum NGH- Intensive treatment unit (ITU) 
328914 MSSA Patient sputum NGH- Intensive treatment unit (ITU) 
NGH: Newcastle General Hospital 
5.4.1g.i Molecular typing of an outbreak using SmaI-multiplex PCR. 
Initially, diagnostic PCR was used to confirm the presence of coa in all four MSSA 
isolates. Subsequently, the epidemiology of the outbreak isolates was examined by 
SmaI-multiplex PCR. The results obtained from SmaI-multiplex PCR typing showed 
that the MSSA isolates were distinguishable and that each isolate showed a distinct 
profile (Fig. 5.12). The profile of isolate 328492 was identical to MSSA strain 
NCTC6571 (Oxford strain) and this profile has been seen in previous outbreaks (B & 
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F). Isolates 328914, 328533 and 328534 showed unique profiles that resembled CA-
MSSA (Fig. 5.12). 
 
                       Figure 5. 12: SmaI-multiplex PCR profiles of four outbreak G MSSA 
isolates together with control S. aureus strains. 
 
5.4.2 Comparative analysis of the SmaI-multiplex PCR, MLST and SCCmec 
typing methods. 
Nineteen representatives of SmaI-multiplex PCR profiles selected from the 59 
MSSA and MRSA isolates that were isolated from the outbreak A-G were analysed 
using the fingerprint analysis software (BioNumerics v3.50, Applied Maths). The 19 
representatives were analysed by MLST typing and the MRSA isolates also by SCCmec 
typing. Sixteen different sequence types were identified among the 19 SmaI-multiplex 
PCR profiles (Fig. 5.13).  
Comparative analysis of the SmaI-multiplex PCR and MLST data by UGPMA 
and MLST phylogenetic tree data (Fig. 5.13) showed that the two methods were in good 
agreement. The ST5 MSSA isolates, which showed very similar but distinguishable 
SmaI-multiplex PCR profiles, were grouped in one cluster (Fig.5.13, green box). In the 
same cluster as the EMRSA-15 (ST22) variants (Fig. 5.13, red box). Isolates FOUTB11, 
16 and 18, that were identified as sequence types ST47, ST45 and ST46, respectively, 
were clustered by SmaI-multiplex PCR in separate groups (Fig.5.13, blue box).  
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The results obtained from the present study confirm that SmaI-multiplex PCR 
typing is more discriminatory than MLST since it distinguished between several S. 
aureus that have same sequence type (ST5). In addition, SmaI-multiplex PCR 
distinguished between some variants of EMRSA-15, which shared the same sequence 
(ST22) and SCCmec (IV) types (Fig.5.13, red box).  
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Figure 5. 13:  The UPGMA dendrogram based on SmaI-multiplex PCR profiles and MLST phylogenetic tree showing the genetic relationship of  
19 representatives of clinical MSSA and MRSA strains isolated from outbreaks. Yellow colour refers to control strains.
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5.4.3   A multiplex PCR diagnostic assay for the detection mecA, coa and 
PVL genes  
Due to huge number of S. aureus isolates that need to be tested for the presence 
of the mecA, coa and PVL genes, a multiplex PCR assay was designed for their 
detection using the primer pairs in Table 5.1. The resulting assay was evaluated against 
known clinical MSSA and MRSA outbreak isolates, in addition to some reference 
staphylococcal strains.  
The results indicated that the performance and accuracy of assay was high 
(100%) and it correctly identified the genotypes of all the isolates tested, including the 
positive and negative controls (Fig.5.14). The expected sizes of PCR products of all 
three genes (coa 248bp, mecA 346bp, and PVL 448bp) were consistently observed in all 
the test strains.  
 
 
Figure 5.14: Multiplex diagnostic assay against MSSA and MRSA strains. CNS: coagulase 
negative staphylococci.  
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5.4.4 Evaluation of the SmaI-multiplex PCR against known PFGE types of 
UK epidemic-MRSA strains from the Health Protection Agency (HPA) 
PFGE collection 
On 16
th
 of December 2009, twenty-four EMRSA strains were received from HPA. 
Those strains were typed by PFGE at HPA laboratories in Colindale, London and they 
were received without any information about their epidemiological types. In 
collaboration with Dr Angela Kearns and Dr Barry Cookson of the HPA, the main 
purpose was to evaluate the discriminatory power of the SmaI-multiplex typing method 
against characterised variants of EMRSA-15 and EMRSA-16.   
All strains were received on agar slopes and overnight cultures on agar plates 
were prepared for the epidemiological typing. The HPA strains were analysed by SmaI-
multiplex PCR and showed that, with one notable exception (strain ZZ0900003), all 
were identifiable as either EMRSA-15 or EMRSA-16, or related variants. Ten strains 
generated profiles that were identical to that of EMRSA-15 (Fig. 5.15, labelled yellow). 
Two strains, H053780592 and H0725800475, (Fig. 5.15, labelled orange) appeared to 
be EMRSA-15 variants since their profiles showed only one band difference from the 
original EMRSA-15.  
Eleven strains (Fig. 5.15, labelled red) generated profiles that were related to that 
of the EMRSA-16. However, each has an additional band that was not observed in the 
EMRSA-16 profile generated from the sequenced strain MRSA252 (see controls with 
red arrow, Fig. 5.15). This indicates that MRSA252 may be an atypical EMRSA-16 
strain. Strain ZZ0900003 (Fig.5.15, labelled dark red) generated the same bands as the 
other EMRSA-16 strains but generated an additional two bands (Fig.5.15, red arrows). 
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Figure 5. 15: SmaI-multiplex PCR against known types of UK Epidemic-MRSA strains that received from HPA. Red arrows refer to the bands that 
distinguish between the EMRSA-16 variants. 
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The SmaI-multiplex PCR patterns of HPA strains (Fig.5.15) were analysed using 
the fingerprinting analysis software BioNumerics. Figure 5.16 shows the dendrogram 
(Dice, UPGMA) resulting from a cluster analysis of SmaI-multiplex PCR patterns for 
the HPA strains. The strains were grouped on two main clusters, the EMRSA-15 cluster 
and EMRSA-16 cluster. Within the putative EMRSA-15 cluster, two SmaI-multiplex 
PCR profiles were found showing 90% similarity with the original profile of EMRSA-
15. The putative EMRSA-16 strains also formed two clusters, caused by the single band 
difference between the HPA strains and MRSA252 (EMRSA-16) (Fig. 5.16).  
The MRSA strain (RH06000062), which exhibited a similar but not identical 
SmaI-multiplex PCR pattern to EMRSA-16 (with only one band different) was analysed 
by MLST and SCCmec typing. The MLST and SCCmec analysis confirmed that strain 
RH06000062 was ST36 with SCCmec-II which is the sequence/SCCmec type of 
EMRSA-16. The MRSA strain ZZ06000003, with the unusual SmaI-multiplex PCR 
pattern, was ST5 with SCCmec-IV which is the same as the so-called “pediatric clone” 
(Argudin et al., 2009). 
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Figure 5.16: The UPGMA dendrogram based on SmaI-multiplex PCR patterns of known 
types of UK Epidemic-MRSA strains that were received from HPA. ND: not 
determined.   
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5.4.5  Evaluation of SmaI-multiplex PCR against MRSA strains isolated 
from blood. 
Thirteen MRSA isolates, isolated from the blood of patients at the Freeman Hospital 
(Table 5.9), were typed by SmaI-multiplex PCR.  
Table 5.9:  Sources of MRSA isolates that isolated from blood.  
Isolate no. Patient’s age Site of isolation Unit of isolation 
FMRSA 90 57 Blood Freeman musculoskeletal unit 
FMRSA 92 75 Blood Freeman orthopaedics (F19) 
FMRSA 93 83 Blood Freeman surgical ward (F5) 
FMRSA 94 73 Blood Freeman ENT (F10) 
FMRSA 95 74 Blood Freeman renal unit (F4) 
FMRSA 96 48 Blood Freeman renal unit (F4) 
FMRSA 97 38 Blood Freeman surgical ward (F5) 
FMRSA 142 72 Blood Freeman chest medicine (F29) 
FMRSA 166 69 Blood Freeman liver unit (F12) 
FMRSA 189 80 Blood Freeman critical care (FCC) 
FMRSA 201 78 Blood Freeman cardio ITU (F26) 
FMRSA 234 97 Blood Freeman coronary unit (F9) 
FMRSA 281 97 Blood Freeman coronary unit (F9) 
FMRSA= Freeman MRSA, ENT = ear, nose, throat, ITU= intensive treatment unit.  
 
5.4.5a  SmaI-multiplex PCR typing of blood isolates 
Analysis of the strains isolated from blood samples by SmaI-multiplex PCR revealed 
that all but one isolate, FMRSA 166, showed identical profiles to that of EMRSA-15. 
FMRSA 166 generated the same profile as EMRSA-16 (Fig. 5.17). 
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Figure 5.17: The UPGMA dendrogram based on SmaI-multiplex PCR profiles of thirteen 
MRSA strains isolated from blood. ND: not determined 
 
Three representative isolates (FMRSA142, 166 and 201) isolated from the blood 
samples were analysed by MLST and SCCmec typing. Both techniques confirmed that 
isolates FMRSA142 and 201 were ST22-SCCmec-IV, which is identical to EMRSA-15, 
whereas FMRSA166 was ST36-SCCmec-II, which is identical to EMRSA-16 (Fig. 
5.18).  
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 Figure 5. 18: SCCmec types of three representative MRSA isolates (FMRSA142, 166 and 
201) that were analysed by MLST, together with various control strains 
5.5 Discussion  
MRSA outbreaks are frequently reported and rapid investigation, using 
epidemiological tools, can help the infection control team to take the correct and urgent 
action required to control the further spread of the outbreak. PCR-based epidemiological 
techniques are the most useful in terms of their speed, ease of performance and 
interpretation (Collier et al., 1996).  
The SmaI-multiplex PCR typing technique developed in this study is a novel 
technological approach that is based on similar principles to that of PFGE, namely 
SNPs at SmaI recognition sites. The developed method has been tested against many 
sequenced S. aureus strains in comparison with PFGE and MLST and showed excellent 
discriminatory power and reproducibility. SmaI-multiplex PCR works with rapidly 
extracted chromosomal DNA and can be carried out in as little as 4-6 hours. It complies 
with the requirement of any typing tool, namely that its discriminatory power should be 
sufficient to cluster epidemiologically related strains and discriminate them from 
unrelated strains (Trindade et al., 2003).  
In the current study, we evaluated the developed SmaI-multiplex PCR typing 
technique against S. aureus strains isolated from putative outbreaks (59 MSSA and 
MRSA isolates) and blood samples (13 isolates) from local NHS hospitals. The 
evaluation also included MRSA strains with known PFGE types that were received 
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from the HPA‟s Colindale laboratory. The evaluation was based on several criteria: 
typeability, discriminatory power, stability and epidemiology concordance (Struelens, 
1998).  
Small colony variants (SCV) of S. aureus are non-pigmented, non-haemolytic 
pinpoint slow-growing morphological variants that are only detectable on plates after 
24-72 hours incubation (von Eiff and Becker, 2003; Sifri et al., 2006). Most SCVs of S. 
aureus are auxotrophs for menadione, hemin and thymidine, but rarely require CO2. 
However, CO2-dependent MRSA isolates have been isolated from nasal colonization 
and infection sites. It has been reported that SCVs have been associated with persistent, 
antibiotic resistant and relapsing infections (Sifri et al., 2006; Gomez-Gonzalez et al., 
2010). In the present study, seven CO2-dependent MRSA isolates were recovered from 
an outbreak in a regional liver transplant unit (RLU) at the Freeman Hospital (outbreak 
A). These isolates appeared to be SCVs since they grew very slowly after 48 hours 
incubation under aerobic conditions, but more rapidly after 24 hours in the presence of 
5% CO2. These isolates were confirmed to have mecA and coa genes but were PVL 
negative. Using the SmaI-multiplex PCR typing technique, all of the CO2-dependent 
MRSA isolates showed profiles that were identical to that of EMRSA-15 (Fig. 5.1). 
This was confirmed by results obtained from PFGE, MLST and SCCmec typing. All 
isolates were ST22-SCCmec-IV (EMRSA-15) and had PFGE profiles that were 
identical to EMRSA-15 excepting for one isolate that differed from the other isolates by 
the presence of a single band (Fig. 5.1). This PFGE type is a known EMRSA-15 variant 
identified originally in the study of Hallin et al. (2007).  
S. aureus is the most common cause of surgical wound infections (SWIs) and 
surgical units are, indeed, the most affected by post-operative S. aureus infections. In 
cardiac surgery units, SWIs often develop into bloodstream infections that are 
associated with an increase in morbidity and mortality (Carrier et al., 2002). It is 
thought that most S. aureus surgical-site infections are caused by the patient‟s 
endogenous S. aureus flora that are usually MSSA (Kluytmans et al., 1996; Trouillet et 
al., 2005). In the current study, a small outbreak of three MSSA isolates was recovered 
from patients in a cardio surgery unit with post-operative wounds (outbreak B). All 
three isolates were confirmed by PCR to harbour the coa gene but were mecA negative. 
One of the isolates (243759Q) encoded the PVL determinant (Fig. 5.2). The isolates 
were typed using the SmaI-multiplex PCR technique and each isolate generated a 
unique SmaI-multiplex PCR profile (Fig. 5.3), ruling out a common source of the 
outbreak. Although, the SmaI-multiplex PCR profile of MSSA 243759Q was closely 
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related to that of EMRSA-15, it was shown to have a sequence type of ST772, which is 
a CA-MRSA and belongs to clonal complex 1 (CC1) (Strommenger et al., 2008). The 
profile of MSSA isolate 2445552 was similar to that of MRSA-252 (EMRSA-16) but 
lacks the mecA band and has an additional band that not observed in MRSA252. Isolate 
2445552 was found to be sequence type ST30, and it is thought that southwest Pacific 
MRSA clone (ST30-SCCmec-IV) has emerged by the introduction of SCCmec-IV into 
a successful ST30-MSSA clone (Enright et al., 2002). MRSA ST30-SCCmec-IV is 
closely related to EMRSA-16 (ST36-SCCmec-IV) and both belong to the same clonal 
complex, namely CC30. MSSA isolate 241094X had a SmaI-multiplex PCR profile that 
was distinct and a sequence type of ST5. MSSA ST5 strains have been identified to be 
the predominant MSSA clone in Belgium (Hallin et al., 2007) and to be prevalent in the 
ICUs of French hospitals (Karauzum et al., 2008). Moreover, MSSA-ST5 has been 
isolated from both community and hospital infection and Enright reported that ST5-
MSSA formed ST5-MRSA-II which led initially to ST5-VISA-II and more recently to 
ST5-VRSA-II (Enright, 2003).      
S. aureus outbreak C consisted of 17 isolates in two clusters. All of these 
isolates encoded the coa and mecA genes excepting the blood isolate 246957K. 
Although, lacking mecA, isolate 246957K was weakly positive when tested by the 
penicillin binding protein latex test – possibly due to contamination of the original 
colony with an MRSA isolate (Sakoulas et al., 2001). Molecular characterisation of this 
outbreak using SmaI-multiplex PCR typing demonstrated the discriminatory power of 
this technique. As EMRSA-15 is the predominant epidemic MRSA clone in the north of 
England (Wilson et al., 2010), unsurprisingly, most of these outbreak isolates were 
related to this strain. Interestingly, the SmaI-multiplex PCR technique discriminated 
isolate 149941G as a variant of EMRSA-15 (Fig. 5.4, labelled orange). Two CA-MRSA 
isolates (148858X and 155309B) were identified among the outbreak since they showed 
profiles that were identical to the well-characterised CA-MRSA strain, MW2 (Fig. 5.4, 
labelled red). Their profiles were confirmed to have sequence/SCCmec types ST1-
SCCmec-IV, which is a CA-MRSA clone. This is a clear indicator that CA-MRSA is 
beginning to rival epidemic HA-MRSA in UK hospitals although it is still relatively 
rare. In this outbreak, two unique SmaI-multiplex PCR profiles were found in associated 
with MRSA isolates 063369Y and 081157C (Fig. 5.4, labelled white). MLST typing 
confirmed that isolate 063369Y was ST45-SCCmec-IV, which is the so-called Berlin 
clone and most common in Belgium, Finland, Germany and Sweden (Enright et al., 
2002). Isolates 081157C was ST94-SCCmec-I. Currently, only one ST94-MSSA isolate 
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has been annotated in the MLST website which was isolated from a case of 
conjunctivitis in Cuba in 1998.   
Thirteen MRSA isolates were isolated from outbreak D that included patients, 
members of staff and the environment within a medical ward. There was a suspicion 
that a specific member of staff was the source of the outbreak because he/she worked 
between the medical ward and the baby care unit that was involved in outbreak C. The 
isolates of outbreak D were sent by the infection control office to the HPA laboratories 
at Colindale to be analysed by PFGE. The epidemiological data obtained from SmaI-
multiplex PCR typing indicated that the profiles of all thirteen isolates were identical to 
EMRSA-15 (Fig. 5.6). The SmaI-multiplex PCR results were confirmed by the PFGE 
analysis, which revealed that all isolates are EMRSA-15. However, PFGE was more 
discriminatory since it identified four PFGE-subtypes of EMRSA-15 within this set of 
isolates.          
In this study, most staphylococcal outbreak strains isolated from wounds were 
generally caused by MSSA that are usually of endogenous origin. It is noteworthy that 
the highest rate of MSSA nasal colonisation was among people younger than 18 years 
of age whereas MRSA colonisation was more likely in older people (Kenner et al., 
2003). Four MSSA isolates of outbreak E were recovered from the infection sites (3 
from wounds and one from blood) of four child patients. Diagnostic PCR confirmed the 
presence of coa and the absence of mecA among these isolates. Each isolate showed a 
unique SmaI-multiplex PCR profile indicating that they were of independent origin. The 
profile of MSSA isolate 262547 was similar to that of HA-MSSA (Fig.5.7) and had 
ST47. All nine currently annotated ST47 isolates are MSSA strains isolated in the UK. 
The SmaI-multiplex PCR profiles of the remaining three MSSA isolates indicated that 
they could be CA-MSSA. Isolates 251510 and 257076 were ST5 though they showed 
related but different SmaI-multiplex PCR profiles. ST5-MSSA is most common in 
Poland, Slovenia and the UK. MSSA 263437 showed a similar SmaI-multiplex PCR 
profile as the sequenced strain MSSA476 (CA-MSSA), but with one additional band. 
Isolate 263437 was ST789, originally isolated from bovine mastitis in Japan (Hata et 
al., 2010).  
The MSSA isolates from outbreak (F) were isolated from the post-operative 
wounds of patients in a cardio surgery unit. Isolates 246870Y and 260348K had 
identical profile that was similar but distinguishable to 249168X profile and their 
profiles are related to that of CA-MSSA strains (Fig. 5.9). Further analysis using MLST 
showed that MSSA 246870Y was ST5 while MSSA 249168X was ST15 - both 
Chapter 5: Evaluation of the SmaI-multiplex PCR against S.aureus outbreaks         148 
sequence types associated with CA-MSSA (O‟Brien et al., 2009). MSSA isolates 
256500X, 257012H and 275089D showed the same profile, and this profile was 
identical to MSSA strain NCTC6571 (Oxford strain). This profile, representatives of 
which were also reported in previous outbreak B, was shown to be ST30. MSSA 
isolates 248596Y and 273140Y showed unique profiles and had sequence types ST772 
and ST47, respectively (Fig. 5.9). While a unique SmaI-multiplex PCR profile was 
found with MSSA isolate 269537M, it was similar to that of MSSA strain NCTC8325, 
which is ST8. MSSA 269537M was found to be ST931, which is single locus variant 
(SLV) of ST8.   
 The Brazilian-Hungarian clone ST239-SCCmec-III is the most common clone 
in South East Asia (China, Pakistan, Indonesia, Singapore, Sri Lanka, Thailand, Hong 
Kong and India) (Cho et al., 2006; Shabir et al., 2010; Yao et al., 2010). Although, this 
multidrug resistant MRSA clone has been reported in Europe, including the UK, it is 
not common in UK hospitals (Enright et al., 2002). MRSA isolate 275462Y generated a 
SmaI-multiplex PCR profile (Fig. 5.10) that was not seen in any of the other isolates 
analysed in this study. When tested by MLST/SCCmec, isolate 275462Y was found to 
be ST239-SCCmec-III and therefore the Hungarian-Brazilian clone. Additional 
information about the patient revealed him/her to have been involved in a road traffic 
accident in Pakistan in 2005 where he/she sustained a leg injury that resulted in 
oestomyelitis. The patient continues to travel regularly to this country.   
MRSA isolate 277064Q was typed with the outbreak F isolates. Isolate 277064Q 
was isolated from the screening sample of a patient at Newcastle General Hospital 
(NGH). This isolate showed a unique SmaI-multiplex PCR profile that was similar to 
HA-MRSA strains, although not EMRSA-15 or EMRSA-16. Isolate 277064Q was 
found to be ST46/SCCmec-V (Fig.5.9; Fig. 5.13), a clonal type that has been reported 
in Finland (Vainio et al., 2008). 
Four MSSA isolates (outbreak G) were reported in patients in the ITU at 
Newcastle General Hospital. Epidemiological characterization showed that each isolate 
had a distinct SmaI-multiplex PCR profile (Fig. 5.12). The profile of isolate 328492 was 
identical to that of MSSA NCTC6571 (Oxford strain) and this profile was seen in 
previous outbreak isolates (B & F). It was found to be ST30. The SmaI-multiplex PCR 
profile of MSSA isolate 328914 was similar in some respects with the profiles of two 
MSSA isolates (ST5 isolate 246870Y and ST15 isolate 249168X) seen in outbreak F. 
Isolate 328914 was ST83, a single locus variant of ST5 with a SNP in the yqiL allele, 
Both ST83 and ST5 belong to clonal complex CC5. MSSA isolates 328534 and 328533 
Chapter 5: Evaluation of the SmaI-multiplex PCR against S.aureus outbreaks         149 
had closely related SmaI-multiplex PCR profiles and were ST72 and ST464, 
respectively. Although, ST72 is mainly associated with community-acquired infections, 
it has been implicated in some hospital infections (Luedicke et al., 2010). Interestingly, 
those isolates belong to ST72, representatives of which have been isolated from bovine 
milk in Japan (Hata et al., 2010) and since ST464 clone associated with cattle 
(Andreoletti et al., 2009), it is possible that isolates 328534 and 328533 might have 
been introduced into the ITU by carrier associated with animals. 
Nineteen isolates representing all of the SmaI-multiplex PCR profiles in the 59 
staphylococcal outbreaks isolates were analysed using the BioNumerics fingerprinting 
software. The 19 representatives were also subjected to MLST analysis and 16 different 
sequence types were identified. What is important about these data (Fig. 5.13) is that the 
SmaI-multiplex PCR typing technique accurately clustered the isolates according to the 
MLST data. A good example is that of isolates FOUTB11, 16 and 18, which were 
grouped in a cluster by SmaI-multiplex PCR. These isolates belong to sequences types 
ST47, ST45 and ST46 respectively, which are part of clonal complex 45 (Fig. 5.13, blue 
box).        
Although, the correlation between the SmaI-multiplex PCR and MLST 
techniques were high, the former was more discriminatory. This is clearly shown in the 
case of the MSSA isolates in ST5, which generated three closely related but distinct 
SmaI-multiplex PCR profiles (Fig. 5.13, green box). In addition, SmaI-multiplex PCR 
could discriminate some variant clones of epidemic strains among outbreak isolates: 
two ST22-EMRSA-15-SCCmec-IV isolates showed profiles that differed by a single 
band (Fig. 5.13, red box).  
Throughout the investigations of the outbreaks, SmaI-multiplex PCR typing 
provided valuable epidemiological information and was able to distinguish clearly 
between MSSA or MRSA isolates even in small outbreaks. The timely provision of the 
epidemiological information helped the infection control team in their investigation of 
these outbreaks, in some cases ruling out potential common sources of the infections.    
The presence of the coa gene was used for identification of S. aureus while the 
mecA gene was used as an indicator for MRSA. In addition, PVL is associated with 
sever S. aureus infections. The detection of those genes can provide useful information 
about clinical isolates, particularly when detected during ongoing outbreaks. A 
multiplex PCR was developed for the simultaneous detection of these genes. This 
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diagnostic assay showed an excellent performance against known PVL-positive MSSA 
and MRSA strains (Fig. 5.14).   
The evaluation of the SmaI-multiplex PCR typing against HPA MRSA strains 
that have known PFGE types provided the opportunity to assess the discriminatory 
power of this technique against variants within the same EMRSA clonal type. SmaI-
multiplex PCR typing was able to discriminate some but not all EMRSA variants: 
distinguished two EMRSA-15 variants and three EMRSA-16 variants among the 24 
HPA EMRSA strains. MRSA strain ZZ09000003 showed an interesting and novel 
SmaI-multiplex PCR profile: it has the same basic profile as MRSA-252 (EMRSA-16) 
but with three additional unique bands (Fig. 5.15). Strain ZZ09000003 also has the 
same basic profile of VISA strains (Mu50, Mu3 and N315) with four additional bands. 
According to the PFGE data, strain ZZ09000003 is a variant of EMRSA-16 but is 
sequence type ST5 with SCCmec-IV. This is the same sequence and mecA type as 
pediatric clone-USA800 (Sousa-Junior et al., 2009).  
 
Further evaluation for the developed SmaI-multiplex PCR technology was 
carried out on thirteen clinical MRSA isolates. These isolates were recovered from the 
blood of hospitalized patients in different units at the Freeman Hospital. Approximately 
90% of those patients were older than 70 years of age, which reflects the fact increasing 
age is a risk factor for MRSA bacteraemia (Heo et al., 2007). The results showed that 
EMRSA-15 was present in 12 of these patients, while the remaining patient was 
infected by an EMRSA-16 strain (Fig. 5.17). Further analysis of two representative 
EMRSA-15 strains and the EMRSA-16 confirmed the SmaI-multiplex PCR results: 
FMRSA142 and 201 isolates were EMRSA-15 (ST22-SCCmec-IV and the FMRSA166 
was EMRSA-16 (ST36-SCCmec-II).     
 
In conclusion, the developed SmaI-multiplex PCR technique showed excellent 
typeability and reproducibility with stability. It was more discriminatory than MLST 
and was easy to perform and interpret. It does not require any special expertise or 
equipment and can therefore be performed in any routine clinical microbiology 
laboratory. The rapid DNA extraction method that was developed in the current study 
helped to reduce the sample processing time to between 4 and 6 hours. While the SmaI-
multiplex PCR technique did not discriminate between all variants of the main UK 
epidemic clones that have been identified by PFGE, it was able to distinguish some of 
them. The SmaI-multiplex PCR technique proved to be a useful tool for providing 
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reliable epidemiological information for the investigation of clinical staphylococcal 
outbreaks. 
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6. General discussion  
There is no doubt that S. aureus, whether methicillin-susceptible or methicillin-
resistant, will continue to be a primary cause of nosocomial infections well into the 
foreseeable future. Consequently, an understanding of epidemiological characteristics of 
S. aureus will continue to be essential in the management of its infections in both the 
hospital and community settings. The purpose of any epidemiological study is to 
identify relationships between isolated strains. In the investigation of an outbreak, 
epidemiological typing provides information about the outbreak isolates and helps to 
establish whether it is due to spread of a single clone. In addition, typing technique can 
provide essential information about population changes during a long-term 
epidemiological surveillance. For decades the epidemiological characterisation of S. 
aureus relied on phenotypic characteristics such as antibiograms, sensitivity to 
bacteriophages and serological features. In recent years, however, more advanced 
molecular epidemiological tools have been introduced such PFGE, MLST and SCCmec. 
Those genotyping methods are variable in their resolving power, reproducibility, and 
the degree of expertise and cost of the equipment required.   
PFGE profiling is based on the analysis of intact bacterial DNA by specific 
restriction enzymes. It results in the generation of a relatively small number of large 
fragments that can only be separated by PFGE. This technique has been used 
extensively for the analysis of MRSA strains and shows a high level of discrimination. 
Consequently, it has become established as the gold standard for MRSA typing 
(Schmitz et al., 1998). However, PFGE has many disadvantages for routine 
epidemiological typing. Those disadvantages are time-consuming nature of the 
procedure (4-8 days), the cost of electrophoresis equipment (>£10,000) and need for 
special expertise.       
MLST is sequence-based genotyping method that relies on the identification of 
allelic variations in the sequences of seven housekeeping genes. MLST provides 
unambiguous data with very high reproducibility and it has been proven to be a valuable 
technique for tracing of the global spread of MRSA clones, particularly in long-term 
analyses. MLST also provides beneficial information about the evolution of MRSA 
clones (Enright et al., 2000). SCCmec is a large mobile genetic element that carries the 
methicillin resistance determent, mecA. SCCmec elements are diverse in their structures 
and genetic contents. Consequently, these elements have been classified into various 
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types that can be used to study the epidemiology of MRSA (Oliveira and Lencastre, 
2002). SCCmec typing can be used in combination with MLST to improve its 
discriminatory power. Nevertheless, MLST is currently relatively expensive, requires 
specialised equipment and needs highly trained personnel, or access to a commercial 
sequencing centre (Stepan et al., 2004). In many cases, MLST is not sufficiently 
discriminatory for single MRSA outbreaks even when combined with SCCmec typing. 
For the reasons outlined above, neither PFGE nor MLST/SCCmec typing are used 
routinely in clinical microbiology laboratories for the analysis of ongoing outbreaks. 
We therefore identified the need for a discriminatory technique that was both rapid and 
could be applied in a routine clinical microbiology setting.  
In the first step of this study, a large collection of MRSA isolates was obtained 
from the local NHS Trust hospitals in Newcastle upon Tyne. This collection contained 
more than 400 MRSA isolates, collected randomly from screening and clinical samples 
over a period of about two months. Chapter 3 describes the clinical and epidemiological 
information of these MRSA isolates. S. aureus has maintained a close relationship with 
humans and about 30 to 40% of the population carries S. aureus somewhere in or on 
their bodies (most commonly the nasal cavity) (Champer, 2001). In the current study, a 
high rate (57%) of MRSA carriage was found among hospital patients. Furthermore, 
increasing age was a clear risk factor, linked to both colonisation and infection. More 
than seventy percent of MRSA patients were, unsurprisingly, older than 60 years of age. 
For any clinical microbiology laboratory, it is important to distinguish between MRSA, 
MSSA and methicillin-resistant
 
coagulase-negative staphylococci (MRCNS). For 
accurate identification purposes, both coa and mecA are used as markers to identify 
MRSA and, in this study, both genes were targeted by PCR to confirm their correct 
identification. 
We established the PFGE, MLST and SCCmec typing methods in our 
laboratory, and evaluated their use against some of the isolates in our collection of 
MRSA isolates. Twenty MRSA isolates were selected for PFGE analysis and this 
revealed EMRSA-15 to be the predominant MRSA strain in the Newcastle upon Tyne 
hospitals. Three PFGE types, each variants of EMRSA-15, were identified among the 
20 MRSA isolates. In conjunction with reference strains, each of the PFGE types was 
subjected to further analysis by MLST/SCCmec typing. This revealed that all of the 
variants were ST22/SCCmec-IV, again corresponding to EMRSA-15. Although a 
relatively small number of MRSA isolates were typed throughout these studies, the 
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results confirm previous reports (Jonas et al., 2002; Monnet et al., 2004; Wilson et al., 
2010) that EMRSA-15 (i.e. ST22/SCCmecIV) is the main nosocomial EMRSA clone in 
north-east of England. PFGE was clearly more discriminatory than MLST, particularly 
between variants of EMRSA-15. However, in contrast to MLST, high quality PFGE 
data can only be delivered following extensive technical experience in its application. 
Like others, we also concluded that MLST is not sufficiently discriminatory for the 
investigation of potential outbreak strains (Hardy et al., 2006). This makes the use of 
both methods of limited value in routine clinical laboratories, especially, in developing 
countries. 
Development of a novel SmaI-multiplex PCR typing technology 
The central aim of this study was to develop a novel genotyping technology that 
is suitable for routine use in routine clinical hospitals laboratories. This method was 
designed to combine the simplicity of PCR and, ideally, the discriminatory power of 
PFGE. It needed to be rapid, to require low-level expertise and to employ equipment 
likely to be already available in clinical laboratories. Also, the generated 
epidemiological data should ideally show concordance with data from other 
epidemiological techniques. Chapter 4 describes a novel genotyping technology for 
MSSA and MRSA strains. The newly developed typing system is based around the 
SmaI macrorestriction fragments output from PFGE analyses. The S. aureus genome is 
AT-rich (32.8% CG) (Wong et al., 2008), which accounts the selection of the GC-rich 
SmaI (CCC↓GGG) sites for macrorestriction fragment analysis. However, instead of the 
time-consuming DNA extraction and digestion techniques associated with PFGE, a 
multiplex PCR technique was devised to identify SmaI-based SNPs from rapidly 
extracted chromosomal DNA.  
As a first stage in the development of a new typing method, the DNA sequences 
of eighteen S. aureus strains were analysed using a series of bioinformatic tools to 
determine the number and locations of their SmaI restriction sites. The number of SmaI 
restriction sites was, as expected, found to be between 24 to 29. The genomes of the 
sequenced S. aureus strains have between five and six ribosomal RNA (rRNA) operons 
and each operon usually include two SmaI restriction sites (Green and Vold, 1993; 
Wada et al., 1993). In current study, the sites within the rRNA operons were excluded 
due to their high-sequence similarity and the likelihood that their use would result in the 
generation of false-positive PCR amplicons.     
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In the second stage in the development of the new typing method, the gene 
neighbourhood sequences of the syntenic regions either side of potential SmaI target 
sites were aligned. A matrix of the SmaI gene neighbourhoods was constructed and 10 
SmaI-sites were chosen according to their discriminatory power. In order to approach 
the discriminatory power of PFGE, a set of forward primers was designed that 
incorporated all or part of the SmaI at the 3‟ end. The cognate reverse primers were 
designed to produce uniquely sized fragments using well-conserved regions. The 
presence of a PCR product should therefore reflect the presence or the absence of 
specific SmaI restriction sites in the bacterial chromosomal DNA, with the specific 
target sites being identified from the size of the amplicon. Initial evaluation of validity 
of new strategy included the design primers for first six target SmaI sites. They were 
tested in uniplex PCRs then multiplexed against unrelated S. aureus strains NCTC8325, 
EMRSA-15, EMRSA-16 and MRSA-PVL+. The primers showed specificity and 
distinguished between most of these strains, with exception of EMRSA-15 and 
EMRSA-16. Interestingly, the group-5 primer pairs of SmaI generated variable PCR 
fragments among test strains (Fig. 4.5), which potentially could be used to increase the 
discriminatory power of this technique.  
In the third stage of development, the discriminatory power of the new method 
was improved to distinguish between the most prevalent UK clones, namely EMRSA-
15 and EMRSA-16. Four new SmaI-group primers were designed and, when tested, 
clearly differentiated between epidemic strains EMRSA-15 and EMRSA-16 (Fig. 4.10). 
It is interesting to note that the discriminatory of SmaI-sites were found to be located 
throughout the entire S. aureus genome and therefore to reflect genetic variations 
throughout the whole genome (Fig. 4.4).   
A multiplex PCR with ten primers was optimized in several phases and in the 
last optimization phase all primers were redesigned using the Visual OMP
TM
 
(Oligonucleotide Modeling Platform) DNA analysis software. This software optimized 
primer homology, secondary structure, annealing temperature and assay conditions. The 
first evaluation of the new 10 primer pairs was carried out in two master mixes of 
multiplex PCR reactions. The master mix prepared in this study showed the best overall 
performance (Fig. 4.11). The discriminatory power of the new primers was most clear 
when the annealing temperature was 56˚C. However, the primers of SmaI-groups 3, 4 
and 10 failed to discriminate as expected between some of the strains due to the 
production of false-positive amplicons (Fig. 4.12). The reason for this was found to be 
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the presence of syntenic SmaI sites with SNPs that the primers could not differentiate 
between; CCCTGG in the case of group 3 and CCCAGG in the cases of groups 4 and 
10. In an attempt to eliminate these false-positive products, the primers for those three 
groups were redesigned using the Visual OMP software. The new primers of groups 3 
and 4 only amplified products from the expected strains with no false-positive 
amplicons. However, it was not possible to design a primer pair for the group-10 site as 
it persisted in generating false-positive amplicons. Consequently this site was excluded 
and replaced by a primer pair that identified the presence of the mecA gene in the 
multiplex PCR. The typeability, discriminatory power and reproducibility of the SmaI-
multiplex PCR were investigated against fourteen reference strains (NCTC8325, 
MRSA252, MSSA476, COL, JH9, N315, Mu3, Mu50, MW2, USA300FPR3757, 
EMRSA-15, USA1000, USA1100 and CA-629). All strains showed 100% typeability 
by a novel method with high discriminatory power. The test strains were found to have 
distinct profile with the exception of very closely related HA-VISA strains Mu50, Mu3 
and N315 that, as expected, showed the same SmaI-multiplex PCR profile (Fig. 4.17). 
These strains also share the same sequence (ST5) and SCCmec (II) types and showed a 
close relationship in a molecular evolutionary genetics analysis (MEGA) study 
(Highlander et al., 2007).  
The specificity of the SmaI-multiplex PCR technique was assessed against a 
large number of coagulase positive staphylococci (i.e. S. aureus). Consequently, when 
the specificity of the multiplex primers was tested against two sequenced coagulase-
negative staphylococci (CNS) strains, a methicillin resistant S. epidermidis (RP62A) 
and methicillin sensitive S. epidermidis (12228), with the exception of the mecA primer 
pair, no other PCR products were generated. This confirmed that the nine primer pairs 
were specific to S. aureus (Fig. 4.16).  
PFGE is usually reserved for reference typing, enabling microbiologist to 
monitor the history of an epidemic over the longer term rather than in real-time. For this 
purpose, the discriminatory power of the method is the most important parameter. In the 
current study, all fourteen of the reference strains that were typed by SmaI-multiplex 
PCR were subsequently analysed by PFGE. Moreover, the MLST and SCCmec types of 
the reference strains were already established with the exception of strain CA-629, 
which was, established as sequence type ST87 and SCCmec-V. The SmaI-multiplex 
PCR typing data were comparable with the PFGE data and was more discriminatory 
than MLST in distinguishing between these reference strains. The congruence between 
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SmaI-multiplex PCR, PFGE and MLST was clearly seen when the data was used to 
cluster the strains (Fig.4.19). SmaI-multiplex PCR grouped the strains into the same 
four clusters as PFGE and this was almost matched by MLST. Cluster 1 included 
laboratory strain NCTC8325, CA-MRSA USA300 and HA-MRSA COL strains with 
sequence types ST8 and ST250 belonging to clonal cluster CC8. The hypervirulent CA-
MRSA MW2 is closely related to CA-MSSA476 and both belong to sequence type ST1 
(Holden et al., 2004). These strains were distinguishable by SmaI-multiplex PCR and 
PFGE and were grouped in very tight cluster (Fig. 4.19). 
VISA Mu50, Mu3, JH9 and N315 are indistinguishable by MLST as 
ST5/SCCmec-II. While Mu50, Mu3 and N315 gave identical SmaI-multiplex PCR 
profiles, JH9 was distinguishable from the other strains (Fig. 4.19). However, although 
Mu50, N315 and JH9 showed closely related PFGE types, they were distinguishable. 
Data from this and the two previous clusters clearly show that SmaI-multiplex PCR 
typing is more discriminatory than MLST but less discriminatory than PFGE.  
Epidemic strains EMRSA-15 and EMRSA-16 are a major cause for concern for 
UK hospitals and their prevalence has reached alarming proportions. More recently, the 
spread of CA-MRSA has been reported in some hospitals (Huang et al., 2006, Kennedy 
and Deleo, 2009), and distinguishing between HA-MRSA and CA-MRSA has become 
an important issue in relation to infection control since they show differences in 
toxigenicity and antibiotic resistance patterns. In the presence study, SmaI-multiplex 
PCR not only distinguished between EMRSA-15 and EMRSA-16, but was also able to 
differentiate clearly between well known CA-MRSA strains (USA1000, USA1100 and 
CA-629). Moreover, the clustering of those strains on the basis of the SmaI-multiplex 
PCR profiles was in agreement with both PFGE and MLST (Fig. 4.19). 
A simple nomenclatural system for a novel SmaI-multiplex PCR profiles was 
proposed based on the presence and absent of the nine SmaI-sites according to their 
order on the genome (i.e. mecA-1 to SmaI-9) (Table 4.7). For example, SmaI-multiplex 
PCR type 2 of the COL strain, was given the SmaI-profile 1-0-0-1-0-1a-1-0-0-0, with 
the binary referring to the presence or absence of an amplicon at a specific allele and the 
letter on the group 5 referring to the length of the variable PCR products generated by 
the SmaI-group 5 primer pair. 
In summary, our studies demonstrate that the SmaI-multiplex PCR typing 
technique is a promising method for the typing both hospital-acquired and community-
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acquired strains of MSSA and MRSA. In combination with the rapid DNA extraction 
protocol introduced in this study, the newly developed typing method can be carried out 
in as little as 4 hours. The technology was developed and evaluated against sequenced 
S. aureus strains and the next stage of the work involved an evaluation of the technique 
in real time on actual clinical outbreaks. 
Evaluation of SmaI-multiplex PCR typing on actual clinical outbreaks and other 
clinical isolates  
For any typing technique to be effective it needs to distinguish unambiguously 
between unrelated strains in the investigation of a single outbreak. Consequently, SmaI-
multiplex PCR was evaluated on ongoing clinical outbreaks. In Chapter 5 we described 
the application of SmaI-multiplex PCR for the analysis of about 60 isolates that were 
recovered during outbreaks of S. aureus infection, a set of strains with known PFGE 
profiles received from HPA and a set of strains isolated from blood.   
The first evaluation was against seven outbreak isolates of a CO2-dependent 
MRSA that were isolated from patients and a member of staff in the regional liver 
transplant unit (RLU) of the Freeman Hospital. These isolates were originally classified 
as small colony variants (SCVs) of S. aureus before their CO2-dependency was 
identified. The epidemiological characterization of the CO2-dependent MRSA isolates 
using SmaI-multiplex PCR showed that they had identical profiles to EMRSA-15, and 
this was subsequently were confirmed by PFGE and MLST. All CO2-dependent MRSA 
isolates were ST22-SCCmec-IV (i.e the EMRSA-15 type) and had PFGE profiles that 
were, excepting in one case, identical to EMRSA-15. The single exception differed with 
respect to a single band and was classified as a variant of EMRSA-15. Although, PFGE 
was slightly more discriminatory, the SmaI-multiplex PCR data was in agreement with 
both MLST and PFGE (Table 5.2). 
The remaining 52 outbreak isolates were typed only by SmaI-multiplex PCR and 
the resulting epidemiological data was sent to the infection control office at the Freeman 
Hospital on the same day as the isolates were received. Nineteen SmaI-multiplex PCR 
profiles were observed among the outbreak isolates and isolates that were 
representatives of these profiles were subsequently analysed by MLST. This analysis 
confirmed that SmaI-multiplex PCR had a better resolving power than MLST since only 
16 MLST types were found among the 19 SmaI-multiplex PCR profiles (Fig. 5.13). In 
addition, SmaI-multiplex PCR distinguished between isolates that have the same 
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sequence type (ST5) and between some variants of EMRSA-15 within the same MLST 
and SCCmec type (ST22/SCCmec-IV; see Fig. 5.13). The UPGMA clustering method, 
used to predict phylogenies from genetic comparison data, was in most cases, in good 
agreement with the MLST phylogenetic tree (Fig. 5.13). The observation that SmaI-
multiplex PCR was able to identify phylogenies of clinical isolates (Chapter 5) 
supported the data on the reference strains (Chapter 4) in which showed a high 
correlation was observed between SmaI-multiplex PCR and MLST (Fig. 4.19).     
Since multiplex PCR is quicker and more cost-effective than a uniplex PCR, a 
simple diagnostic multiplex PCR assay for detection the coa, mecA and PVL genes was 
reported in this study. The proposed diagnostic assay showed high specificity against 
staphylococcal isolates (Fig. 5.14) by providing an efficient and reliable identification 
of S. aureus strains. Consequently, this assay represents an important tool for the initial 
identification of MSSA and MRSA producers of PVL.      
The HPA provides UK clinical microbiology laboratories with a microbial 
identification and typing data service for human pathogens. In collaboration with the 
HPA, twenty-four MRSA isolates with known PFGE types were received for a detailed 
assessment of SmaI-multiplex PCR typing. The HPA MRSA isolates were SmaI-
multiplex PCR typed directly from DNA extracted by the rapid extraction protocol (25 
min). The resulting SmaI-multiplex PCR profiles correctly distinguished between 
epidemic strains EMRSA-15 and EMRSA-16, but only differentiated between two 
variants of EMRSA-15 (out of 12) and three variants of EMRSA-16 (out of 12) (Fig. 
5.15).  
 As the last evaluating step, thirteen MRSA blood isolates were used to 
determine the discriminatory power of the developed SmaI-multiplex PCR technology. 
Ninety-two percent (n=12) of the isolates showed identical SmaI-multiplex PCR profile 
to that of EMRSA-15, while the remaining isolate was identified as EMRSA-16 (Fig. 
5.17). Three representatives (two EMRSA-15 isolates and one EMRSA-16) were 
further analysed by MLST. The MLST data confirmed the SmaI-multiplex PCR data 
which revealed that both EMRSA-15 representatives were EMRSA-15 (ST22-SCCmec-
IV) isolates and representative of EMRSA-16 was an EMRSA-16 (ST36-SCCmec-II). 
These findings indicate the discriminatory power of a novel typing method and also 
reflected the dominance of the EMRSA-15 clone among MRSA bacteraemias among 
patients at the Freeman Hospital. 
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In conclusion, we described a novel SmaI-multiplex PCR technique for the 
typing both MSSA and MRSA strains. The new technology is high throughput, 
relatively cheap and provides reliable and comparable genotyping data. At the same 
time, the SmaI-multiplex PCR meets most of the criteria of a useful typing method: it is 
simple, inexpensive, highly discriminatory and does not require sophisticated equipment 
or expertise. Consequently, SmaI-multiplex PCR could be used routinely in any clinical 
microbiology laboratory since it relies on standard clinical laboratory apparatus (i.e. 
PCR machine and agarose gel electrophoresis). The current study demonstrates that 
SmaI-multiplex PCR typing can provide real-time information for the investigation of 
ongoing S. aureus hospital outbreaks. SmaI-multiplex PCR proved to be more 
discriminatory than MLST/SCCmec typing, but less discriminatory than PFGE. As 
previously mentioned, PFGE is more sensitive to rapid genetic changes (e.g. point 
mutation) while MLST monitors accumulated genetic changes that occurs slowly over 
time. The SmaI-multiplex PCR technique can sometimes identify single genetic events 
(e.g. changes in SmaI-sites), and the distribution of SmaI targets throughout the entire 
genome may enable it to discover slowly accumulating genetic changes. Moreover, the 
observed correlation between SmaI-multiplex PCR and MLST in identifying the 
phylogenies of clinical isolates is a good indicator for the validity of SmaI-multiplex 
PCR in study of S. aureus evolution.  
Although, the current SmaI-multiplex PCR protocol takes between 4 to 6 hours, 
it would be possible to adapt this technology towards an automated genotyping assay 
using RT-multiplex PCR. This would reduce the processing time to less than 60 
minutes. Since individual targets are identifiable on the basis of the size of their 
amplicons, the RT-PCR output could be processed directly via dedicated analytical 
software.  
The development of the SmaI-multiplex PCR for studying the epidemiology of 
Staphylococcus aureus is not complete and future work needs to be aimed at improving 
its discriminatory power so that it is equal to or better than that of PFGE. One possible 
approach to achieving this is to exploit the presence of Staphylococcus aureus repeat 
(STAR) elements. The current study has already shown that the presence of STAR 
elements can improve the discriminatory power at the SmaI-group 5 site, in which we 
have currently identified 5 amplicon size variations (a-e).  
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As a preliminary to understanding whether STAR elements can be used for 
epidemiological analyses, a BLAST analysis was carried out to identify the number and 
location of STAR elements within the genomes of the currently sequences S. aureus 
strains. This analysis has revealed that the numbers of STAR elements at the different 
locations are highly variable (Table 6.1). The distinct feature of these elements is that 
they contain a signature sequence (GGGGCCCC) that can be present in many copies at 
a single locus, flanked by invariable sequences. The invariable sequences either side of 
the STAR elements could then be targeted by PCR primers to generate amplicons of 
various sizes.  
 
           Table 6.1: Number of STAR elements among the sequenced S. aureus strains. Gray 
highlighted strains are closely related. 
S. aureus strains STAR element no.  
RF122 57 
USA300 68 
COL 71 
JH1 70 
JH9 70 
MRSA252 61 
MSSA476 78 
MW2 83 
Mu3 75 
Mu50 75 
N315 76 
NCTC 8325 70 
Newman 76 
USA300_TCH1516 69 
 
Six loci (uvrA, trxB, glpQ, acnA, icaC and atpC) were selected to illustrate the 
potential of STAR elements to distinguish between closely related S. aureus strains. For 
example strains N315, Mu3 and Mu50 are difficult to distinguish using conventional 
molecular typing techniques since they have identical sequence and SCCmec types 
(ST5-SCCmec-II) and have closely related PFGE profiles (Fig. 4.19). Closely related 
JH1 and JH9 strains are also undistinguishable by PFGE (Sieradzki et al., 2003). 
Although the STAR element profiles of these strains would be very similar, differences 
within acnA locus would be sufficient to distinguish Mu3 from Mu50 and N315. 
However, STAR elements could not be used to differentiate between strains JH1 and 
JH9 (Table 6.2 and Appendix D). Overall, this bioinformatical analysis clearly indicates 
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the potential of using STAR elements for increasing the discriminatory power of SmaI 
multiplex PCR. Ultimately, the aim is to distinguish between PFGE variants of 
EMRSA-15 and EMRSA-16. However, until and unless the genome sequences of these 
variants are published, it will be necessary to determine the value of STAR elements by 
experimentation. It is worth exploring such a strategy since, if successful, it could 
considerably enhance the value of SmaI multiplex PCR by introducing a second-stage 
assay when the current technique fails to distinguish between potential outbreak strains. 
 
 
Table 6.2: The numbers of STAR element repeats identified within six loci among the 
sequenced S. aureus strains. Gray highlighted strains are closely related strains that 
can be distinguished by the STAR elements within the acnA locus. 
                STAR elements loci 
Strain 
uvrA trxB glpQ acnA icaC atpC 
RF122 1 4 0 0 1 0 
MW2 2 3 2 1 2 1 
MSSA476 2 3 0 2 2 1 
USA300 3 5 3 2 2 1 
USA300TCH 3 4 3 2 2 1 
MRSA252 1 3 0 0 1 4 
COL 2 2 0 2 0 1 
N315 3 6 1 3 1 1 
Mu3 3 6 1 0 1 1 
Mu50 3 6 1 3 1 1 
Newman 3 6 2 0 1 1 
NCTC8325 0 0 0 0 2 1 
JH1 0 0 0 0 0 1 
JH9 0 0 0 0 0 1 
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Appendix A            
  Media, Buffers and Solutions 
 The chemicals and reagents which were used in this study 
Chemicals  Supplier  
Agarose : 
      Traditional agarose   
      PFGE agrose (Certified Megabase Agarose) 
 
PEQLAB 
Bio-Rad 
Low melting point (LMP) agarose Biogene 
Trizma Base Sigma 
EDTA (Ethylene diamino tetra actic acid) Sigma 
Boric acid  Sigma 
Lysostaphin Sigma 
Lysozyme  Bio-Rad 
Polyethylene glycol (PEG) 6000 Sigma 
Ethedium Bromide   Fluka 
Phenylmethylsulfonyl fluoride (PMSF)  Sigma  
Proteinase K : 
 Extraction chromosomal DNA for PCR 
 Extraction chromosomal DNA for PFGE 
 
QIAgen  
Bio-Rad 
Taq polymerase   Fermentas 
dNTP Fermentas 
MgCl2 Fermentas 
BSA NewEngland   Biolab 
Glass beads 106 microns  Sigma 
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 Growth media 
Nutrient Medium                                        (per litre) pH 7.5    ( autoclave) 
          „Lab_Lemco‟ Powder                                                   10g 
Peptone                                                                       10g 
NaCl                                                                             5g 
Agar                                                                           15g 
 
Brain Heart Infusion Medium                      (per litre) pH 7.0   (autoclave) 
Brain Heart, Infusion from (solids)                               6g 
Peptic Digest of Animal Tissue                                     6g 
Pancreatic Digest of Gelatin                                     14.5g 
Dextrose                                                                         3g 
NaCl                                                                               5g 
Agar                                                                             15g 
 
Blood Agar           
   ATM Blood agar was prepared (at the Freeman hospital) according to 
manufacturer‟s instructions. Columbia agar (CM331; Oxoid) was prepared and 
cooled to 50ºC and 5% of horse blood and 4 mg of aztreonam per litre were added. 
Nalidixic acid blood agar was prepared as with Columbia agar above, and then 
adding 5% of horse blood and 30mg of nalidixic acid per litre (Perry et al. 2003).    
 
 Buffers  
TN Buffer                                                     (per litre) pH 7.6   (autoclave) 
 Tris HCl                                                               10mM 
 NaCl                                                                      1mM 
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Tris-EDTA (TE) Buffer                             (per litre) pH 7.5          (autoclave) 
 Tris                                                                      10mM 
EDTA                                                                    1mM 
                  
                  
Tris-Borate-EDTA (TBE) Buffer (5x stock)   (per litre) pH 8.0           
 Tris                                                                       53.9g 
Boric acid                                                              27.5g 
EDTA                                                                   3.75g 
 
               
Lysis Buffer (5x stock)  pH 8.0                            (autoclave)      
 Tris                                                                       25mM 
EDTA                                                                    25mM 
Sucrose                                                                    0.3M 
dd H2O                                                                   200ml 
 
 Solutions 
Glycerol Solution (70%)                                      (per 100ml)      (autoclave)      
Glycerol (100%)                                                     70ml 
ddH2O                                                                     30ml 
        
Lysostaphin Solution (1mg/ml)                                      (filter-sterilized) 
Lysostaphin                                                             1mg 
          NaCl (100mM)                                                          1ml      
         
     
Sodium chloride solution (1M NaCl)                                (autoclave) 
NaCl                                                                        5.8g 
          ddH2O                                                                      100ml      
Appendixes                                                                                                                                  185 
 
Polyethylene glycol (PEG) 20% (w/v) / 2.5M NaCl solution     (filter-sterilized) 
Polyethylene glycol (PEG) 20% (w/v)                      40% (w/v) 
NaCl                                                                          5M 
           ddH2O                                                                      50ml      
 
 
Pheylmethysulfonyl fluoride (100mM PMSF)        
Pheylmethysulfonyl fluorid                                      0.174g 
Isoprpanol (100%) (w/v)                                            10ml 
 
Ethidium Bromide (EtBr) staining solution(1µg/ml)     (kept in dark and cold place)  
Ethidium Bromide (10mg/ml)                                    100µl 
TBE Buffer (0.5x stock)                                            1 liter 
 
 
Ethidium Bromide (EtBr) staining solution (0.5µg/ml)(kept in dark and cold place)   
Ethidium Bromide (10mg/ml)                                      50µl 
TBE Buffer (1x stock)                                                1 liter 
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Appendix C 
Design of primers for multiplex PCR using visual OMP
TM
 DNA software 
The second phase primers were designed using the visual OMP
TM 
(Oligonucleotide Modelling Platform) software. The OMP
TM 
allows the users to design 
primers and probes for multiple specific sites and optimizes the secondary structure, 
homology, annealing temperature of primers and assay conditions. The design of primer 
pairs using this software was carried out through several steps: 
1- The analysis is started by selecting File/new project and experiment, and 
then opening a blank sequences form. This is used to enter the target 
sequence (e.g. from an NCBI genome file). 
 
2- The experimental conditions Tab is selected and the appropriate values 
entered into the solution condition text boxes (the manufacture recommends 
running the PCR at 55°C, 50 mM NaCl, 1.5 MgCl2 at pH 7.0.  This step can 
be reiterated when the target (DNA sequence) changes.   
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3- A simulation hybridization is run by pressing the “simulate experiment” icon 
on the toolbar.  
 
 
4- Select “yes” to see the results. 
 
 
5- Clicking the “View” link (Red circle) allows the user to see the structure 
target with second structure.  
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6- The “Probe/Primer Design” tab is clicked and the target name selected.  
 
 
7- The range of primer (e.g. 110-160bp) is selected. 
  
8- The characteristics of range are then seen in a dialog box.  
 
 
9- In case of our study, the forward primer should contain the SmaI site 
(CCCGGG) at its 3‟-end and therefore the range of designs are limited at 3‟-
end of forward primer. 
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10-  To design a primer pair around desired range, the primer pairs were selected 
from the “Design Type” column. 
  
11-  Selecting the “Design” tag (red circle) facilitates the design the two primers 
and one probe, with the software will automatically resolving all 
crosshybridization reactions. 
 
 
12-  The software provides about 50 solutions for each set of conditions and each 
solution contains three oligos: two primers and one probe. 
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13- The required solution is selected and then added to the experiment. 
 
 
14- The sequences are renamed and the target changed to double-stranded 
DNA.
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15- The simulation is then run with to see the percentage of bound to the target 
(red circles). 
   
16-  In the case of the SmaI-group 6 target, the programme identified that the 
secondary structure of the target reduces the PCR efficiency to ~52% (Red 
circle). 
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17- However, increasing the primer length and adding PCR adjunct can 
overcome the problem and increase the PCR efficiency to 97% (Red circle). 
Step 2 can be reiterated if needed. 
 
 
 
18- As the CCCGGG sequence at 3‟ end of forward primer is optimal for hairpin 
formation, removing two GG bases at 3‟ end increased the PCR efficiency. 
 
19- The software also assesses the hybridization between different sequences at 
different concentrations and temperatures. 
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 Appendix D 
 
 
The STAR element within upstream of uvrA  and downstream of hprK loci among S. aureus strains 
S. aureus 
strains 
Position Strand Upstream 
Gene 
Name 
Gene Downstream 
Gene 
Name 
Downstream Gene 
(same strand) 
Name 
Downstream 
same strand 
bp 
Sequence 
 RF122 784876 + uvrA(+) -/- hprK(+) hprK(+) -243 aattgggaatccaatttctcTGTGTTGGGGCCCCgccaactaattcgaatttat 
 USA300 829079 + uvrA(+) -/- hprK(+) hprK(+) -353 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
 USA300 829134 + uvrA(+) -/- hprK(+) hprK(+) -298 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
 USA300 829189 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattccaatatat 
 COL 850680 + uvrA(+) -/- hprK(+) hprK(+) -298 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
 COL 850735 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattccaatatat 
 MRSA252 856882 + uvrA(+) -/- hprK(+) hprK(+) -243 aattgagaatccaatttctcTGTGTTGGGGCCCCgccaactaattcgaatttat 
MSSA476 812230 + uvrA(+) -/- hprK(+) hprK(+) -298 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
MSSA476 812285 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattccaatatat 
MW2 813802 + uvrA(+) -/- hprK(+) hprK(+) -298 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
 MW2 813857 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattccaatatat 
 Mu3 843714 + uvrA(+) -/- hprK(+) hprK(+) -354 ctaaagaaaaagtatttcttTATGTTGGGGCCCAccccaacttgcattgtttgt 
 Mu3 843770 + uvrA(+) -/- hprK(+) hprK(+) -298 aatttcttttcgaaattctcTGTGTTGGGGCCCCgccaacttgcattgcctgta 
 Mu3 843825 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattacaatatat 
 Mu50 842269 + uvrA(+) -/- hprK(+) hprK(+) -354 ctaaagaaaaagtatttcttTATGTTGGGGCCCAccccaacttgcattgtttgt 
 Mu50 842325 + uvrA(+) -/- hprK(+) hprK(+) -298 aatttcttttcgaaattctcTGTGTTGGGGCCCCgccaacttgcattgcctgta 
 Mu50 842380 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattacaatatat 
 N315 818076 + uvrA(+) -/- hprK(+) hprK(+) -354 ctaaagaaaaagtatttcttTATGTTGGGGCCCAccccaacttgcattgtttgt 
 N315 818132 + uvrA(+) -/- hprK(+) hprK(+) -298 aatttcttttcgaaattctcTGTGTTGGGGCCCCgccaacttgcattgcctgta 
 N315 818187 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattacaatatat 
 Newman 819569 + uvrA(+) -/- hprK(+) hprK(+) -353 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
 Newman 819624 + uvrA(+) -/- hprK(+) hprK(+) -298 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
 Newman 819679 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattccaatatat 
TCH1516 842909 + uvrA(+) -/- hprK(+) hprK(+) -353 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
TCH1516 842964 + uvrA(+) -/- hprK(+) hprK(+) -298 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaacttgcattgtttgta 
TCH1516 843019 + uvrA(+) -/- hprK(+) hprK(+) -243 aatttcttttcgaaattcttTATGTTGGGGCCCCgccaactaattccaatatat 
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The STAR element within upstream of trxB locus among S. aureus strain 
S. aureus 
strains 
Position Strand Upstream 
Gene 
Name 
Gene Downstream Gene 
Name 
Downstream Gene 
(same strand) 
Name 
Downstream 
same strand 
bp 
Sequence 
 RF122 790139 + trxB(+)  SAB0718c(-)  SAB0719(+)  SAB0719(+)  -464 gctgactttccgccagctttTGTGTTGGGGCCCCgcccccaacttgcattgtct 
 RF122 790198 + trxB(+)  SAB0718c(-)  SAB0719(+)  SAB0719(+)  -405 aattgggaatccaatttctcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
 RF122 790310 + trxB(+)  SAB0718c(-)  SAB0719(+)  SAB0719(+)  -293 aattgggaatccaatttctcTTTGTTGGGGCCCAcaccccaactcgcattgcct 
 RF122 790368 + trxB(+)  SAB0718c(-)  SAB0719(+)  SAB0719(+)  -235 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 USA300 834568 + trxB(+)  -/- SAUSA300_0748(+)  SAUSA300_0748(+)  -463 gctgactttccgccagcttcTGTGTTGGGGCCCCgccaacttgcacattattgt 
 USA300 834624 + trxB(+)  -/- SAUSA300_0748(+)  SAUSA300_0748(+)  -407 gctgacttttcgtcagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
 USA300 834680 + trxB(+)  -/- SAUSA300_0748(+)  SAUSA300_0748(+)  -351 aattgggaatccaatttctcTATGTTGGGGCCCAcaccccaactcgcattgcct 
 USA300 834738 + trxB(+)  -/- SAUSA300_0748(+)  SAUSA300_0748(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 USA300 834796 + trxB(+)  -/- SAUSA300_0748(+)  SAUSA300_0748(+)  -235 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 COL 856114 + trxB(+)  -/- SACOL0830(+)  SACOL0830(+)  -293 gctgactttccgccagcttcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
COL 856172 + trxB(+)  -/- SACOL0830(+)  SACOL0830(+)  -235 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
MRSA252 862264 + trxB(+)  -/- SAR0820(+)  SAR0820(+)  -351 gctggcggaaagtcagcttcTGTGTTGGGGCCCAccccccaactcgcattgcct 
MRSA252 862322 + trxB(+)  -/- SAR0820(+)  SAR0820(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCCaccccaacttgcacattatt 
MRSA252 862380 + trxB(+)  -/- SAR0820(+)  SAR0820(+)  -235 gctgactttacgtcagcttcTTTGTTGGGGCCCCtgactataattgaaaaaagc 
MSSA476 817664 + trxB(+)  -/- SAS0730(+)  SAS0730(+)  -348 gctgacttttcgtaagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
MSSA476 817719 + trxB(+)  -/- SAS0730(+)  SAS0730(+)  -293 aaattcttttcgaaattctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
MSSA476 817777 + trxB(+)  -/- SAS0730(+)  SAS0730(+)  -235 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 MW2 819236 + trxB(+)  -/- MW0727(+)  MW0727(+)  -348 gctgacttttcgtaagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
 MW2 819291 + trxB(+)  -/- MW0727(+)  MW0727(+)  -293 aaattcttttcgaaattctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 MW2 819349 + trxB(+)  -/- MW0727(+)  MW0727(+)  -235 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
Mu3 849205 + trxB(+)  -/- SAHV_0762(+)  SAHV_0762(+)  -527 gctgacttatcgtaagcttcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 Mu3 849263 + trxB(+)  -/- SAHV_0762(+)  SAHV_0762(+)  -469 aatttcttttcgaaattctcTTTGTTGGGGCCCAcaccccaacttgcattgtct 
 Mu3 849322 + trxB(+)  -/- SAHV_0762(+)  SAHV_0762(+)  -410 aattggaaatccaatttctcTGTGTTGGGGCCCAcaccccaacttgcattgtct 
 Mu3 849381 + trxB(+)  -/- SAHV_0762(+)  SAHV_0762(+)  -351 aattggaaatccaatttctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 Mu3 849439 + trxB(+)  -/- SAHV_0762(+)  SAHV_0762(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCAcaccccaacttgcattgtct 
 Mu3 849498 + trxB(+)  -/- SAHV_0762(+)  SAHV_0762(+)  -234 aattggaaatccaatttctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 Mu50 847760 + trxB(+)  -/- SAV0765(+)  SAV0765(+)  -527 gctgacttatcgtaagcttcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 Mu50 847818 + trxB(+)  -/- SAV0765(+)  SAV0765(+)  -469 aatttcttttcgaaattctcTTTGTTGGGGCCCAcaccccaacttgcattgtct 
 Mu50 847877 + trxB(+)  -/- SAV0765(+)  SAV0765(+)  -410 aattggaaatccaatttctcTGTGTTGGGGCCCAcaccccaacttgcattgtct 
 Mu50 847936 + trxB(+)  -/- SAV0765(+)  SAV0765(+)  -351 aattggaaatccaatttctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 Mu50 847994 + trxB(+)  -/- SAV0765(+)  SAV0765(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCAcaccccaacttgcattgtct 
 Mu50 848053 + trxB(+)  -/- SAV0765(+)  SAV0765(+)  -234 aattggaaatccaatttctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 N315 823567 + trxB(+)  -/- SA0720(+)  SA0720(+)  -527 gctgacttatcgtaagcttcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 N315 823625 + trxB(+)  -/- SA0720(+)  SA0720(+)  -469 aatttcttttcgaaattctcTTTGTTGGGGCCCAcaccccaacttgcattgtct 
 N315 823684 + trxB(+)  -/- SA0720(+)  SA0720(+)  -410 aattggaaatccaatttctcTGTGTTGGGGCCCAcaccccaacttgcattgtct 
A
p
p
en
d
ix
es                                                                                                                   1
9
5 
Appendixes                                                                                                                                  196 
 N315 823743 + trxB(+)  -/- SA0720(+)  SA0720(+)  -351 aattggaaatccaatttctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 N315 823801 + trxB(+)  -/- SA0720(+)  SA0720(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCAcaccccaacttgcattgtct 
 N315 823860 + trxB(+)  -/- SA0720(+)  SA0720(+)  -234 aattggaaatccaatttctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 Newman 825058 + trxB(+)  -/- NWMN_0733(+)  NWMN_0733(+)  -463 gctgactttccgccagcttcTGTGTTGGGGCCCCgccaacttgcacattattgt 
 Newman 825114 + trxB(+)  -/- NWMN_0733(+)  NWMN_0733(+)  -407 gctgacttttcgtcagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
 Newman 825170 + trxB(+)  -/- NWMN_0733(+)  NWMN_0733(+)  -351 aattgggaatccaatttctcTATGTTGGGGCCCAcaccccaactcgcattgcct 
 Newman 825228 + trxB(+)  -/- NWMN_0733(+)  NWMN_0733(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
 Newman 825286 + trxB(+)  -/- NWMN_0733(+)  NWMN_0733(+)  -235 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagagttgaaaaaagc 
 Newman 832378 + trxB(+)  -/- NWMN_0733(+)  NWMN_0733(+)  -463 gctgactttccgccagcttcTGTGTTGGGGCCCCgccaacttgcacattattgt 
CH1516 848398 + trxB1(+)  USA300HOU_0793(-)  USA300HOU_0794(+)  USA300HOU_0794(+)  -463 gctgactttccgccagcttcTGTGTTGGGGCCCCgccaacttgcacattattgt 
TCH1516 848454 + trxB1(+)  USA300HOU_0793(-)  USA300HOU_0794(+)  USA300HOU_0794(+)  -407 gctgacttttcgtcagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
TCH1516 848510 + trxB1(+)  USA300HOU_0793(-)  USA300HOU_0794(+)  USA300HOU_0794(+)  -351 aattgggaatccaatttctcTATGTTGGGGCCCAcaccccaactcgcattgcct 
_TCH1516 848568 + trxB1(+)  USA300HOU_0793(-)  USA300HOU_0794(+)  USA300HOU_0794(+)  -293 aatttcttttcgaaattctcTGTGTTGGGGCCCAcaccccaactcgcattgcct 
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The STAR element within upstream of glpQ locus among S. aureus strain 
S. aureus 
strains 
Position Strand Upstream 
Gene 
Name 
Gene Downstream 
Gene 
Name 
Downstream Gene 
(same strand) 
Name 
Downstream 
same strand 
bp 
Sequence 
 USA300 940537 - glpQ(-)  -/- gudB(+)  SAUSA300_0856(-)  -6326 gctgactttccaccagcctcTGTGTTGGGGCCCCgactatttttgaaaagagcg 
 USA300 940593 - glpQ(-)  -/- gudB(+)  SAUSA300_0856(-)  -6382 gctgactttccgccagcctcTGTGTTGGGGCCCCgccaacttgcacactattgt 
 USA300 940707 - glpQ(-)  -/- gudB(+)  SAUSA300_0856(-)  -6496 gctgacttttcgccagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
 MW2 924484 - glpQ(-)  -/- gluD(+)  MW0835(-)  -6325 aatttcttttcgaaattctcTGTGTTGGGGCCCCgactatttttgaaaagagcg 
 MW2 924541 - glpQ(-)  -/- gluD(+)  MW0835(-)  -6382 aattggctccccaatttctcTGTGTTGGGGCCCAtccccaacttgcattgcctg 
Mu3 1002300 - glpQ(-)  -/- gudB(+)  SAHV_0948(-)  -6325 gctgactttccaccagcctcTGTGTTGGGGCCCCgactatttttgaaaagagcg 
 Mu50 1000856 - glpQ(-)  -/- gluD(+)  SAV0953(-)  -6325 gctgactttccaccagcctcTGTGTTGGGGCCCCgactatttttgaaaagagcg 
 N315 924572 - glpQ(-)  -/- gluD(+)  SA0814(-)  -6325 gctgactttccaccagcctcTGTGTTGGGGCCCCgactatttttgaaaagagcg 
 Newman 917240 - glpQ(-)  NWMN_0829(+)  gudB(+)  NWMN_0823(-)  -6382 gctgactttccgccagcctcTGTGTTGGGGCCCCgccaacttgcacactattgt 
 Newman 917354 - glpQ(-)  NWMN_0829(+)  gudB(+)  NWMN_0823(-)  -6496 gctgacttttcgccagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
TCH1516 954485 - glpQ2(-)  -/- gudB(+)  kapB(-)  -6326 gctgactttccaccagcctcTGTGTTGGGGCCCCgactatttttgaaaagagcg 
TCH1516 954541 - glpQ2(-)  -/- gudB(+)  kapB(-)  -6382 gctgactttccgccagcctcTGTGTTGGGGCCCCgccaacttgcacactattgt 
TCH1516 954655 - glpQ2(-)  -/- gudB(+)  kapB(-)  -6496 gctgacttttcgccagcttcTGTGTTGGGGCCCCgccaacttgcattgtctgta 
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The STAR element within upstream of acnA locus among S. aureus strain 
S. aureus 
strains 
Position Strand Upstream 
Gene 
Name 
Gene Downstream 
Gene 
Name 
Downstream Gene 
(same strand) 
Name 
Downstream 
same strand 
bp 
Sequence 
 USA300 1366621 - acnA(+)  -/- opuD(+)  mscL(-)  -2608 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
 USA300 1366737 - acnA(+)  -/- opuD(+)  mscL(-)  -2724 aattgggaatccaatttctcTTTGTTGGGGCCCAtccccaacttgcacattatt 
 COL 1390424 - acnA(+)  -/- opuD1(+)  mscL(-)  -2608 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
 COL 1390540 - acnA(+)  -/- opuD1(+)  mscL(-)  -2724 aattgggaatccaatttctcTTTGTTGGGGCCCAtccccaacttgcacattatt 
 MSSA476 1379324 - acnA(+)  -/- SAS1288(+)  mscL(-)  -2608 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
 MSSA476 1379440 - acnA(+)  -/- SAS1288(+)  mscL(-)  -2724 aattgggaatccaatttctcTTTGTTGGGGCCCAtccccaacttgcacattatt 
MW2 1350828 - acnA(+)  -/- opuD(+)  mscL(-)  -2608 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
Mu50 1425051 - acnA(+)  -/- opuD(+)  mscL(-)  -2606 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
Mu50 1425167 - acnA(+)  -/- opuD(+)  mscL(-)  -2722 aattgggaatccaatttctcTTTGTTGGGGCCCAtccccaacttgcacattatt 
Mu50 1425223 - acnA(+)  -/- opuD(+)  mscL(-)  -2778 actgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcattgtctgta 
N315 1348722 - acnA(+)  -/- opuD(+)  mscL(-)  -2606 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
N315 1348838 - acnA(+)  -/- opuD(+)  mscL(-)  -2722 aattgggaatccaatttctcTTTGTTGGGGCCCAtccccaacttgcacattatt 
N315 1348894 - acnA(+)  -/- opuD(+)  mscL(-)  -2778 actgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcattgtctgta 
USA300TCH 1380568 - acnA(+)  -/- sbcC(+)  lysC1(-)  -24818 aatttcttttcgaaattctcTGTGTTGGGGCCCCtgactagaattgaaaaaagc 
USA300TCH 1380684 - acnA(+)  -/- sbcC(+)  lysC1(-)  -24934 aattgggaatccaatttctcTTTGTTGGGGCCCAtccccaacttgcacattatt 
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The STAR element within upstream of icaC locus among S. aureus strain 
Organism Position Strand Upstream 
Gene 
Name 
Gene Downstream Gene 
Name 
Downstream Gene 
(same strand) 
Name 
Downstream 
same strand 
bp 
Sequence 
 RF122 2700901 + icaC(+)  SAB2545c(-)  lip(-)  SAB2563(+)  -17147 gctgactttccgccagcttcTATGTTGGGGCCCCacaccccaactcgcattgcc 
 USA300 2830246 + icaC(+)  -/- lip(-)  SAUSA300_2620(+)  -16770 cctgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcacattattgt 
 USA300 2830302 + icaC(+)  -/- lip(-)  SAUSA300_2620(+)  -16714 gctgactttccgccagcttcTTTGTTGGGGCCCCgccaacttgcattgtttgta 
 MRSA252 2855709 + icaC(+)  SAR2752(+)  lip1(-)  SAR2769(+)  -16714 aattgggaatccaatttctcTTTGTTGGGGCCCCgccaacttgcattgcctgta 
MSSA476 2756248 + icaC(+)  -/- lip1(-)  SAS2572(+)  -16769 cctgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcacattattgt 
MSSA476 2756304 + icaC(+)  -/- lip1(-)  SAS2572(+)  -16713 gctgactttccgccagcttcTTTGTTGGGGCCCCgccaacttgcattgtttgta 
MW2 2776908 + icaC(+)  -/- lip1(-)  MW2606(+)  -16769 cctgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcacattattgt 
MW2 2776964 + icaC(+)  -/- lip1(-)  MW2606(+)  -16713 cctgactttccgccagcttcTTTGTTGGGGCCCCgccaacttgcattgtttgta 
Mu3 2839484 + icaC(+)  SAHV_2654(+)  lip(-)  SAHV_2671(+)  -16657 aatttcttttcgaaattcttTTTGTTGGGGCCCCgccaagatattacttgaata 
Mu50 2837845 + icaC(+)  SAV2670(+)  lip1(-)  SAV2687(+)  -16657 aatttcttttcgaaattcttTTTGTTGGGGCCCCgccaagatattacttgaata 
N315 2774131 + icaC(+)  SA2462.1(+)  lip1(-)  SA2479(+)  -16657 aatttcttttcgaaattcttTTTGTTGGGGCCCCgccaagatattacttgaata 
NCTC8325 2778809 + icaC(+)  -/- SAOUHSC_03006(-)  SAOUHSC_03006.1(+)  -2941 cctgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcacattattgt 
NCTC8325 2778865 + icaC(+)  -/- SAOUHSC_03006(-)  SAOUHSC_03006.1(+)  -2885 gctgactttccgccagcttcTTTGTTGGGGCCCCgccaacttgcattgtttgta 
Newman 2836402 + icaC(+)  -/- lip(-)  NWMN_2585(+)  -16714 cctgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcattgtttgta 
TCH1516 2830392 + icaC(+)  USA300HOU_2670(-)  lip(-)  USA300HOU_2682(+)  -10464 cctgactttccgccagcttcTATGTTGGGGCCCCgccaacttgcacattattgt 
TCH1516 2830448 + icaC(+)  USA300HOU_2670(-)  lip(-)  USA300HOU_2682(+)  -10408 gctgactttccgccagcttcTTTGTTGGGGCCCCgccaacttgcattgtttgta 
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The STAR element within upstream of atpC locus among S. aureus strain 
Organism Position Strand Upstream 
Gene 
Name 
Gene Downstream Gene 
Name 
Downstream Gene 
(same strand) 
Name 
Downstream 
same strand 
bp 
Sequence 
 USA300 2220287 - atpC(-)  -/- SAUSA300_2056(-)  SAUSA300_2056(-)  -579 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
 COL 2156485 - atpC(-)  -/- SACOL2093(-)  SACOL2093(-)  -579 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
 JH1 2261267 - atpC(-)  -/- SaurJH1_2175(-)  SaurJH1_2175(-)  -579 ttaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
 JH9 2261392 - atpC(-)  -/- SaurJH9_2137(-)  SaurJH9_2137(-)  -579 ttaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
 MRSA252 2258987 - atpC(-)  -/- SAR2189(-)  SAR2189(-)  -579 aattgggaatccaatttcttTATGTTGGGGCCCCgtcaactactgccaaatata 
 MRSA252 2259046 - atpC(-)  -/- SAR2189(-)  SAR2189(-)  -638 gctgactttccgccagctttTGTGTTGGGGCCCCgcccccaacttgcattgtct 
 MRSA252 2259103 - atpC(-)  -/- SAR2189(-)  SAR2189(-)  -695 ctaaagaaaaagtatttcttTATGTTGGGGCCCAccccaacttgcacattaatg 
 MRSA252 2259268 - atpC(-)  -/- SAR2189(-)  SAR2189(-)  -860 aattgggaatacaatttctcTTTGTTGGGGCCCCaccggcaaggttgactagaa 
 MSSA476 2160694 - atpC(-)  -/- SAS2004(-)  SAS2004(-)  -579 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
MW2 2181589 - atpC(-)  -/- MW2025(-)  MW2025(-)  -579 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
 Mu3 2233015 - atpC(-)  -/- SAHV_2085(-)  SAHV_2085(-)  -579 ttaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
Mu50 2231377 - atpC(-)  -/- SAV2101(-)  SAV2101(-)  -579 ttaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
N315 2154945 - atpC(-)  -/- SA1903(-)  SA1903(-)  -579 ttaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
NCTC8325 2167209 - atpC(-)  -/- SAOUHSC_02339(-)  SAOUHSC_02339(-)  -214 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
Newman 2224868 - atpC(-)  -/- NWMN_2005(-)  NWMN_2005(-)  -579 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
TCH1516 2220681 - atpC(-)  -/- USA300HOU_2091(-)  USA300HOU_2091(-)  -579 ctaaagaaaaagtatttcttTATGTTGGGGCCCCgtcaactactgccaaataca 
 
 
A
p
p
en
d
ix
es                                                                                                                     2
0
0 
